

Author Index

Abdel-Haq B, *see* Salvetti, 963
Abiko Y, *see* Matsumura, 719
Abraham PA, *see* Opsahl, 221
Adamantidis M, *see* Libersa, 808
Aladjem M, *see* Aviv, 335
Alberti A, *see* Bracchetti, 261
Alcazar JM, *see* Ruilope, 979
Alcocer L, *see* Cobo, 73
Ale JJ, *see* Milei, 1519
Alicandri C, *see* Boni, 265
Aliot E, *see* Simon, 1467
Amende I, Herrmann G, Simon R, Hood WP Jr., Wenzlaff P, Lichtlen PR. Protective effects of pretreatment with intracoronary nifedipine on myocardial ischemia and dysfunction, 887
Amery A, *see* Staessen, 1237
Amici E, *see* Gambelli, 951
Amstein R, *see* Fetkovska, 105
Ansani L, *see* Longhini, 751
Antona C, *see* Monopoli, 59
Aoki T, *see* Hayashi, 969
Arakawa K, *see* Sasaki, 1033
Arcaro G, *see* Sheiban, 957
Arosio E, *see* Sheiban, 957
Arrigo F, Consolo F. Long-term therapy with slow-release nifedipine in essential hypertension, 941
Ash KO, *see* Hunt, 357
Ashino K, *see* Minamisawa, 1417
Assogna G, *see* Lavezzi, 119
Assogna G, *see* Malatino, 123
Audouin P, *see* Sellier, 320
Aviv A, Aladjem M. Essential hypertension in blacks: Epidemiology, characteristics and possible roles of racial difference in sodium, potassium, and calcium regulation, 335
Bachmann KF, *see* Gansser, 475
Baracca E, *see* Longhini, 751
Baranowska B. The effect of clonidine on hormone release mediated through activation of opiate receptors, 1113
Barat JL, *see* Bricaud, 861
Barilla F, Pelliccia F, Valente A, Cianfrroca C, Romeo F, Reale A. Acute effects of nifedipine versus isosorbide dinitrate on exercise tolerance in patients with isolated coronary artery occlusion and collaterals, 905
Barlow CW, Friedman BM, Myburgh DP, Soicher ER, Steenkamp WFJ, Smith DHG. Effects of therapy with diet and simvastatin on atherosclerosis in hypercholesterolemic patients, 1389
Bartels GL, Remme WJ, Wiesfeld ACP, Kok FJ, Look MP, Krauss XH,
Kruyssen HACM. Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure, 705
Baudet M, *see* Lardoux, 1337
Bauer JH, *see* Reams, 207
Bauer JH, *see* Reams, 1331
Bauer U, *see* Haerer, 515
Bayés de Luna A, Guindo J, Borja J, Roman M, Madoery C. Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study, 651
Bayés de Luna A, Opie LH. Introduction to symposium on arrhythmias, 649
Bel KJ, *see* Tio, 695
Benchekroun N, *see* Catroux, 816
Bentivoglio M, *see* Corea, 1501
Berckmans T, *see* Detry, 841
Bergamini M, *see* Dorigo, 1477
Berioli S, *see* Corea, 1501
Bernard A, *see* de Marneffe, 523
Bernier M, *see* Curtis, 1169
Bhigjee AI, *see* Hoosen, 363
Bianchini C, *see* Corea, 1501
Bigger JT Jr. Clinical aspects of trial design: What can we expect from the cardiac arrhythmia suppression trial?, 657
Biglioli P, *see* Monopoli, 59
Blaauw GJ, *see* Van Zweiten, 1443
Boni E, Alicandri C, Fariello R, et al. Effect of enalapril on parasympathetic activity, 261
Bonnet J, *see* Bricaud, 861
Borggrefe M, Breithardt G. Holter monitoring vs. programmed ventricular stimulation, 555
Boriani G, *see* Capucci, 281
Borja J, *see* Bayés de Luna, 651
Borsatti A, *see* Calo, 983
Bottero G, Morosetti P, Morosetti M, Meloni C, Meschini L, Taccone Gallucci M, Casciani CU. Acute effects of sublingual nifedipine on left ventricular function in hemodialysis hypertensive patients, 991
Boujelben F, *see* de Marneffe, 523
Boussens B, *see* Bricaud, 861
Bracchetti D, Gradnik R, Alberti A, et al. Comparison of bisoprolol and captopril for the treatment of essential hypertension in the elderly, 261
Breithardt G, *see* Borggrefe, 555
Bricaud H, Brottier L, Barat JL, Combe C, Boussens B, Bonnet J. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy, 861
Brigden G, *see* Broadhurst, 435
Broadhurst PA, Brigden G, Heber M, Lahiri A, Raftery EB. Twenty-four hour ambulatory blood pressure profile of a new, sustained-release preparation of nicardipine, 435
Brochier M, *see* Monpere, 824
Brottier L, *see* Bricaud, 861
Brugada J, *see* Brugada P, 619
Brugada P, Smeets JLRM, Brugada J, Farré J. Mechanism of action of sotalol in supraventricular arrhythmias, 619
Brune S, Schmidt T, Tebbe U, Kreuzer H. Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure and cardiac output in patients with heart failure, 85
Brunelli C, Spallarossa P, Ghigliotti G, Caudullo M, Iannetti M, Caponnetto S. Intravenous nifedipine prevents ergonovine-induced myocardial ischemia in patients with stable effort angina, 909
Bühler FR, *see* Fetkovska, 105
Bühler FR, *see* Kiowski, 935
Burke TJ, Singh H, Schrier RW. Calcium handling by renal tubules during oxygen deprivation injury to the kidney prior to reoxygenation, 1319
Burns RJ, *see* Leenen, 499
Burton JR, Haraphongse M, Hsu L, Kapagoda CT, Rossall RE, Schlaut B, Seranartne MPJ. Risk stratification after percutaneous transluminal coronary angioplasty, 687
Cacciatore L, *see* Coto, 77
Calo L, Cantaro S, Piccoli A, d'Angelo A, Giannini S, Williams HE, Borsatti A. Effect of nifedipine on urinary excretion of calcium and calcium-controlling hormones in essential hypercalcemia, 983
Cambar J, *see* Catroux, 816
Camm AJ. Current antiarrhythmic therapy overview, 531
Camm AJ, *see* Kaye, 1157
Camous JP, *see* Givelin, 1105
Cantaro S, *see* Calo, 983
Caponnetto S, *see* Brunelli, 909
Capucci A, Boriani G, Marchesini J, et al. Minimal effective concentration of propafenone and 5-hydroxypropafenone in acute and chronic therapy, 281
Caron J, *see* Libersa, 567
Carpentier A, *see* Fabiani, 797

Casciani CU, *see* Bottero, 991

Cassina L, *see* Sechi, 63

Castaldo B, *see* Coto, 77

Catroux P, Benekroun N, Robert J, Cambar J. Influence of trimetazidine on deleterious effect of oxygen radical species in post-ischemic acute renal failure in the rat, 816

Caudullo M, *see* Brunelli, 909

Cavallotti G, *see* di Somma, 1151

Cernoch K, *see* Haerer, 515

Challenger V, *see* Waller, 899

Chalmers J, *see* Minson, 27

Chávez A, *see* Cobo, 73

Chazov EI, Oganov RG. Preventative cardiology, 755

Cherchi A, Lai C, Onnis E, Orani E, Pirisi R, Pisano M Rosaria, Soro A, Corsi M. Propionyl carnitine in stable effort angina, 481

Chiarielli M, *see* Santinelli, 681

Cianfranca C, *see* Barilla, 905

Cianfranca C, *see* Pelliccia, 1515

Clauser P, *see* Maupoil, 791

Cleroux J, *see* Mancia, 1223

Clozel J-P, Véniant M, Osterrieder W. The structurally-novel Ca^{2+} channel blocker Ro 40-5967 which binds to the (H^+) desmethylverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts, 731

Cobo C, Alcocer L, Chávez A. Effects of ketanserin on left ventricular hypertrophy in hypertensive patients, 73

Cocozza M, *see* Coto, 77

Coetzee WA, Enous R, Opie LH. Trimetazidine: Effects on delayed afterdepolarizations (DADs) and upstroke velocity of the action potential, 806

Coffman JD. Pathogenesis and treatment of Raynaud's phenomenon, 45

Collins KJ. Age-related changes in autonomic control: The use of beta-blockers in the treatment of hypertension, 1257

Comba AZ, *see* Milei, 1519

Combe C, *see* Bricaud, 861

Condorelli M, *see* Santinelli, 681

Conrad KA, *see* Fagan, 493

Consolo F, *see* Arrigo, 941

Conti A, *see* Monopoli, 59

Corea L, Bentivoglio M, Bertioli S, Bianchini C, Savino K, Sardina M. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind placebo-controlled study with 24-hour ambulatory blood pressure monitoring, 1501

Corona P, *see* Sellier, 820

Corsi M, *see* Cherchi, 481

Costagliola C, Fasano ML, Iuliano G, Ferrara LA. Effects of ketanserin on intraocular pressure, 97

Coto V, Cocozza M, Oliviero U, Lucariello A, Picano T, Castaldo B, Iovino V, Cacciatore L. Regression of left ventricular hypertrophy and systolic function during long-term treatment with ketanserin, 77

Coumel P. Comments of P. Coumel, 1183

Coumel P. Encainide vs. flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias, 579

Coumel P, *see* Dessertenne, 1177

Coumel P, *see* Le Clercq, 1161

Covi G, *see* Sheiban, 957

Cox JP, *see* O'Malley, 1249

Cribier A, *see* Lardoux, 1337

Crozier IG, Ikram H, Nicholls MG, Low CJS. Twenty-four hour profile of the hypotensive action of felodipine in essential hypertension, 439

Curtis MJ, Bernier M, Szende G. Torsades de pointes: a re-evaluation, 1169

Daffronchio A, *see* Mancia, 1223

Dahlof B, *see* Hansson, 1253

D'Aliche P. Electrocardiographic assessment of trimetazidine antiischemic properties, 810

Dall JLC. Key factors in the treatment of the elderly hypertensive, 1263

Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study, 853

d'Angelo A, *see* Calo, 983

Danielsson B, *see* Larsson, 253

David D, *see* Rocha, 1525

Deanfield JE. Total ischemic burden in patients with coronary artery disease, 833

Decker J, *see* Jost, 1037

Decker JW, *see* Lichtlen, 1047

De Divitiis O, *see* Di Somma, 1151

De Graeff PA, *see* Tio, 695

De Jong JW. Myocardial energy metabolism, 756

De Landsheere C, *see* Rigo, 847

De Langen CDJ, *see* Tio, 695

Della-Valentina P, *see* Dalla-Volta, 853

Demange J, *see* Monpere, 824

De Marnette M, Waterschoot P, Bernard A, Dubois P, Boujelben F, Liebens I, Englert M. Electrophysiologic effects of intravenous xamoterol in patients with sinus node dysfunction, 523

Den Boer MO, Sassen LMA, van der Giesen WJ, Saxena PR, Verdouw PD. Effects of dilevalol in the anesthetized pig with a partially occluded coronary artery, 1461

Denjoy I, *see* Le Clercq, 1161

De Paola M, *see* Santinelli, 681

Desideri A, *see* Dalla-Volta, 853

Dessertenne F. Ventricular tachycardia with two variable foci, 1171

Dessertenne F, Coumel P, Fabiato A. Ventricular fibrillation and torsades de pointes, 1177

Detry J-M, Fesler R, Berckmans T, Le Clercq P. A new semi-automated algorithm to quantify Holter-detected myocardial ischemia: Preliminary experience in the Trimetazidine European Multicenter Trial (TEMS), 841

De Verneuil D, *see* Lardoux, 1337

Dews I, *see* Marks, 93

Dieterich HA, *see* Thormann, 1403

Diets R, *see* Haass, 289

DiSomma S, Liguori V, Petitto M, Cavalotti G, Savonitto S, de Divitiis O. Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients, 1151

Dorigo P, Gaion RM, Bergamin M, Giacometti A, Valentini E, Maragno I. Comparison between the cardiac effects induced by muzolamine and furosemide in guinea-pig atria, 1477

Dorigo P, Gaion RM, Maragno I. Involvement of purine compounds in the inotropic action of milrinone, 509

Doyle AE. Serotonin antagonists and vascular protection, 13

Drici M, *see* Gibelin, 1105

Drolet G, *see* Minson, 27

Drummer OH, *see* Louis, 1281

Dubois P, *see* de Marneffe, 523

Ducloux G, *see* Monpere, 824

Duhaylongsod FG, *see* Iverson, 269

Dunnmon PM, *see* Firth, 1363

Dupuis B, *see* Libersa, 808

Dustan HP. Obesity and hypertension in blacks, 395

Dworkin LW. Impact of calcium entry blockers on glomerular injury in experimental hypertension, 1325

Dzau VS, *see* Gibbons, 237

Dzwonczyk S, *see* Grover, 465

Ebina T, *see* Minamisawa, 1417

Edgar B, *see* Hasselgren, 1495

Edvardsson N, *see* Juul-Moeller, 631

Ethymiopoulos C, *see* Kirch, 487

Ehring T, Heusch G. Felodipine prevents the poststenotic myocardial ischemia induced by α_2 adrenergic coronary constriction, 443

Ekbom T, *see* Hansson, 1253

Elsner D, *see* Rieger, 1395

Emura S, *see* Ohta, 1021

Endoh M, Satoh H, Norota I, Hirano K. Effects of a new 1,3 thiazole derivative ZSY-39 on force of contraction and cyclic AMP content in canine ventricular muscle, 1127

Englert M, *see* de Marneffe, 523

Enous R, *see* Coetzee, 806

Epstein M. Introduction to focused section on calcium antagonists and the kidney, 1317

Erne P, *see* Kiowski, 935

Fabiani J-N, Jebara V, Carpentier A. Perioperative assessment of the quality of myocardial protection, 797

Fabiato A, *see* Dessertenne, 1177

Fagan TC, Conrad KA, Mayshar PV, Mackie MJ. Relationship between age and the cardiovascular response to meals, 493

Fagard R, *see* Lijnen, 321

Fagard R, *see* Staessen, 1237

Fantini G, *see* Mattioli, 505

Fariello R, *see* Boni, 265

Farré J, *see* Brugada, 619

Fasano ML, *see* Costagliola, 97

Fasoli G, *see* Scognamiglio, 923

Fehske KJ, *see* Haerer, 515

Ferracini F, *see* Fetkovska, 105

Ferrara LA, *see* Costagliola, 97

Ferrari AU, *see* Mancia, 1223

Fesler R, *see* Detry, 841

Fetkovska N, Pletscher A, Ferracini F, Amstein R, Bühler FR. Impaired uptake of platelet 5 hydroxytryptamine in essential hypertension: Clinical relevance, 105

Fiocchi G, *see* Fogari, 1145

Firth BG, Dunnmon PM. Left ventricular dilatation and failure post-myocardial infarction: Pathophysiology and possible pharmacologic interventions, 1363

Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grun G. Excessive mural calcium overload—A predominant causal factor in the development of stenosing coronary plaques in humans, 1005

Fleckenstein-Grun G, *see* Fleckenstein, 1005

Fogari R, Zoppi A, Tettamanti F, Malamani G, Pasotti C. The effect of celi-prolol on the blood lipid profile in hypertensive patients with high cholesterol levels, 1287

Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celi-prolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease, 1145

Forlani A, *see* Monopoli, 59

Frankel D, *see* Leenen, 499

Frey M, *see* Fleckenstein, 1005

Friedman BM, *see* Barlow, 1389

Fudo T, *see* Kambara, 919

Gagnol JP, *see* Puech, 549

Gaior RM, *see* Dorigo, 509

Gaior RM, *see* Dorigo, 1477

Gambelli G, Amici E, Selvanetti A. Effects of nifedipine on left ventricular diastolic function in hypertension; Echo Doppler study, 951

Gansser RE, Schneeweiss A, Weiss M, Bachmann KF. Hemodynamic and coronary vasodilative action of two nitruglycerin oral spray formulations, 475

Garay G, *see* Milei, 1519

Garay R. Typology of Na⁺ transport abnormalities in erythrocytes from essential hypertensive patients. A first step towards the diagnosis and specific treatment of different forms of primary hypertension, 373

Gaudel P, *see* Lardoux, 1337

Ghiglotti G, *see* Brunelli, 909

Ghione S, *see* Rosa, 133

Giacometti A, *see* Dorigo, 1477

Giannattasio C, *see* Mancia, 1223

Giannini S, *see* Calo, 983

Giasi M, *see* Santinelli, 681

Gibbons GH, Dzau VS. Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension, 237

Gibelin P, Sbirrazzuoli V, Drici M, Camous JP, Lapalus P, Morand P. Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure, 1105

Ginsburg R, *see* Narita, 723

Ginsburg R, *see* Narita, 1097

Giovannetti R, *see* Salvetti, 963

Goldhammer E, *see* Silke, 457

Gonatas LM, *see* Swartz, 413

Gotoh E, *see* Minamisawa, 1417

Gould SE, *see* McCarthy, 115

Gould SE, *see* Marks, 93

Gould SE, Silas JH, Hosie J. Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?, 89

Gradnik R, *see* Bracchetti, 261

Grassi G, *see* Mancia, 1223

Greco G, *see* Malatino, 123

Grover GJ, Dzwonczyk S, Parham CS, Slep PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs, 465

Guarnieri C, Mucari C. Beneficial effect of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle, 814

Guerret M, *see* Rocha, 1525

Gugliotta HO, *see* Milei, 1519

Guindo J, *see* Bayés de Luna, 651

Haass M, Dietz R, Purgaj J, et al. Plasma concentrations of atrial natriuretic peptide during physical exercise in patients with congestive heart failure, 289

Haddy FJ. Digitalislike circulating factor in hypertension: Potential messenger between salt balance and intracellular sodium, 343

Haerer W, Bauer U, Sultan N, Cernoch K, Mouselimis N, Fehske KJ, Hetzel M, Stauch M, Hombach V. Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure—A placebo-controlled trial, 515

Haitus B, *see* Obel, 613

Halabi A, *see* Kirch, 487

Hall WD, *see* Szalachic, 427

Hampton JR. Flosequinan for congestive heart failure. What promise does it hold?, 1313

Hananian G, *see* Lardoux, 1337

Hansson L, Dahlöf B, Ekblom T, Lindholm L, Schersten B, Wester P-O. Key learnings from the STOP-hypertension study: An update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly, 1253

Hanyok JJ, MacNeil DJ. Sotalol versus class I and II antiarrhythmic agents, 603

Hara A, *see* Matsumura, 719

Haraphongse M, *see* Burton, 687

Harpey C, *see* Maridonneau-Parini, 818

Harpey C, *see* Maupoil, 791

Harpey C, *see* Sellier, 820

Hashimoto K, Ohbayashi Y, Kinoshita M. Left ventricular effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs, 1449

Hasselgren B, Ronn O, Edgar B, Johansson P, Wall B. Pharmacokinetic, haemodynamic and diuretic/natriuretic effects of felodipine administered as an extended release tablet, 1495

Hattori Y, *see* Saito, 987

Haudenschild CC. Pathogenesis of atherosclerosis: state of the art, 993

Hayashi H, Iwase M, Aoki T, Yokota M. Assessment of left ventricular function after sublingual administration of nifedipine in patients with moderate to severe hypertension, 969

Hayashi M, *see* Kambara, 919

Hearse DJ. Ischemia, reperfusion, and the determinants of tissue injury, 767

Heber M, *see* Broadhurst, 435

Hecker H, *see* Jost, 1037

Hecker H, *see* Lichten, 1047

Henry PD. Antithrombotic effects of calcium-channel blockers: Possible mechanisms of action, 1015

Herrmann G, *see* Amende, 887

Hester RK, Shibata S. KT-362 related effects of intracellular calcium release

and associated clinical potential: Arrhythmias, myocardial ischemia, and hypertension, 1345

Hetzl M, *see* Haerer, 515

Heusch G, *see* Ehring, 443

Heusch G, *see* Linder, 1375

Higuchi N, *see* Ohta, 1021

Hiltgen M, *see* Lardoux, 1337

Hirano K, *see* Endoh, 1127

Hirsch A, *see* Szlachcic, 427

Hodzman GP, *see* Phillips, 1209

Holt D, *see* Robinson, 529

Hombach V, *see* Haerer, 515

Honore E, *see* Libersa, 808

Hood WP Jr, *see* Amende, 887

Hoosen S, Seedat YK, Bhigjee AI. A study of urinary and intracellular sodium and potassium, renin, aldosterone and hypertension in blacks and Indians in Natal, 363

Hosie J, *see* Gould, 89

Houplon M, *see* Lardoux, 1337

Houplon M, *see* Simon, 1467

Hsu L, *see* Burton, 687

Huetting J, *see* Thormann, 1403

Hugenholz PG, *see* Jost, 1037

Hugenholz PG, *see* Lichtlen, 1047

Hunt SC, Williams R, Ash KO. Changes in sodium-lithium countertransport correlate with changes in triglyceride levels and body mass index over 2-1/2 years of follow-up in Utah, 357

Iannetti M, *see* Brunelli, 909

Ibsen H, Westberg B. The efficacy and tolerability of long-term felodipine treatment in hypertension, 641

Imura O, Shimamoto K, Komura H. Effects of slow-release nifedipine on water-sodium, uric acid, and calcium metabolism, and on aldosterone secretion in patients with essential hypertension, 977

Ikram H, *see* Crozier, 439

INTACT Study Group, *see* Jost, 1037

INTACT Study Group, *see* Lichtlen, 1047

Iovino V, *see* Coto, 77

Ishii M, *see* Minamisawa, 1417

Iuliano G, *see* Costagliola, 97

Iverson LG, Duhaylongsod FG, Young J, et al. Porcine heparin increases post-operative bleeding in cardiopulmonary bypass patients, 269

Iwase M, *see* Hayashi, 969

Jaillon P. Pharmacokinetics and metabolism of encainide, 561

Jardine R, *see* Obel, 613

Jebara V, *see* Fabiani, 797

Jianjun Liu, *see* Nayler, 879

Johansson P, *see* Hasselgren, 1495

John SM, *see* McCarthy, 115

Johnston A, *see* Robinson, 529

Johnston CI, *see* Phillips, 1209

Jost S, Deckers J, Rafflenbeul W, Hecker H, Nellessen U, Wiese B, Hugenholtz PG, Lichtlen PR, INTACT Study Group. Features of the angiographic evaluation of the INTACT Study, 1037

Jost S, Rafflenbeul W, Mogwitz B, et al. Vasodilatory effects of nisoldipine on coronary arteries—correlation with plasma levels, 273

Jost S, *see* Lichtlen, 1047

Jung L, *see* Kirch, 487

Juul-Moeller S, Edvardsson N, Rehnqvist N. Sotalol versus quinidine in the maintenance of sinus rhythm after direct current conversion of atrial fibrillation, 631

Kahles H, *see* Riegger, 1395

Kahn JC, *see* Rocha, 1525

Kambara H, Mohiuddin I, Tamaki N, Fudo T, Hayashi M, Nohara R, Konishi J, Kawai C. Effects of nifedipine on cardiac function in patients with coronary artery disease evaluated with ambulatory radionuclide monitoring, 919

Kantor M, *see* Pederson, 451

Kaplan NM. Individual differences mean that the cost of treatment of hypertension cannot readily be quantified, 1439

Kapoor V, *see* Minson, 27

Kappagoda CT, *see* Burton, 687

Karpanou EA, *see* Vyssoulis, 81

Kato H, *see* Ohta, 1021

Katz RJ. Mechanisms of nitrate tolerance: A review, 927

Kawai C, *see* Kambara, 919

Kaye GC, Mehta D, Wafa S, Camm AJ. Acute electrophysiologic effects of an HT2=Serotonin antagonist, ketanserin, in humans, 1157

Kazda S, *see* Knorr, 1027

Keane WF, *see* Opsahl, 221

Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil, 1075

Kinoshita M, *see* Hashimoto, 1449

Kiowski W, Erne P, Buhler FR. Use of nifedipine in hypertension and Raynaud's phenomenon, 935

Kirch W, Milferstadt S, Halabi A, Rocher I, Efthymiopoulos C, Jung L. Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity, 487

Klein H, *see* Trappe, 1425

Klenner C, *see* Roman, 745

Knorr AM, Kazda S. Influence of nifedipine on experimental arteriosclerosis, 1027

Kochsiek K, *see* Riegger, 1395

Kok FJ, *see* Bartels, 705

Komura H, *see* Imura, 977

Konishi J, *see* Kambara, 919

Konishi M, Sakakura M, Tsushima N. Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension, 101

Koskinen P, *see* Rapola, 737

Kourtis TK, *see* Vyssoulis, 81

Krauss XH, *see* Bartels, 705

Kremer P, *see* Thormann, 1403

Kreuzer H, *see* Brune, 85

Kromer EP, *see* Riegger, 1395

Kruyssen HACM, *see* Bartels, 705

Kulbertus H, *see* Rigo, 847

Ladetto PE, *see* Lavezzaro, 119

Lahiri A, *see* Broadhurst, 435

Lai C, *see* Cherchi, 481

Lamon KD. Evaluation of celiprolol, a new cardioselective beta-adrenergic blocker with vasodilating properties in the treatment of mild to moderate hypertension in the elderly, 1291

Langford HG, Watson RL. Potassium and calcium intake, excretion, and homeostasis in blacks, and their relation to blood pressure, 403

Lapalus P, *see* Gibelin, 1105

Lardoux H, Louvard Y, de Vernejoul D, Picot C, Baudet M, Hiltgen M, Houplon M, Ponsonnaille J, Richard M, Lucioni R, Rocher R, Hanania G, Gaudefau P, Cribier A, Letac B. French multicenter trial of anistreplase versus heparin in acute myocardial infarction, 1337

Larochelle P. Hypertension in the elderly, 947

Larsson R, Lindsjö MK, Danielsson B, et al. Felodipine in the treatment of patients with severe hypertension and impaired renal function, 253

Lavanchy N, *see* Rossi, 812

Lavezzaro G, Ladetto PE, Valente M, Stramignoni D, Zanna C, Assogna G, Salvetti A. Ketanserin and captopril interaction in the treatment of essential hypertensives, 119

Lebrec D. Portal hypertension: Serotonin and pathogenesis, 33

Lechi A, *see* Sheiban, 957

LeClercq JF, Denjoy I, Mentré F, Coumel P. Flecainide acetate dose-concentration relationship in cardiac arrhythmias: Influence of heart failure and amiodarone, 1161

Leclercq, *see* Detry, 841

Leenen FHH, Burns RJ, Myers MG, Frankel D. Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy, 499

Lenzi M, *see* Salvetti, 963

Letec B, *see* Lardoux, 1337

Libersa C, Caron J, Rouet R. In vitro and in vivo electrophysiological effects of encainide, 567

Libersa C, Honore E, Adamantidis M, Rouet E, Dupuis B. Antiischemic effect of trimetazidine enzymatic and electric response in a model of in-vitro myocardial ischemia, 808

Lichtlen P, *see* Trappe, 1425

Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Nikutta P, Deckers JW, INTACT study group. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: Results of the INTACT Study (International Nifedipine Trial on Antiatherosclerotic Therapy), 1047

Lichtlen PR, *see* Amende, 887

Lichtlen PR, *see* Jost, 1037

Liebens I, *see* Marneffe, 523

Liguori V, *see* Di Somma, 1151

Lijnen P, M'Buyama-Kabangu J-R, Fangard R, et al. Erythrocyte concentrations and transmembrane fluxes of sodium and potassium in essential hypertension: Role of intrinsic and environmental factors, 321

Lijnen P, *see* Staessen, 1237

Linder C, Heusch G. ACE inhibitors for the treatment of myocardial ischemia?, 1375

Lindholm L, *see* Hansson, 1253

Lindsjö MK, *see* Larsson, 253

Llewellyn-Smith I, *see* Minson, 27

Longhini C, Ansani L, Musacci G, Mele D, Vaccari M, Baracca E, Sgobino P. The effect of captopril on peripheral hemodynamics in patients with essential hypertension: Comparison between oral and sublingual administration, 751

Look MP, *see* Bartels, 705

Louis WJ, Drummer OH, Tung L-H. Pharmacology of celiprolol, 1281

Louvard Y, *see* Lardoux, 1337

Low CJS, *see* Crozier, 439

Lucariello A, *see* Coto, 77

Lucioni R, *see* Lardoux, 1337

Lund-Johansen P, *see* Omvik, 1135

McAllister RG Jr., *see* Swartz, 413

McCarthy GL, *see* McCarthy ST, 115

McCarthy ST, McCarthy GL, John SM, Gould SE. A placebo-controlled crossover study of ketanserin in elderly hypertensive patients, 115

McKenna W, *see* Robinson, 529

Mackie MJ, *see* Fagan, 493

MacNeil DJ, *see* Hanyok, 603

McNeil JJ, Silagy CA. Hypertension in the elderly: Epidemiology and pathophysiology, 1197

Madoery C, *see* Bayés de Luna, 651

Magagna A, *see* Salvetti, 963

Malamani G, *see* Fogari, 1287

Malatino LS, Stancanelli B, Greco G, Polizzi G, Assogna G, Zanna C, Tamburino G. Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension, 123

Mancia G, Cleroux J, Daffonchio A, Ferrari AU, Giannattasio C, Grassi G. Reflex control of circulation in the elderly, 1223

Mancini M, Pauciullo P. Clinical relevance of hyperlipidemia, 1385

Maraglino G, *see* Dalla-Volta, 853

Maragno I, *see* Dorigo, 509

Maragno I, *see* Dorigo, 1477

Marchand X, *see* Rocha, 1525

Marchesini J, *see* Capucci, 281

Maridonneau-Parini I, Harpey C. Trimetazidine protects the human red blood cell against oxygen free radical damage, 818

Marigliano A, *see* Sechi, 63

Marks C, Dews I, Gould SE, Stephens J, Van den Burg M. The effects of ketanserin on ventricular ectopic activity in man, 98

Martin J, *see* Rossi, 812

Maseri A. Mechanisms of myocardial ischemia, 827

Masia S, *see* Sechi, 63

Massie B, *see* Szlachcic, 427

Matsumura H, Hara A, Abiko Y. Effect of diltiazem on the oxyhemoglobin level of myocardial cells in the isolated, perfused rat heart during hypoxia, 719

Mattioli AV, Modena MG, Fantini G, Mattioli G. Atenolol in dilated cardiomyopathy: A clinical instrumental study, 505

Mattioli G, *see* Mattioli, 505

Maupoil V, Rochette L, Clauser P, Harpey C. Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart, 791

Mayshar PV, *see* Fagan, 493

Mazzone A, Ricevuti G. Interaction between morphine and granulocytic aggregation in myocardial ischemia, 303

M'Buyama-Kabangu J-R, *see* Lijnen, 321

M'Buyama-Kabangu J-R, Tambwe M. The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertension, 389

Mehta D, *see* Kaye, 1157

Mele D, *see* Longhini, 751

Melis A, *see* Sechi, 63

Melon P, *see* Rigo, 847

Meloni C, *see* Bottero, 991

Mentré F, *see* LeClere, 1161

Meschini L, *see* Bottero, 991

Meza H, *see* Roman, 745

Milazzotto F, *see* Natale, 1509

Milei J, Ale JJ, Garay G, Otero F, Comba AZ, Gugliotta HO, Storino RA. Hemodynamic effects of chronic 4'-epi-adrinomycin administration, 1519

Milferstädt S, *see* Kirch, 487

Millar RN Scott, *see* Obel, 613

Mills E, *see* Minson, 27

Minamisawa K, Shionoiri H, Sugimoto K, Ueda S, Ashino K, Ebina T, Gotoh E, Ishii M. Depressor effects and pharmacokinetics of single and consecutive doses of delapril in hypertensive patients with normal or impaired renal function, 1417

Minson J, Chalmers J, Drolet G, Kapoor V, Llewellyn-Smith I, Mills E, Morris M, Pilowsky P. Central serotonergic mechanisms in cardiovascular regulation, 27

Mitrovic J, *see* Thormann, 1403

Modena MG, *see* Mattioli, 505

Mogwitz B, *see* Jost, 273

Mohiuddin I, *see* Kambara, 919

Momose Y, Sasayama S. Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes, 713

Monopoli A, Conti A, Forlani A, Ongini E, Antoni C, Biglioli P. 5-Hydroxytryptamine induces contraction in isolated human mammary artery: Effects of ketanserin, 59

Monpere C, Brochier M, Demange J, Ducloix G, Warin JF. Combination of trimetazidine with nifedipine in effort angina, 824

Montressor G, *see* Sheiban, 957

Mook PH, *see* Tio, 695

Morand P, *see* Givelin, 1105

Morgan KG. The role of calcium in the control of vascular tone as assessed by the Ca^{2+} indicator aequorin, 1355

Morganroth J. Determination of antiarrhythmic drug efficacy in the treatment of ventricular arrhythmias, 669

Morikami Y, *see* Yasue, 915

Morosetti M, *see* Bottero, 991

Morosetti P, *see* Bottero, 991

Morris M, *see* Minson, 27

Moss AJ. Identification of patients at increased risk for potentially malignant arrhythmias, 665

Mouselimis N, *see* Haerer, 515

Muller-Schweinitzer E. Venoconstrictor responses to dihydroergocristine and dihydroergotamine: Evidence for the involvement of 5-HT-like receptors, 1455

Mulrow J, *see* Robinson, 529

Musacci G, *see* Longhini, 751

Muscaria C, *see* Guarneri, 814

Myburgh DP, *see* Barlow, 1389

Myers MG, *see* Leenen, 499

Nakamura H, *see* Suzukawa, 69

Nappi JM, *see* Pool, 1089

Narita H, Zera PH, Ginsburg R. Mechanism of action of clentiazem on human coronary artery and myocardium, 1097

Narita N, Ginsburg R. In vitro study of effect of clentiazem on rabbit aorta and on myocardium, 723

Natali E, Ricci R, Milazzotto F. Effects of acute administration of gallopamil on left ventricular relaxation and filling dynamics in acute myocardial infarction assessed by doppler echocardiography, 1509

Nayler WG, Jianjun Liu, Pangiotopoulos. Nifedipine and experimental cardio-protection, 879

Nellessen U, *see* Jost, 1037

Nesto RW. Rationale for treatment of silent myocardial ischemia: Focus on nifedipine, 929

Nicholls MG, *see* Crozier, 439

Nieminen MS, *see* Rapola, 737

Nikutta P, *see* Lichten, 1047

Nohara R, *see* Kambara, 919

Norota I, *see* Endoh, 1127

Norris RJ. Introduction: Efficacy of celi-prol in hypertension and angina pectoris, 1195

Obel IWP, Jardine R, Haitus B, Scott Miller RN. Efficacy of oral sotalol in re-entrant ventricular tachycardia, 613

O'Brien E, *see* O'Malley, 1249

Oganov RG, *see* Chazov, 755

Ohbayashi Y, *see* Hashimoto, 1449

Ohmori K, *see* Ohta, 1021

Ohta Y, Higuchi N, Emura S, Takashima T, Oogushi K, Kato H, Ohmori K, Sunaga T. Quantitative analysis of anti-atherosclerotic effect of nifedipine in cholesterol-fed rabbits, 1021

Okazawa M, *see* Saito, 987

Olivero U, *see* Coto, 77

O'Malley K, Cox JP, O'Brien E. Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: Focus on systolic hypertension, 1249

Omvik P, Lund-Johansen P. The initial hemodynamic response to newer antihypertensive agents at rest and during exercise: Review of visacor, doxazosin, nisoldipine, tiapamil, perindopril, pinacidil, dilevalol, and carvedilol, 1135

Ongini E, *see* Monopoli, 59

Onnis E, *see* Cherchi, 481

Oogushi K, *see* Ohta, 1021

OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure, 419

Opie LH. Discussion: Cerebral blood flow, cardiovascular reflexes, and respiratory function, 1233

Opie LH. Discussion: Overview of epidemiology, systolic hypertension, and neurohumoral mechanisms, 1215

Opie LH. Discussion: Overview of major trials and key factors in treatment, 1269

Opie LH. Discussion: Required beta-blocker profile: Data on celiprolol, 1297

Opie LH. Forum on torsades de pointes: Introduction, 1167

Opie LH. Myocardial ischemia—metabolic pathways and implications of increased glycolysis, 777

Opie LH. Required beta-blocker profile in the elderly, 1273

Opie LH. What is new in myocardial ischemia, 765

Opie LH, *see* Bayés de Luna, 649

Opie LH, *see* Coetze, 806

Opsahl JA, Abraham PA, Keane WF. Renal effects of angiotensin converting enzyme inhibitors: Non-diabetic chronic renal disease, 221

Orani E, *see* Cherchi, 481

Osterrieder W, *see* Clozel, 731

Otero F, *see* Milei, 1519

Ourbak P, *see* Sellier, 820

Pala A, *see* Sechi, 63

Paleologos AA, *see* Vyssoulis, 81

Panagiotopoulos S, *see* Nayler, 879

Parham CS, *see* Grover, 465

Pasotti C, *see* Fogari, 1287

Pauciullo P, *see* Mancini, 1385

Pederson TR, Kantor M. Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol, 451

Pelliccia F, Cianfranca C, Romeo F, Reale A. Hypertrophic cardiomyopathy: Long-term effects of propranolol versus verapamil in preventing sudden death in "low-risk" patients, 1515

Pelliccia F, *see* Barilla, 905

Pellinen TJ, *see* Rapola, 737

Petitto M, *see* Di Somma, 1151

Phillips PA, Hodzman GP, Johnston CI. Neuroendocrine mechanisms and cardiovascular homeostasis in the elderly, 1209

Picano T, *see* Coto, 77

Piccoli A, *see* Calo, 983

Picot C, *see* Lardoux, 1337

Pilowsky P, *see* Minson, 27

Pirisi R, *see* Cherchi, 481

Pisano M Rosaria, *see* Cherchi, 481

Pitsavos CE, *see* Vyssoulis, 81

Pletscher A, *see* Fomkova, 105

Poletti L, *see* Fogari, 1145

Polimeni PI, *see* Smyth, 291

Polizzi G, *see* Malatino, 123

Ponsommaire J, *see* Lardoux, 1337

Pool PE. Efficacy of encainide in supraventricular arrhythmias, 573

Pool PE, Nappi JM, Weber MA. Antihypertensive monotherapy with tablet (prompt-release) diltiazem: Multicenter controlled trials, 1089

Porter V, *see* Szlachcic, 427

Poston L. Sodium transport inhibitors in pregnancy-induced hypertension, 351

Puech P, Gagnol JP. Class IC drugs: Propafenone & flecainide, 549

Purgaj J, *see* Haass, 289

Quintanilla AP, Wagener OE. Diuretics and cation transport in hypertensive blacks, 383

Rafflenbeul W, *see* Jost, 273

Rafflenbeul W, *see* Jost, 1037

Rafflenbeul W, *see* Lichten, 1047

Raftery EB, *see* Broadhurst, 435

Rapola JM, Pellinen TJ, Koskinen P, Toivonen L, Nieminen MS. Hemodynamic effects of pindolol and atenolol at rest and during isometric exercise: A non-invasive study with healthy volunteers, 737

Reale A, *see* Barilla, 905

Reale A, *see* Pelliccia, 1515

Reams GP, Bauer JH. Acute and chronic effects of angiotensin converting enzyme inhibitors on the hypertensive kidney, 207

Reams GP, Bauer JH. Effects of calcium antagonists on the hypertensive kidney, 1331

Rehnqvist N. Prevention of sudden death by beta-blockade, 675

Rehnqvist N, *see* Juul-Moeller, 631

Remme WJ, *see* Bartels, 705

Reneman RS, Van der Starre PJA. Serotonin and acute cardiovascular disorders, 19

Ricci R, *see* Natale, 1509

Ricevuti G, *see* Mazzone, 303

Richard M, *see* Lardoux, 1337

Rieger GAJ, Kahles H, Wagner A, Kromer EP, Elsner D, Kochsiek K. Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure, 1395

Rigo P, de Landsheere C, Melon P, Kultbertus H. Imaging of myocardial metabolism by positron emission tomography, 847

Rizzardi G, *see* Fogari, 1145

Robert J, *see* Catroux, 816

Robertson JIS. Carcinoid syndrome and serotonin: Therapeutic effects of ketanserin, 53

Robertson JIS. Closing remarks. Serotonin and vascular disease: A survey, 137

Robinson K, Johnston A, Walker S, Mullan J, Holt D, McKenna W. Stability of plasma amiodarone levels during chronic oral therapy, 529

Rocha P, Guerret M, David D, Marchand X, Kahn JC. Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment, 1525

Rocher I, *see* Kirch, 487

Rocher R, *see* Lardoux, 1337

Rochette L, *see* Maupoil, 791

Rockstroh JK, *see* Schmieder, 1487

Roman M, *see* Bayés de Luna, 651

Roman O, Meza H, Klenner C. Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients, 745

Romeo F, *see* Barilla, 905

Romeo F, *see* Pelliccia, 1515

Ronn O, *see* Hasselgren, 1495

Rosa C, Ghione S. Effect of ketanserin on pain perception in arterial hypertension, 133

Rossall RE, *see* Burton, 687

Rossi A, Lavanchy N, Martin J. Antiischemic effect of trimetazidine 31P-NMR spectroscopy study in the isolated rat heart, 812

Rouet E, *see* Libersa, 808

Rouet R, *see* Libersa, 567

Ruolope LM, Alcazar JM. Renal effects of calcium entry blockers, 979

Rutan GH. Systolic hypertension in the elderly, 1208

Saito Y, Shirai K, Uchino J, Okazawa M, Hattori Y, Yoshida T, Yoshida S. Effect of nifedipine administration on pulse wave velocity (PWV) of chronic hemodialysis patients—two years trial, 987

Sakai K, *see* Kinoshita, 1075

Sakakura M, *see* Konishi, 101

Salvetti A, Magagna A, Abdel-Haq B, Lenzi M, Giovannetti R. Nifedipine interactions in hypertensive patients, 963

Salvetti A, *see* Lavezzaro, 119

Sami M. Comparative hemodynamics of antiarrhythmic drugs, 545

Santinelli C, *see* Santinelli, 681

Santinelli V, Turco P, DePaolo M, Simmino D, Giasi M, Santinelli C, Chiarriello M, Condorelli M. Propafenone in Wolff-Parkinson-White syndrome at risk, 681

Sardina M, *see* Corea, 1501

Sasaki J, Arakawa K. Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension, 1033

Sasayama S, *see* Momose, 713

Sassen LMA, *see* Den Boer, 1461

Satoh H, *see* Endoh, 1127

Satoh K, *see* Yoneyama, 1119

Satoh K, *see* Yoneyama, 1469

Saunders E. Cellular mechanisms in hypertension and therapeutic implications in blacks, 317

Savino K, *see* Corea, 1501

Savonito S, *see* Di Somma, 1151

Saxena PR, *see* Den Boer, 1461

Sbirazzuoli V, *see* Gibelini, 1105

Schersten B, *see* Hansson, 1253

Schlaut B, *see* Burton, 687

Schlepper M, *see* Thormann, 1403

Schmidt T, *see* Brune, 85

Schmieder RE, Rockstroh JK. When is discontinuation of antihypertensive therapy indicated?, 1487

Schneeweiss A, *see* Gansser, 475

Schrier RW, *see* Burke, 1319

Scognamiglio R, Fasoli G. Effects of nifedipine on left ventricular diastolic dysfunction after myocardial infarction, 923

Scott Millar RN. Efficacy of sotalol in controlling re-entrant supraventricular tachycardias, 625

Sechi LA, Tedde R, Cassisa L, Pala A, Marigliano A, Masia S, Melis A. Evidence for a direct and non-receptor-mediated action of 5HT₂ antagonists on transmembrane cation transport systems, 63

Seedat YK, *see* Hoosen, 363

Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina, 822

Sellier P, Harphey C, Corona P, Audouin P, Ourbak P. Acute effects of trimetazidine on ergometric parameters in effort angina, 820

Selvanetti A, *see* Gambelli, 951

Senaratne MPJ, *see* Burton, 687

Sgobino P, *see* Longhini, 751

Sharma SK, *see* Silke, 457

Sharpe N. Cardiac effects of ACE inhibitors, 243

Sheibani I, Covis G, Zenorini C, Arcaro G, Arrosio E, Tonni S, Montressor G, Lechi A. Early regression of left ventricular diastolic abnormalities in hypertensive patients treated with nifedipine, 957

Shibata S, *see* Hester, 1345

Shimamoto K, *see* Iimura, 977

Shionoiri H, *see* Minamisawa, 1417

Shirai K, *see* Saito, 987

Shulman NB. Cellular mechanisms and their implications in hypertensive blacks, 315

Silagy CA, *see* McNeil, 1197

Silas JH, *see* Gould, 89

Silke B, Goldhamer E, Sharma SK, Verma SP, Taylor SH. An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease, 457

Simon JP, Zannad F, Trechot P, Thisse JY, Houplon M, Aliot E. Acute hepatitis after a loading dose of intravenous amiodarone, 1467

Simon R, *see* Amende, 887

Singh BN. Is class III activity important?, 597

Singh H, *see* Burke, 1319

Singh RB. Calcium and blood pressure, 301

Sleph PG, *see* Grover, 465

Smeets JLRM, *see* Brugada, 619

Smimmo D, *see* Santinelli, 681

Smith DHG, *see* Barlow, 1389

Smyth DD, Polimeni PI. Drag reducing polymers: A novel class of diuretic and natriuretic compounds, 297

Soicher ER, *see* Barlow, 1389

Soro A, *see* Cherchi, 481

Spallarossa P, *see* Brunelli, 909

Specchia G. Increased coronary tone in exertional angina: The beneficial effects of calcium antagonists, 893

Staessen J, Fagard R, Lijnen P, Van Hoof R, Amery A. Review of the major hypertension trials in the elderly, 1237

Stancanelli B, *see* Malatino, 123

Stauch M, *see* Haerer, 515

Steenkamp WFJ, *see* Barlow, 1389

Stephens J, *see* Marks, 93

Storino RA, *see* Milei, 1519

Stramignoni D, *see* Lavezzaro, 119

Strandgaard S. Cerebral blood flow in the elderly: Impact of hypertension and antihypertensive treatment, 1217

Strano A. Introduction: Nifedipine and cardioprotection, 877

Sugimoto K, *see* Minamisawa, 1417

Sulton N, *see* Haerer, 515

Sunaga T, *see* Ohta, 1021

Suzukawa M, Nakamura H. Effects of ketanserin tartrate on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human skin fibroblasts, 69

Swales JD. Membrane transport of ions in hypertension, 367

Swartz SL, Gonasan LM, McAllister RG Jr., Thadani U. A multicenter comparison of isradipine and prazosin for treatment of essential hypertension, 413

Szende G, *see* Curtis, 1169

Szalachic J, Hall WD, Tubau JF, Porter V, Vollmer C, Wollam G, Hirsch A, Massie B. Left ventricular hypertrophy reversal with labetalol and propranolol: A prospective, randomized double-blind study, 427

Taccione Gallucci M, *see* Bottero, 991

Taira N, *see* Yoneyama, 1119

Taira N, *see* Yoneyama, 1469

Takashima T, *see* Ohta, 1021

Tamaki N, *see* Kambara, 919

Tamburino G, *see* Malatino, 123

Tambwe M, *see* M'Buyamba-Kabangu, 389

Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade, 1229

Taylor SH, *see* Silke, 457

Tebbe U, *see* Brune, 85

Tedde R, *see* Sechi, 63

Tettamanti F, *see* Fogari, 1145

Tettamanti F, *see* Fogari, 1287

Textor SC. ACE inhibitors in renovascular hypertension, 229

Thadani U, *see* Swartz, 413

Thimm F, *see* Fleckenstein, 1005

Thind GS. Angiotensin converting enzyme inhibitors: Comparative structure, pharmacodynamics, 199

Thisse JY, *see* Simon, 1467

Thomis JA. Encainide: An updated safety profile, 585

Thormann J, Huetting J, Kremer P, Wissmann J, Mitrovic J, Dieterich HA, Schlepper M. Exoximone: True inotropic effects? Do they cause ischemia? Analysis of endsystolic pressure-volume relations using the conductance (volume) catheter technique, 1403

Tio RA, de Langen CDJ, de Graeff PA, Van Gilst WH, Bel KJ, Wolters KGTP, Mook PH, van Wijngaarden J, Wesseling H. The effects of oral pretreatment with zofenopril, and an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiological stability in the pig, 695

Toivonen L, *see* Rapola, 737

Toni S, *see* Sheiban, 957

Touboul P. Electrophysiological evaluation of antiarrhythmic drugs, 535

Toutouzas PK, *see* Vyssoulis, 81

Trappe H-J, Klein H, Lichtlen P. Sotalol in patients with life-threatening ventricular tachyarrhythmias, 1425

Trechot P, *see* Simon, 1467

Tushima N, *see* Konishi, 101

Tubau JF, *see* Szlachcic, 427

Tung LH, *see* Louis, 1281

Turco P, *see* Santinelli, 681

Uchino J, *see* Saito, 987

Ueda S, *see* Minamisawa, 1417

Vaccari M, *see* Longhini, 751

Valente A, *see* Barilla, 905

Valente M, *see* Lavezzaro, 119

Valentini E, *see* Dorigo, 1477

Van Brummelen P, *see* Van Zweiten, 1443

Van den Burg M, *see* Marks, 93

Van der Giessen WJ, *see* Den Boer, 1461

Van der Starre PJA, *see* Reneman, 19

Van Gilst WH, *see* Tio, 695

Van Hoof R, *see* Staessen, 1237

Vanhoutte PM. Serotonergic antagonists and vascular disease, 7

Van Oene JC. Oral dosing with ketanserin to control high blood pressure in the elderly, 111

Van Wijngaarden J, *see* Tio, 695

Van Zweiten PA, Blauw GJ, van Brummelen P. The role of serotonin in cardiovascular diseases and their treatment, 1443

Véniant M, *see* Clozel, 731

Verdouw PD, *see* Den Boer, 1461

Verma SP, *see* Silke, 457

Viena P, *see* Dalla-Volta, 853

Vollmer C, *see* Szlachcic, 427

Vyssoulis GP, Karanou EA, Pitsavos CE, Paleologos AA, Kourtsis TK, Toutouzas PK. Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives, 81

Wafa S, *see* Kaye, 1157

Wagener OE, *see* Quintanilla, 383

Wagner A, *see* Riegger, 1395

Walker S, *see* Robinson, 529

Wall B, *see* Hasselgren, 1495

Waller D, Challenor V. The combination of slow-release nifedipine and atenolol for stable angina, 299

Warin JF, *see* Monpere, 824

Waterschoot P, *see* de Marneffe, 523

Watson RL, *see* Langford, 403

Weber MA, *see* Pool, 1089

Weinberger MH. Racial differences in antihypertensive therapy: Evidence and implications, 379

Weiner CP. The role of serotonin in the preeclampsia-eclampsia syndrome, 37

Weiss M, *see* Gansser, 475

Wenzlaff P, *see* Amende, 887

Wesseling H, *see* Tio, 695

Westberg B, *see* Ibsen, 641

Wester P-O, *see* Hansson, 1253

Wiese B, *see* Jost, 1037

Wiesfeld ACP, *see* Bartels, 705

Williams HE, *see* Calo, 983

Williams R, *see* Hunt, 357

Wissemann J, *see* Thormann, 1403

Wollam G, *see* Szlachcic, 427

Wolters KGTP, *see* Tio, 695

Woosley RL. New concepts affecting the use of antiarrhythmic agents, 541

Yamada H, *see* Yoneyama, 1469

Yasue H, Morikami Y. Efficacy of slow-release nifedipine on ischemic attacks in patients with variant angina, 915

Yokota M, *see* Hayashi, 969

Yoneyama F, Satoh K, Taira N. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism, 1119

Yoneyama F, Yamada H, Satoh K, Taira N. Cardiac versus coronary dilator effects of SD-3211, a new nondihydropyridine calcium antagonist in isolated, blood-perfused dog hearts, 1469

Yoshida S, *see* Saito, 987

Yoshida T, *see* Saito, 987

Young J, *see* Iverson LIG, 269

Zanna C, *see* Lavezzaro, 119

Zanna C, *see* Malatino, 123

Zannad F, *see* Simon, 1467

Zenorini C, *see* Sheiban, 957

Zera PH, *see* Narita, 1097

Zoppi A, *see* Fogari, 1145

Zoppi A, *see* Fogari, 1287

Subject Index

Ablation (catheter), used with additional antiarrhythmic therapy, 533

Abstract translations from symposium on serotonin and vascular disease, 141-187

Acetabulol antihypertensive treatment for blacks, 389, 390, 391

blood lipid profile affected, 1277 for LVH regression, 432 respiratory function in the elderly affected, 1231

ACE inhibitors, *see* Angiotensin-converting enzyme inhibitors

Acetylcholine, baroreceptor modulation of heart rate in aged subjects, 1234

Acetyl salicylic acid, drug interaction, 965

Acidosis inhibitory effect and severity of ischemia, 780

ischemia-induced reduction by trimetazidine, 858

trimetazidine effects during ischemia and reperfusion, 812

Action-potential duration
OPC-8490 effect, 713-716
prolonged class III drugs, 598-602
sotalol for prolongation, 625

Action potentials, upstroke velocity and trimetazidine, 806-807

Acute Infarction Ramipril Efficacy Study (AIRE), ACE inhibitors and myocardial ischemia, 1381

Adenosine arrhythmias, 532
involved in the inotropic action of milrinone, 509-512

Adenosine diphosphate (ADP)
serotonin amplifying platelet reaction, 19-20
stimulation of endothelium, 9, 11

Adenosine triphosphate (ATP)
anaerobic production of, 777, 778, 779, 788-785
cause of flushes, 55
content related to impairment in contraction and relaxation, 1366
dysfunctional endothelium, 11
glycolytic, and ischemic contracture, 785-786

involved in the inotropic action of milrinone, 509-512

serotonin content of platelets paralleled by, 138

sodium, -potassium-ATPase pump, 321-322, 324, 326-330

spared by potassium-channel-activation-induced decreases in intracellular calcium, 473

Adrenergic blockers
activity related to weight reduction in obese patients, 400
to reverse left ventricular hypertrophy, 427-432

Adrenergic nerves, serotonin's tyramine-like effect, 9

Adrenergic receptors, dobutamine infusion benefits influenced by, 1109-1110

Adrenoceptors, clonidine effect, 1113, 1116

Adriamycin (ADM), dose-dependent cardiomyopathy as risk, 1519

Aequorin, calcium indicator used in vascular smooth muscle, 1355-1361

Afterload reduction, augmentation of LV function after nifedipine administration, 969, 971-972, 974

Aging
autonomic nervous control constraints in beta blocker use for hypertension, 1257
baroreceptor ability to cause blood pressure changes affected, 1223-1227
bisoprolol vs. captopril treatment for hypertension, 261-264
effect on essential hypertension renal disease, 207
as factor in platelet sensitivity and response to 5HT, 106, 107, 108

hypertension treatment, 1263-1267
neuroendocrine control of cardiovascular homeostasis, related to, 1209-1212
relationship with cardiovascular response to meals, 493-496

AGT (decapeptide)
experimental myocardial ischemia, 1377-1378, 1381
formation interactions and conversion to AGT II, 1375-1379, 1381-1382

Airways
beta-blockers effects in hypertensives with chronic obstructive lung disease, 1145-1148
respiratory function in the elderly affected by beta blockade, 1229-1232

Ajmaline, effect on conduction characteristics of AV pathways, 621

Alacepril, vs. delapril, 1417

Aldosterone
as factor in salt-induced changes in arterial pressure, 400
lower level found in elderly, 1211
nifedipine effect in hypertension, 977
renal Na, K-ATPase activity affected, 385
urinary and intracellular studies of blacks and Indians, 364

Allopurinol, to decrease oxygen ion production, 800, 801, 802

Alpha₁-adrenergic receptors
HMG CoA reductase activity, 69, 72
hypertrophy regression related to blockage, 80

Alpha adrenergic system, stimulation producing chronotropic and inotropic effects on the heart, 1368-1369

Alpha-adrenoceptors
dilevalol considered as one, 1461-1465
increase of platelets with Raynaud's phenomenon, 45-46
ketanserin and internal mammary artery, 60
Raynaud's phenomenon, 46, 47

Alpha blockers
combined with beta blockers in labetalol for lowering hypertension in blacks, 380
to reverse left ventricular hypertrophy, 427

Alpha-methyldopa, combined with nifedipine for hypertension, 938

Alprenolol, enhanced by diuretic use in elderly, 1274-1275

Ambulatory blood pressure, control by nifedipine, 435-437

Ambulatory monitoring, verapamil 240 SR vs. verapamil 120 SR in arterial hypertension, 1501-1506

Ambulatory radionuclide detector (VEST), nifedipine effect on cardiac function with coronary artery disease, 919-922

AMHT trial, hypertension in the elderly, 948

Amiloride
hemodynamic interactions in hypertensives, 1151-1154
respiratory function in the elderly affected, 1231
STOP-Hypertension Study treatment, 1254

Amiloride congener 6-iodoamiloride, interfering with passive sodium permeability in membranes, 386

2-Amino, 5-phosphono valerate (2APV), 29, 30

Amiodarone
acute hepatitis after loading dose, 1467-1468
antiarrhythmic drug, 532-533
arrhythmias complicating hypertrophic cardiomyopathy, 529

AV nodal tachycardia, 535-538
combination therapy for atrial fibrillation and paroxysmal supraventricular tachycardia, 551
combination therapy with sotalol, 617
combination therapy with flecainide, 1161-1162, 1164
dilated cardiomyopathy, 529
effect on conduction characteristics of AV pathways, 621, 623
inotropic and hemodynamic effects, 546-547
ischemic heart disease, 529
paroxysmal atrial fibrillation, 582
plasma level stability during chronic oral therapy, 529-530
preventing atrial fibrillation in WPW syndrome, 684
proarrhythmia incidence during EPS testing, 539
programmed ventricular stimulation, 556
restrictive cardiomyopathy, 529
shown to reduce mortality in ventricular tachycardia, 653-654
side effects late in developing, 552
systemic hypertension, 529
vagal atrial fibrillation, 581
Wolff-Parkinson-White syndrome, 529

Amiodopine
effect on hypertensive kidney, 1331-1334
exercise hemodynamics in coronary artery disease, 457-462
therapy for reduced left ventricular reserve, 462

Amplification, serotonin effect, 19

Amrinone
cardiotonic agent for congestive heart failure, 1127, 1133
inotropic action, 509, 512
to improve cardiac function, 1411

Anaerobic metabolism, glycolysis in ischemia, 777-788

Anaerobiosis, glycolysis regulation and 777, 778-780

Anaesthesiology, myocardial energy metabolism, 756

Anaesthetics, effects on myocardial adenosine nucleotides, 756

Angina pectoris, *see also* Effort angina; Variant angina after meal phenomenon partially mediated through hemodynamic effects, 496 celiprolol treatment, 1195-1196, 1276, 1291, 1294 diltiazem tablet form treatment, 1089, 1094-1095 elderly hypertensives, 1197 exercise hemodynamics compared for 3 calcium-channel blockers, 457-462 frequency reduced by beta blockers, 675-676 intracoronary nifedipine before coronary angioplasty, 887 nicorandil for treatment, 1075, 1078, 1080-1085, 1453 nifedipine combined with atenolol, 899-903 nifedipine vs. nisoldipine, 451-455 nisoldipine vs. nifedipine, 451-455 nitrate therapy, 249 nitroglycerin oral spray formulations compared, 475-480 pathophysiology, 899-900 percutaneous transluminal coronary angioplasty and, 690 preventive aspects of cardiology, 755 proprionyl carnitine activity evaluated, 481-485 prostaglandin anti-ischemic effect, 1377 symptom for diagnosis of coronary artery disease, 833-838 trimetazidine effect, 820-825 trimetazidine vs. nifedipine for treatment, 853-859 verapamil treatment, 1509

Angiotensin digital vasoconstriction and ketanserin, 46 formation and interactions with bradykinin, prostaglandin, and sympathetic nervous system, 1375-1382 sodium homeostasis and ANP, 1210-1211 stimulating VSMC growth, 239

Angiotensin converting enzyme inhibitors acute and chronic effects on essential hypertensive kidney, 207-214 antiproliferative effect, 1003 cardiac effects, 243-244 class and side effects, 199, 205 combined with flosequinan, 1314 combined with nifedipine for hypertension, 938 comparative structure, 199 coronary blood flow and, 1378-1379 delapril, 1417-1422 diagnostic role for renovascular hypertension, 231 felodipine antihypertensive therapy, 258 for elderly hypertensives, 1193, 1196, 1267

glomerular sclerosis lessened in animals by therapy, 1325, 1328 hemodynamic mechanism of newer anti-hypertensive agents, 1135, 1139-1141 hypertensives not normalizing blood pressure, 376 infarct size, 1381 in renovascular hypertension, 229-234 ketanserin combination for hypertensives, 119-122 mechanism of action, 200-201, 751 myocardial ischemia treatment not recommended as yet, 1375-1382 nifedipine interaction, 964, 966 nondiabetic chronic renal disease affected, 221-225 pharmacodynamics, 199, 203 pharmacokinetics, 199, 201-203 racial differences in response, 338, 380, 381 renal hemodynamic effects, 203-204 reversible myocardial events, 1378-1380 systolic hypertension treatment in the elderly, 1207 therapy of choice for elderly, 1303, 1304 to prevent and/or attenuate hypertension end-organ damage, 197 vagal tone influence without sympathetic activity influence, 267 vascular hypertrophy in hypertension, 237-241 zofenopril oral pretreatment effect on early reperfusion and electrophysiologic stability, 695-702

Angiotensinogen intrarenal effects of angiotensin II, 209 messenger RNA in tissues, 201 produced within the vasculature, 239

Angiotensin II attenuating effect of vasodilating drugs, 249 blockade of effects by saralasin affecting parasympathetic activity, 267 paroxysm interrupted by agents, 229-233 growth stimulant for cardiac muscle and vascular smooth muscle cells, 243 high level in PTH serum as cause of hypertension, 355 intrarenal effects and essential hypertension kidney, 207, 209-210, 213-214 open-heart surgery, 19, 23 pressor sensitivity enhanced by serotonin, 38, 39, 40

Anipamil, antiatherogenic effects and mechanisms of action, 1016-1018

Anistreplase, vs. heparin in acute myocardial infarction trial, 1337-1343

Antacids, decreasing absorption of captopril, 202

Antiarrhythmic drugs classification and spectrum, 532-533 comparative hemodynamics, 545-547 efficacy in ventricular arrhythmia treatment, 669-673 electrophysiologic evaluation, 535-539 flecainide cause of functional hepatic and renal failure, 1164 ketanserin not recommended in combination, 14, 16, 17 safety, 653 stereochemical influences, 541

Antiarrhythmic effects, beta blockade and ischemic heart disease, 675, 676

Antiarrhythmic therapy, propafenone minimum effective concentration values, 281-287

Antisympathetics, racial differences in response among hypertensives, 380

Antithrombin III, preeclampsia, 40

Aortic valve disease, plasma concentrations of atrial natriuretic peptide, 290, 293

Apolipoproteins, nifedipine effect in mild hypertension, 1033-1035

Aprindine, proarrhythmia incidence during EPS testing, 539

Aprinidine, antiarrhythmic drug, 594

Arrhythmias amiodarone treatment when complicating hypertrophic cardiomyopathy, 529 antiarrhythmic therapy overview, 531-534 carotid sinus massage, 532 sotalol treatment, 1425-1431 strategies for management, 532

Arrhythmogenesis, ruled out by acute drug test before using class I antiarrhythmic agents, 653, 654

Arrhythmogenic substrate definition, 560 trigger factors facilitating ventricular tachycardia (VT) or ventricular fibrillation (VF), 555

Arteriolosclerosis, essential hypertensive renal disease and, 209

Arteriosclerosis calcium antagonist influence, 1027-1030 cold pressor responses in the elderly, 1260 essential hypertensive renal disease and, 209

Arteriosclerosis obliterans, 47

Arteriosclerotic hypertension, isolated systolic hypertension in the elderly, 1205

Arterioventricular nodal reentry tachycardia (AVNRT), sotalol for long-term control, 625-627, 628

Aspirin prescribed for percutaneous transluminal coronary angioplasty patients, 688 suppressing diet-induced atherosclerosis in monkeys, 1015 therapy inhibiting serotonin delivery, 138

to control incidence of preeclampsia, 37, 40

Asthma
 beta blocker effect on respiratory function, 1145-1148, 1234-1235
 celiprolol interference in treatment, 1285, 1291
 propranolol side effect, 1516
 respiratory function in elderly and beta blockade, 1229-1232

Asymptomatic ventricular dysfunction, improved by converting enzyme inhibition, 244

Atenolol
 antihypertensive treatment for blacks, 389, 390, 391
 antihypertensive treatment for elderly in trial, 1239
 blood lipid profile affected, 1277
 combination therapy for hypertension, 947, 948
 combined with nifedipine for stable angina, 899-903
 compared to bisoprolol, 261
 dose adjustment when glomerular filtration rates fall, 1273, 1274
 drug interactions, 964, 965
 effect on blood lipid profile in hypertensives with high cholesterol, 1287-1289
 effect on respiratory function in hypertension with chronic obstructive lung disease, 1145-1148
 for black hypertensives, 383
 for LHV regression, 432
 hemodynamic response, 737-742, 1139
 in dilated cardiomyopathy, 505-507
 in-vitro adrenoceptor activities, 1288, 1284
 ischemic heart disease treatment, 676
 ketanserin vs. bendrofluazide administration, 127-128
 no kinetic interaction with nifedipine, 1529
 plasma ANP increase in elderly essential hypertensives, 1211
 pretreatment before nisoldipine or nifedipine for angina pectoris, 451, 452, 453, 455
 reduction of ischemia, 931, 932
 STOP-Hypertension Study treatment, 1254
 to decrease systolic BP in elderly with IISH, 1206
 24-hour action and timing of cardiovascular events, 437
 used with a diuretic in the elderly, 1274
 vs. celiprolol, 1195, 1276-1277, 1284, 1291-1294

Atheroma
 cerebral blood flow with atherosclerosis in elderly, 1218
 formation and hemodynamic factors, 1015, 1018
 formation as evidence of nifedipine long-term benefit, 883, 884

progression of, and nifedipine, 1047-1065
 retardation of, and nifedipine, 1047-1065

Atherosclerosis
 cerebral blood flow in the elderly, 1217, 1218, 1219
 early stage coronary analyzed by coronary angiography in INTACT study, 1037-1044
 ketanserin effect, 61, 123, 125
 nifedipine antiatherosclerotic effect in cholesterol-fed rabbits, 1021-1025
 nifedipine preventing coronary artery disease, 1047-1065
 pathogenesis: state of the art, 993-1003
 progression suppressed by calcium-channel blockers, 1015-1019
 pulse wave velocity affected by nifedipine in chronic hemodialysis patients, 987-990
 regression with lowered plasma lipid levels and elimination of atherogenic diets, 1389, 1391, 1392
 serotonin and hypertension, 5, 9, 11, 13, 1446

Atrial fibrillation/flutter
 class IC drug therapy, 549-550, 552
 conversion followed by sinus rhythm maintenance by sotalol or quinidine, 631
 encainide efficacy, 573, 575, 576
 encainide vs. flecainide for vagal, 579-581
 flecainide treatment, 1161
 sotalol to decrease ventricular rate, 619
 Wolff-Parkinson-White syndrome treatment with propafenone, 681, 682-684

Atrial natriuretic peptide (ANP)
 abnormalities in plasma related to total body sodium in elderly, 1210-1211, 1215
 flosequinan effect, 1395, 1398, 1400, 1401
 levels increasing with age, 1305
 plasma concentrations during physical exercise of congestive heart failure patients, 289-295

Atropine
 autonomic blockade restoring nitrate effects, 250
 sinus node disease treatment with intolerable side effects, 525

Australian National BP Study, systolic vs. diastolic BP for chronic heart disease development, 1204, 1241, 1243, 1302, 1303, 1490

Australian Therapeutic Trial in Mild Hypertension, antihypertensive treatment equally good in elderly as total population, 1253

Automatic implantable cardioverter defibrillator (AICD)

sotalol therapy patients (40%) receiving, 1430

ventricular tachycardia, 615

Autonomic control, age-related changes and beta blockers for hypertension, 1257-1261

Autoregulation, cerebral blood flow, 1217, 1218-1219

AV nodal reentry (AVNR) tachycardia, encainide efficacy, 573, 574, 576

Azaperone, zofenopril in experimental infarction, 696

Baltimore Longitudinal Study on Aging, no age-associated decline in cardiac output, 1257-1258

Baroreceptor reflexes, decreased in the elderly, 1273

Baroreceptors, control of blood pressure changes affected by aging, 1223-1227

Baroreflex, sensitivity with age-related differences, 1258-1259

Bartter's syndrome, calcium excretion lowered by PG synthesis inhibitors, 983

Bay K 8644
 calcium channel agonist influenced by muzolimine, 1477-1480, 1482
 calcium increase in platelets of essential hypertensives, 386
 marked cross tachyphylaxis with milrinone, 512

Benzeprilat, coronary blood flow and lactate production affected, 1379-1380

Bendrofluazide
 antihypertensive drug treatment for elderly in trial, 1239
 compared to ketanserin to reduce adverse symptoms of beta blockade, 127-130
 treatment comparing quality of life with ketanserin treatment, 117

Bendroflumethiazide, antihypertensive treatment for blacks, 390

Bepridil
 AV nodal tachycardia, 535-536
 cardiovascular profile similar to SD-3211, 1474
 vs. SD-3211, 1469

Beta-adrenergic blockade, elderly hypertension and choice of drug, 1267

Beta adrenergic system, myocardial contractility, 1366-1368

Beta-adrenoceptor antagonists
 antianginal actions with nifedipine, 900
 dilevalol adequacy, 1461-1465
 pathophysiologic mechanisms in angina, 899
 xamoterol (intravenously) for sinus node dysfunction, 523-526

Beta blockers
 adverse symptoms reduced by serotonin antagonism, 127-130
 age-related decrease in sensitivity in the elderly, 1261
 antihypertensive effects, 261, 264
 AV nodal tachycardia, 535
 black hypertensives' response lower, 380

as cause of asthma in elderly, 1234-1235
 celiprolol effect on forearm arteries of hypertensive patients, 745-748
 celiprolol pharmacology, 1281-1285
 cold pressor responses in elderly hypertensives, 1271
 combined with calcium antagonist for antihypertensive treatment, 641, 644-645, 647
 dilated cardiomyopathy treatment, 505-507
 effect on plasma lipids in patients with hypercholesterolemia, 1287-1289
 effect on respiratory function in hypertensives, 1145-1148
 efficacy as antihypertensive treatment for blacks, 386, 389-390
 felodipine for hypertension, 253
 for elderly hypertensives, 1193
 hypertrophic cardiomyopathy symptoms improved by, 1517
 kinetics influenced by rifampicin, 490
 negative effect on cardiac output, 545
 nifedipine interaction, 964, 966
 normalizing fibrinolytic system, 676
 plasma triglyceride concentration and HDL cholesterol concentration, 69
 preventing sudden cardiac death, 675
 proarrhythmia incidence during EPS testing, 539
 profile in the elderly, 1273-1279
 racial differences in response, 338
 reducing chronotropic response during LBNP tests, 1259
 respiratory function effects in the elderly, 1229-1232
 side effects in elderly hypertensives, 1271
 sotalol, 1425-1431
 STOP-Hypertension Study results of antihypertensive treatments, 1253-1255
 systolic BP treatment in the elderly, 1207
 therapy of choice for elderly, 1303, 1305 to reverse left ventricular hypertrophy, 427
 types of blockade, 676-677
 vs. sotalol, 598-602
 Beta receptor blockade, hemodynamic mechanism of newer antihypertensive agents, 1135, 1138-1139, 1140
 Beta receptors, lymphocyte for dobutamine evaluation, 1106-1107, 1109-1110
 Beta-thromboglobulin, 46
 preeclampsia concentration, 39
 Bethanidine, cold pressor responses abolished by, 1259
 Bezold-Jarisch reflex, triggered by serotonin, 1444
 BHAT Study
 propranolol given to post-infarction population, 676
 PVCs as risk factors, 651
 BHT 920, selective alpha₂-adrenoceptor agonist, 443, 447, 448
 BHT 933
 alpha₂-agonist inducing ischemic dysfunction, 1379
 to induce alpha₂-adrenergic coronary constriction, 443-448
 Bilateral nephrosclerosis, ACE inhibitors, 204
 Bilateral renal artery stenosis, ACE inhibitors, 204
 Biliary tumors, carcinoid syndrome, 53, 54
 Bisoprolol
 double-blind comparison with captopril for elderly hypertensives, 261-264
 heart rate lowered by, 1464-1465
 vs. dilevalol, 1464-1465
 Blacks
 calcium deficit and low K intake causing hypertension, 403-405
 cellular regulation of sodium, potassium, and calcium, 337
 diuretic monotherapy for hypertension, 379
 diuretic response better than ACE inhibitor response for hypertension, 1439
 diuretics and cation transport with hypertension, 383-386
 diuretics for antihypertensive therapy, 390
 heredity and essential hypertension, 335-336
 hypertension frequency excess confirmed, 317-319
 hypertension prevalence rates based on geography and urbanization, 363
 hypertensive end-stage renal disease, 209
 obesity and hypertension, 395-401
 preeclampsia, 351
 pregnancy-induced hypertension, 351
 proposed mechanisms for essential hypertension, 338-339
 sodium-lithium countertransport and lipid correlations, 361
 sodium, potassium transport systems in essential hypertension, 321-330
 systemic regulation of sodium, potassium and calcium, 336-337
 volume expansion found in hypertensives, 376
 Zulu sodium and potassium urinary and intracellular studies, 363-365
 Blood cells (red), trimetazidine to protect against oxygen free radical damage, 818-819
 Blood component therapy, cardiopulmonary bypass patients, 269-272
 Blood lipid profiles, elderly affected by antihypertensive agents, 1277-1278
 Blood pressure
 calcium treatment, 301
 changes caused by baroreceptors affected by aging, 1223-1227
 felodipine antihypertensive therapy, 255-257
 independent of hypertrophy reversal, 79
 nifedipine vs. hydralazine for lowering, 501-502
 reduction by ketanserin, 97, 98
 techniques, 1301
 Body mass index
 correlated with changes in sodium-lithium countertransport, 357-361
 sodium excretion correlated, 364
 Bohr effect, impaired blood oxygen release in exertional angina, 894
 Bradycardia, produced by bisoprolol treatment, 264
 Bradykinin
 cause of flushes, 55
 interaction with angiotensin, 1375, 1376, 1380, 1381-1382
 released from ischemic myocardium, 702
 salutary effect in congestive heart failure, 199, 201
 stimulation of endothelium, 9
 Bristol-Myers Supraventricular and Ventricular Arrhythmias data base, encainide safety profile, 585-591, 594
 Bronchial tumors
 carcinoid syndrome, 53
 ketanserin during anesthesia and operation, 56
 BTS 53554, flosequinan metabolite, 705, 711
 B-2 study, sudden cardiac death, 651-652
 Bufadienolides, blocking K⁺ vasodilatation, 345
 Build and Blood Pressure Study (1959)
 systolic BP elevation associated with increased mortality, 1203
 systolic vs. diastolic BP for chronic heart disease development, 1204
 Bulbospinal serotonin neurons, 28-30
 Bumetanide
 acquired erythrocyte sodium transport abnormalities, 376
 inhibiting sodium and potassium fluxes, 323
 Na, K, Cl cotransport system inhibited, 385
 Bupranolol, not affecting ZSY-39 positive inotropic effect, 1127-1130, 1132
 BW A575C, beta blocker, vs. celiprolol, 1281, 1282
¹⁴C-5HT, 106
 Ca 2⁺ ionophore A23187, stimulation of endothelium, 9
 Caffeine-induced responses, inhibited, and calcium releases, 1348, 1349, 1352
 Calcitonin, serum calcium reduced and atherosclerosis prevented by, 1021
 Calcium
 blockade of entry and nifedipine cardio-protective actions, 877
 cellular regulation differences in blacks vs. whites, 337

deprivation in hypoxic renal injury, 1320, 1321, 1323
 excretion and blood pressure interrelated, 404–405
 free clearance enhanced, 369–370
 hypertension treatment, 301
 nifedipine effect in hypercalcuria, 983–986
 nifedipine effect on metabolism in hypertension, 977
 systemic regulation differences in blacks vs. whites, 336–337
 vascular tone control as assessed by Ca^{2+} indicator aequorin, 1355–1361

Calcium antagonists
 antiarteriosclerotic effects, 1011–1012
 beneficial effects for exertional angina, 893
 clentiazem, 723–729, 1097–1103
 diltiazem in tablet form, 1089–1096
 effect on glomerular filtration rate in kidneys, 1331–1335
 for elderly hypertensives, 1193, 1196
 gallopamil, 1509–1513
 hemodynamic interactions with diuretics for hypertensives, 1151–1155
 hemodynamic mechanism of newer anti-hypertensive agents, 1135, 1139, 1141
 hypertension in the elderly, 948–950
 hypertension-related arteriosclerosis or arteriosclerosis, 1027
 hypertrophic cardiomyopathy symptoms improved by, 1517
 intracellular effects of KT-362, 1345, 1352
 left ventricular diastolic function therapy for impairment, 951–954
 pathophysiologic mechanisms in angina, 899
 reduction of glomerular injury in experimental hypertension, 1325–1329
 renal function affected, 1317
 renal hemodynamics affected, 979–981
 Ro 40-5967 compared to verapamil for negative inotropic effects, 731–736
 therapy of choice for elderly, 1303, 1304
 variant angina treatment, 917
 verapamil 240 SR vs. verapamil 120 SR, 1501–1506

Calcium-channel blockers
 antiatherogenic effects and mechanisms of action, 1015–1019
 antihypertensive effects equipotent in races, 380, 381
 antihypertensive treatment in blacks, 336
 arrhythmias, 532
 elderly hypertensives, 1267
 enhancing LV diastolic filling in coronary artery disease, 1509–1513
 exercise hemodynamics of amlodipine, diltiazem and verapamil, 457–462
 ischemic injury and, 1321–1323
 isradipine as antihypertensive treatment, 413–417
 negative effect on cardiac output, 545
 nifedipine as prototype, 879
 retardation of coronary artery disease in rabbits, 1047
 systolic hypertension treatment in the elderly, 1207
 nifedipine effect in hypercalcuria, 983–986
 Calcium entry blockers (CEB), antihypertensive first-line treatment for blacks, 390–392
 Calcium indicators, calcium role in control of vascular tone assessed by, 1355–1361
 Calcium overload, causal factor in stenosing coronary plaque, 1005–1012
 Calcium release, KT-362 negative inotropic effect, 1345, 1347–1352
 Calcium uptake, muzolimine effect, 1477, 1479, 1481, 1482
 Canine ventricular myocardium, ZSY-39, 1127–1133
 Canrenone, steroid nature of digitalis-like factor, 346
 Captopril
 absorption rate decreased by antacids, 202
 absorption rate modified by food, 201, 202, 205
 active sulphydryl group ACE inhibitor, 199, 200
 autoregulation of cerebral blood flow affected, 1218
 beta-receptor density increased, 1367
 blood pressure and heart rate responses with norepinephrine, 1377
 blood-pressure lowering effect and indomethacin, 201
 blood pressure normalization without Na^+ transport abnormalities, 376–377
 cardiac effects, 244
 cerebral blood flow in rats affected, 1233
 chronic effects on renal function, 212
 combination therapy with nifedipine for hypertension, 965
 congestive heart failure, 205
 coronary blood flow affected, 1378, 1379, 1380
 double-blind comparison with bisoprolol for elderly hypertensives, 261–264
 effect on changes induced by nitroprusside, 250
 effect on forearm arteries of hypertensive patients, 748
 effect on peripheral hemodynamics in hypertensive patients, 751–754
 effect on renal parameters, 204
 elimination kinetics, 203, 204
 glycosuria as side effect with chronic renal failure, 225
 improving reperfusion-induced cardiac dysfunction, 204
 infarct size reduced by, 1381
 interaction with indomethacin, 964
 ketanserin interaction in treating hypertension, 119–122
 left ventricular diastolic function therapy for impairment, 951–954
 limiting infarction expansion, 1371, 1372
 LV diastolic function improved by therapy with, 959
 modest SI reduction, 1140
 pharmacokinetic and pharmacodynamic effects, 202
 plasma renin activity after treatment, 231, 233
 pretreatment to increase sensitivity for detection by isotropic renography, 232
 Raynaud's phenomenon, 49
 renal effects, 207, 211–212
 side effects, 202, 205, 225
 sublingual administration for essential hypertension, 751–754
 sulfhydryl ACE inhibitor, 200, 201
 vs. delapril, 1417
 vs. flosequinan, 1314
 vs. metoprolol, 1278–1279
 Carbachol, ZSY-39 concentration-response curve shifted by, 1127–1129, 1131–1133
 Carbachol, acting on calcium channels activated through phosphorylation, 1483
 5-Carboxamidotryptamine, high agonistic potency, 1459
 Carcinoid syndrome
 flushing reduced by ketanserin, 130
 ketanserin long-term use, 57
 serotonin and therapeutic effects of ketanserin, 53–57
 serotonin release, 51, 138, 139
 Cardiac arrest, incidence and definition in clinical trials, 657, 661–663
 Cardiac Arrhythmia Pilot Study (CAPS), 606
 achievements, 659, 660
 cardiac sudden death, 651
 encainide safety evaluation, 585, 586, 591–592
 sudden death definition, 658
 Cardiac Arrhythmic Suppression Trial (CAST)
 cardiac sudden death, 652–653
 clinical aspects of trial design, 657–664
 encainide safety evaluation, 585, 586, 591–592, 594
 hypothesis that sudden cardiac death can be prevented, 669–670
 signal-averaged ECG ancillary study, 662
 sotalol-propranolol and sotalol-quinidine previous multicenter studies, 610
 Cardiac biochemistry, 756
 Cardiac electrophysiology, definition, 765
 Cardiac myocytes, OPC-8490 effect, 713–717
 Cardiac performance, exercise capacity flosequinan, 1398–1401

Cardiac surgery
 perioperative myocardial protection, 797-803
 serotonin effect on systemic and pulmonary hypertension, 19-24

Cardiac transplantation, arrhythmic management, 559

Cardiology, preventive aspects of, 755

Cardiomyopathy, risk stratification process, 665-666; *see also* Hypertrophic cardiomyopathy

Cardioplegia, distribution during cardiac surgery, 797-800, 802-803

Cardiopulmonary bypass operation
 ketanserin during anesthesia and operation, 56
 platelet loss minimized, 269-272

Cardiopulmonary receptors, neuromodulatory influences of volume effect by aging, 1223, 1225-1227

Cardiopulmonary reflex, 1234
 aging effect, 1225-1227

Cardiotonic agent, ZSY-39 for congestive heart failure, 1127-1133

Cardiovascular diseases
 race/sex differences in mortality, 398
 training effects in the elderly, 1265

Cardiovascular reflexes, training effects in the elderly, 1265

Carnitine
 inhibiting pathways of fatty acid metabolism, 766
 modifying intracellular metabolism of fatty acid intermediates, 788
 tissue level proportionate to coronary flow and damage, 481, 484, 485

Carpal tunnel syndrome, digital artery constriction, 47

Carvedilol
 hemodynamic response to, 1135-1138, 1140
 vs. celiprolol, 1281, 1282

Catecholamines
 ACTH control and cortisol release, 1113
 arterial constrictor action, 137, 138
 carcinoid syndrome, 54-55
 increased in children and adolescents with transport abnormalities, 376
 level during open-heart surgery, 19-22
 loss of, responsiveness, and beta-adrenergic function, 1264, 1267
 nifedipine vs. hydralazine effects, 500-503
 preeclampsia-eclampsia, 38, 40
 Raynaud's phenomenon, 46
 release facilitated by paracrine renin-angiotensin system, 239
 zofenopril and reperfusion damage, 697, 700, 702

Celiprolol
 angina pectoris treatment, 1195-1196
 antihypertensive drug for elderly, 1304, 1305
 bioavailability, 1292
 blood cholesterol and, 1298

blood lipid profile affected, 1277
 different from classic beta blockers, 1276
 dose adjustment when glomerular filtration rates fall, 1273, 1274
 effect on blood lipid profile in hypertensives with high cholesterol, 1287-1289
 effect on forearm artery circulation in hypertensive patients, 745-748
 effect on respiratory function in hypertension with chronic obstructive lung disease, 1145-1148
 elderly patient use, 1298-1299
 evaluation in treatment of mild to moderate hypertension in elderly, 1291-1294
 glomerular filtration rate falling requires dose reduction, 1305
 histamine effect not great, 1234-1235
 hypertension treatment, 1195-1196
 in-vitro adrenoceptor activities, 1288
 pharmacodynamics, 1291
 pharmacokinetics, 1291, 1292, 1294
 pharmacology of, 1281-1285
 qualitative differences between celiprolol and other beta blockers, 1297
 smoking not affecting metabolism in elderly, 1274
 vasodilatory capacity, 1275
 vs. atenolol, 1195, 1276-1277, 1284, 1291-1294
 vs. BW A575C, 1282
 vs. carvedilol, 1282
 vs. dilevalol, 1282, 1284
 vs. enalapril, 1195, 1196
 vs. labetalol, 1282
 vs. metoprolol, 1195, 1277
 vs. nicardipine, 1196
 vs. nifedipine, 1196
 vs. pindolol, 1281, 1284
 vs. propranolol, 1281, 1291-1294

Cell viability duration, 765

Cerebral blood flow (CBF)
 discussion of, 1233-1235
 hypertension and antihypertensive treatment in the elderly, 1217

Cerebrovascular disease, elderly hypertensives, 1197, 1198

Chlormadinone acetate, inhibiting Na, K-ATPase, 345

p-Chloro-phenylalanine, inhibiting serotonin synthesis in carcinoid syndrome, 57

Chlorothiazide
 action transport in black hypertensives affected, 384-385
 hypotensive action with plasma volume decline, 388

Chlorpromazine, plasma protein bindings and encainide, 564

Chlorthalidone
 antihypertensive drug treatment for elderly in trial, 1240, 1241
 combination antihypertensive therapy better than monotherapy, 963

nifedipine interaction, 964-966
 to decrease systolic BP in elderly, 1206

Cholesterol
 accumulation and arteriosclerosis development, 1005-1007
 celiprolol effect, 1195
 decreased with prazosin treatment for hypertension, 416, 417
 hyperlipidemia clinical relevance, 1385-1388
 increased with isradipine treatment for hypertension, 416, 417

nifedipine antiatherosclerotic effect in rabbits fed with, 1021-1025

nifedipine effect on serum lipoprotein metabolism with hypertension, 1033-1035
 reduction with simvastatin and diet with atherosclerosis, 1389-1393

risk factor in INTACT study of coronary artery disease, 1053-1056, 1064, 1065

sodium-lithium countertransport and lipid correlations, 357-361

Cholesterol Lowering Atherosclerosis Study (CLAS), colestipol with niacin for lipid-lowering treatment, 1387, 1392

Cholestyramine
 coronary artery disease treatment, 1064
 hyperlipidemia treatment used in U.S. trial, 1385

lipid-lowering Italian trial, 1387
 lipid-lowering treatment for national study, 1386-1387

Chromosomal aberrations, resulting from O₂ free radical damage in ischemia-reperfusion injury, 800, 801

Chronic bronchitis
 beta blocker effect on respiratory function, 1234
 respiratory function in the elderly and beta blockade, 1229-1232

Chronic glomerulonephritis
 ACE inhibitor effect, 222
 felodipine for hypertension, 254, 256

Chronic heart failure, OPC-8212 long-term efficacy and safety for treatment of, 419-424

Chronic interstitial nephritis, felodipine for hypertension, 254

Chronic ischemic heart disease, sulphydryl donor treatment enhancing nitrate action, 248

Chronic lung disease
 beta-blocker effect on respiratory function in hypertensives with, 1145-1148
 sotalol not used for ischemic heart disease, 1431

Chronic obstructive airway disease (COAD), beta-blocker effect on respiratory function in hypertensives with, 1145-1148

Chronic pyelonephritis, ACE inhibitor effect, 222

Chronic renal failure
angiotensin converting enzyme inhibition effect, 204, 221-225
arterial hypertension treated with felodipine, 253
nifedipine effect on pulse wave velocity, 987-990
nitandipine adequate tolerance, 980
progression attenuated by nisoldipine, 980

Chronic treatment, nifedipine influence on hypertension-induced vascular disease, 1028-1030

Cibenzoline, proarrhythmia incidence during EPS testing, 539

Cilestanine (Tenstaten), antihypertensive drug stimulating prostacyclin synthesis, 377

Cilazapril
coronary blood flow affected, 1379, 1380
enalapril analog not created with lysine residue modification, 200
nonsulfhydryl ACE inhibitor, 200
vs. delapril, 1417

Cimetidine
plasma protein bindings and encainide, 564
vs. ranitidine, 487, 490

Cine-videodensitometry, 1042-1043

Circadian rhythms
ischemic heart disease, 768
PVC rate in sotalol vs. propranolol study, 604-606
PVC rate in sotalol vs. quinidine study, 607-608

Cirrhosis
encainide bioavailability, 563, 564
ketanserin for portal pressure decrease, 33, 34
ritanserin for portal pressure decrease, 34

Class IC drugs, clinical efficacy and side effects, 546, 549-552

Class III drugs
site of action and efficacy, 634
to prolong action-potential duration, 598-600, 602

Clentiazem (TA-3090)
chemical structure, 724
effect on rabbit aorta and myocardium, 723-729
mechanism of action on human coronary artery and myocardium, 1097-1103

Clinical cardiologic research, myocardial energy metabolism, 756

Clinical trials
anistreplase vs. heparin in acute myocardial infarction, 1337-1343
antihypertensive drug therapy discontinuation, 1487-1492
design elements, 657-664

Clofibrate, with nicotinic acid for lipid-lowering Swedish treatment, 1386, 1387

Clonidine
antihypertensive treatment for blacks, 390
antihypertensive treatment for elderly in trial, 1241
antisympathetic agent lowering blood pressure, 380
combined therapy with naloxone for hormone inhibition, 1113-1116
digital vasoconstriction and ketanserin, 46
for LVH regression, 431
hormone release affected when mediated by opiate receptors, 1113-1116
nifedipine interactions, 964, 966
serotonin to mediate hypotensive action of, 27, 30-31
vs. nisoldipine, 1077

Cocaine, with 5-HT antagonists, 1456

Coenzyme Q₁₀, 766

Colchicine, mitosis arrested by, 800

Cold pressor responses, autonomic control in elderly, 1259-1261

Cold pressor test, to select patients for discontinuing antihypertensive therapy, 1492

Colestipol
national study of lipid-lowering treatment, 1392
with niacin treatment in Cholesterol Lowering Atherosclerosis Study, 1387

Collagen, serotonin amplifying platelet reaction, 19-20

Collateral circulation, vasomotor effect by nifedipine and isosorbide dinitrate, 905-907

Competitive inhibition, nifedipine suppressive effect on atherosclerosis, 1024-1025

Computer-assisted contour detection system (CAAS), quantitative cine film analysis of INTACT Study angiograms, 1037-1044

Concentration-dose relationship, heart failure and flecainide with amiodarone therapy, 1161, 1163

Conductance (volume) catheter technique, enoximone effect on end-systolic pressure-volume relationship, 1403-1413

Conduction abnormalities, encainide safety profile, 589-590, 592, 593

Conduction intervals, electrophysiological effects of encainide, 567

Congestive heart failure (CHF)
ACE inhibition therapy side effects, 225
angiotensin converting enzyme inhibitors, 199-205, 243, 244
atrial natriuretic peptide concentrations in plasma during physical exercise, 289-295
beta blocker atenolol treatment study, 505-507
converting enzyme inhibitors, 244

dilatation and remodelling antecedent events following myocardial infarction, 1363, 1367-1368

disopyramide contraindicated, 545
dobutamine treatment, 1105-1106, 1109

encainide efficacy for supraventricular arrhythmias, 577

encainide pharmacokinetics, 564

encainide safety profile, 589, 593

enoximone treatment, 1403, 1411, 1413 favorably modified by OPC-8212 treatment, 419, 424

flecainide contraindicated, 546

flosequinan treatment, 1313-1315, 1395-1401

glycerol trinitrate (NTG) oral spray for hemodynamic unloading, 475

nitrates for treatment of, 247

pireetamide monotherapy acute and chronic effects, 515-520

propafenone aggravating or inducing, 653

sulfhydryl donor treatment enhancing nitrate action, 248, 249

Connective tissue diseases, Raynaud's phenomenon, 47-49

Contractility, enoximone to induce increases, 1406, 1408, 1411-1413

Converting enzyme inhibitors
cardiac effects, 244
for left ventricular hypertrophy regression, 243

pretreatment for salvaging myocardial tissue during early reperfusion, 695, 702

vascular response in hypertension, 239-240

Cope-Warrender General Practice Study, 1239

antihypertensive drug study age characteristics, 1253

no randomized control group, 269

Coronary angiography, anistreplase vs. heparin in acute myocardial infarction, 1338-1340, 1342

Coronary angioplasty, intracoronary nifedipine pretreatment protective effects for myocardial ischemia, 887-890

Coronary arteriography, atherosclerosis in hypercholesterolemic patients, 1389, 1390-1392

Coronary artery bypass graft surgery (CABG), 1338, 1340
atherosclerosis regression on simvastatin, 1391

Coronary artery disease
atenolol effect on cardiac contractility, 741
cause of ischemia, 777
chest pain experienced after meals, 493, 496

exercise hemodynamic comparison of 3 calcium-channel blockers, 457-462

Holter monitoring for evaluating total ischemic burden, 555, 841

ketanserin as vasodilator long-term treatment, 85-87

nifedipine effect, 454

nifedipine effect on cardiac function evaluated with ambulatory radionuclide monitoring, 919-922

nifedipine retardation of (INTACT Study), 1047-1065

nisoldipine treatment, 273, 277, 451

pindolol effect on cardiac contractility, 741

plasma concentrations of atrial natriuretic peptide, 290

progression or regression measured by quantitative coronary angiography, 1037-1044

racial differences in hypertension, 337

reduction in ventricular afterload, 448

total ischemic burden with, 833-838

Coronary artery bypass surgery, ketanserin and systemic arterial hypertension, 20-21, 22-23

Coronary atherosclerosis, correlate of angina, infarction and sudden ischemic cardiac death, 827, 828, 830

Coronary blood flow

- ACE inhibitor effect, 1378-1379
- increased by nicorandil by K-channel opening mechanism, 1119-1126

Coronary dilator, vs. cardiac effects of SD-3211, 1469-1475

Coronary Drug Project, niacin for lipid-lowering treatment, 1386

Coronary heart disease (CHD)

- hyperlipidemia prevention trials relevant, 1385-1388
- NTG oral spray to relieve anginal attacks, 475-480

Coronary plaque tissue, calcium overload factor in development of, 1005-1012

Coronary spasm, serotonin pathogenetic role, 1445

"Coronary steal" phenomenon, nifedipine and coronary collaterals, 907

Coronary stenoses

- vasodilation and nifedipine, 273, 276, 277
- vasodilation and nisoldipine, 273-274, 277
- vasomotility and nisoldipine, 275-276

Coronary vasoconstriction, pathophysiological mechanism when exercise-induced, 893-894

Coronary vasomotion

- ergonovine testing and IV nifedipine, 913
- nisoldipine effect on arteries, 273-278

Coronary vasorelaxation, clentiazem treatment, 1097, 1099-1100, 1102, 1103

Corticosteroids, carcinoid syndrome, 57

Costs

- hypertension therapy, 1439-1441

hypertensive medications as of Feb., 1989 in Dallas, Texas, 1440

Creatine-phosphokinase activity (CPK), trimetazidine antiischemic and reperfusion effect, 808-809

Cromakalim

- protective effects on reperfusion function and infarct size in animal models, 465-473
- reference drug used with nicorandil to increase coronary blood flow, 1119-1125

Cyclandelate, Raynaud's phenomenon, 48

Cycletanine (furopyridine), potassium transport stimulated, 385

Cyclic AMP

- OPC-8490 effect, 714, 716
- ZSY-39 inducing, 1127-1133

Cyproheptadine, carcinoid syndrome, 57

Cysteine, synergistic increase of blood flow with isosorbide dinitrate, 250

Debrisoquine

- minimum effective concentration values for antiarrhythmic therapy, 281-283, 285
- poor metabolism phenotype, 543

Deesterification, to form ACE inhibitors, 201, 202

Delapril

- antihypertensive drug for patients with normal or impaired renal function, 1417-1422
- non sulfhydryl ACE inhibitors, 200
- pharmacokinetics, 1417, 1419-1422
- vs. alacepril, 1417
- vs. captopril, 1417
- vs. cilazapril, 1417
- vs. enalapril, 1417
- vs. ramipril, 1417
- with furosemide for hypertension, 1422

Delayed afterdepolarizations (DADs), trimetazidine effects, 806

Dementia, cerebral blood flow in the elderly, 1217, 1218

Deoxyglucose, ¹⁸F studies of glucose to perfusion ratio and FDG uptake, 850

Depressor effect, delapril on ACE activity, 1420, 1422

Desmethyl-imipramine, plasma protein bindings and encainide, 564

Desoxycorticosterone-salt (DOC-SALT) hypertension, HHR combination therapy, 1327-1328

Dexamethasone, reducing digoxinlike immunoreactivity, 346

Diabetes mellitus

- ACE inhibitors for hypertension studied, 202
- beta blockade and, 1278
- cerebral blood flow in the elderly, 1217, 1218

delapril for hypertension, 1422

essential hypertensive renal disease and, 209

obesity related in black women, 398

race/sex differences in mortality from, 398

serotonin having pathogenetic role, 1446

streptozotocin-induced and enalapril for renal protection effects, 204

Diastolic function

- early regression of abnormalities in hypertension given nifedipine, 957-960
- gallopamil changing, 1512-1513
- nifedipine effect after myocardial infarction, 923-927

Diastolic left ventricular filling

- hypertension and diastolic impairment, 951, 952, 954
- LV diastolic abnormalities and regression with nifedipine, 958, 960

Diazepam, plasma protein bindings and encainide, 564

Diazoxide renal function effect, 979

Diclofenac, hydrochlorothiazide interaction, 965

Diet

- atherogenic elimination for hypercholesterolemic patients with atherosclerosis, 1389-1392
- lipid-lowering treatment, 1385-1388
- nonpharmacologic treatment for hypertension, 1487, 1488, 1491

Diethyldithiocarbamate (DDC), reflecting K⁺ permeability after trimetazidine treatment, 818-819

Digibind, hypertension in PIH treatment, 353

Digitalis

- ACE inhibitors and, 205
- acquired erythrocyte sodium transport abnormalities, 375-376
- addition to trimetazidine for ischemic cardiomyopathy, 862
- AV nodal tachycardia, 535
- congestive heart failure treatment, 515
- derivatives inhibiting the sodium, potassium-ATPase pump, 322

OPC-8212 and OPC-8490 as replacements, 717

withdrawal before OPC-8212 for congestive heart failure, 419, 420

Digitalislike circulating substance, activation resulting in hypertension, 343-347

Digoxin

- cross-reacting with Na, K-ATPase inhibitor, 344-346
- plasma protein bindings and encainide, 564
- supraventricular tachycardias' treatment, 628

Dihydralazine, vs. nicorandil, 1082

Dihydroergocristine (DHEC), vasoconstrictor responses to, 1455-1459

Dihydroergotamine (DHE), vasoconstrictor responses to, 1455-1459

Dihydropyridine
 antiatherogenic effects and mechanisms of action, 1016
 inhibiting incorporation of cholestryl esters into macrophages or myocytes, 1027-1030
 renal functions affected, 979

1,4-Dihydropyridine, derivatives, 723

Dihydropyridine calcium antagonists
 nisoldipine, 273-278

5,7-Dihydroxytryptamine (5,7DHT), 28-30

1,25-Dihydroxy-vitamin D
 blacks demonstrating higher levels than whites, 336
 nifedipine effect, 983-986

Dilated cardiomyopathy
 amiodarone for treatment, 529
 atenolol added to conventional therapy, 505-507
 enalapril to reduce mortality from, 675

Dilevalol
 effects on anesthetized pig with partially occluded coronary artery, 1461-1465
 hemodynamic response to, 1135-1138, 1140, 1141
 in-vitro adrenoceptor activities, 1233
 vs. bisoprolol, 1464-1465
 vs. celiprolol, 1282, 1284

Diltiazem
 antiarteriosclerotic effects, 1011
 antiatherogenic effects and mechanisms of action, 1015, 1016
 antihypertensive treatment for blacks, 391
 antihypertensive treatment similar to isradipine, 416, 417
 AV nodal tachycardia, 535
 cardioprotective effect during ischemia and reperfusion, 808-809
 clentiazem as its derivative, 723-729
 decreasing conduction capacity of AV node, 619
 effect on hypertensive kidney, 1331, 1332, 1334
 effect on hypoxic rat heart, 719-722
 effect on LV mass, 503
 efficacy on coronary vasomotility, 896
 exercise hemodynamics in coronary artery disease, 457-462
 for percutaneous transluminal coronary angioplasty, 689, 690
 increasing death rate when prior myocardial infarction and heart failure signs present, 731
 inhibiting vascular myocyte proliferation and migration, 1027, 1028
 in terms of vasodilation, 936, 937
 isovolumic relaxation time reduction induced by, 954
 lipoprotein metabolism effect, 1033
 LV diastolic filling in CAD enhanced, 1509
 no derivatives except clentiazem, 1097

Raynaud's phenomenon, 45, 47, 50, 938-939
 serum calcium reduced and atherosclerosis prevented by, 1021
 tablet form for hypertension, and angina pectoris, 1089-1096
 vs. clentiazem, 1097, 1100-1103
 vs. KT-362, 1346, 1349
 vs. nardipine, 1530, 1531
 vs. nicorandil, 1084
 vs. nifedipine pharmacologic potency vs. SD-3211, 1469, 1474, 1475

Discriminant function analysis, following percutaneous transluminal coronary angioplasty, 690-691

Disopyramide
 decrease in cardiac output and worsening of congestive heart failure, 545
 onset kinetics, 570, 571
 proarrhythmia incidence during EPS testing, 539
 stereochemical influences, 541

Distance meter method, to measure blood flow velocities, 101

Diuretics
 ACE inhibitors and, 204, 205
 antihypertensive and influencing vascular tone and growth, 240
 antihypertensive treatment for blacks, 389, 390
 bendrofluazide, 127-130
 captopril combination therapy and chronic renal effects, 212
 carcinoid syndrome, 57
 cation transport in black hypertensives, 383-386
 effect greater in the elderly, 1210, 1211
 effect on left ventricular hypertrophy on elderly hypertensives, 83
 enalapril combination for renal artery stenosis, 232, 233
 EWPHE study monotherapy for hypertension, 1249
 felodipine ER-10, 20, 40 mg., 1495, 1498-1500
 felodipine for hypertension, 253
 felodipine treatment and ankle edema, 258
 for lowering blood pressure in black hypertensives, 318, 319
 hemodynamic interactions with calcium antagonists for hypertensives, 1151-1155
 hypertrophy reversal not achieved, 79
 ischemic heart disease, 101
 ketanserin not recommended in combination, 14-17
 monotherapy for hypertension in blacks, 379-381
 piretanide in congestive heart failure, 515-520
 plasma triglyceride concentration and HDL cholesterol concentration, 69
 potassium-losing, 93, 95, 139
 potassium-losing and ketanserin treatment, 117

racial differences in response, 338
 reversibility of sodium pump abnormality, 344
 STOP-Hypertension Study results of antihypertensive treatments, 1253-1255
 therapy of choice for elderly, 1303
 thiazide antihypertensive actions, 13 to increase systolic BP in elderly with ISH, 1203, 1205-1207

Dobutamine
 effects on repeated infusion on chronic heart failure, 1105-1110
 vs. enoximone, 1411, 1413

Doppler echocardiography
 gallopamol effect on LV relaxation and filling dynamics in acute myocardial infarction, 1509-1513
 LV function after nifedipine, 969-974
 nifedipine and LV diastolic dysfunction measured, 923-924, 926
 nifedipine effect on LV diastolic function in hypertension, 951-954

Dose response, diltiazem in tablet form, 1089-1095

Double action drugs, hemodynamic response to, 1140-1142

Double peaks phenomenon, 1180-1182

Doxazosin
 hemodynamic response to, 1135-1139
 LDL receptor activity increased in rabbit fibroblasts, 72

Doxorubicine, trimetazidine effect on cardiac energetics when administered with, 814-815

Drug combinations
 atenolol and nifedipine, 646
 felodipine and beta blockers in hypertension, 644-645, 647
 hydrochlorothiazide and beta-blockers, 646
 nifedipine and atenolol, 646

Drug interactions
 amiodarone and encainide, 564
 anticoagulants and encainide, 564
 antidiabetics and encainide, 564
 antipsychotics and encainide, 564
 beta blockers and encainide, 564
 cimetidine and encainide, 564
 digoxin and encainide, 564
 diuretics and encainide, 564
 encainide, 564
 encainide effect on plasma protein bindings of other drugs, 564
 glipizide, 487, 490
 lidocaine, 564
 lignocaine, 487
 mexiletine, 564
 midazolam, 487, 490
 nifedipine, 487, 490, 564, 963-966
 propantheline, 544
 quinidine, 544
 ranitidine, 487-490
 rifampicin, 487-490
 tertatolol, 487-490

theophylline, 487, 490
warfarin, 487, 490

Drug therapy, elderly hypertensives, 1197-1200

Drug tolerance, nitrate tolerance, 247-250

Drug withdrawal, antihypertensive therapy, 1487-1492

Dysfunctional endothelium, preeclampsia-eclampsia syndrome, 38

Dysopyramide, hemodynamics, 547

Echocardiography
atenolol hemodynamic effects assessed, 737, 738, 742
atenolol in dilated cardiomyopathy, 506
pindolol hemodynamic effects assessed, 737, 738, 742
piretanide monotherapy for congestive heart failure, 516, 517, 520
to determine amount of reversal of left ventricular hypertrophy, 429, 430

Effective renal plasma flow, calcium antagonist effect, 1331-1335

Effective renal plasma flow/renal blood flow (ERPF/RBF), 207-214

Efficacy/tolerance ratio
encainide, 584
flecainide, 584

Effort angina, *see also* Angina pectoris
calcium antagonists' beneficial effects, 893-895
ergometric parameters affected by trimetazidine, 820-823
isosorbide dinitrate vs. nifedipine for exercise tolerance, 905-907
nicorandil treatment, 1083, 1085
nifedipine to increase exercise capacity, 912-913
nifedipine vs. isosorbide dinitrate for exercise tolerance, 905-907
proprietary carnitine activity evaluated, 481-485
trimetazidine combined with nifedipine for treatment, 824-825
trimetazidine vs. nifedipine for treatment, 853-859

Eisenmenger's physiology, clentiazem therapy, 1097

Elderly
angiotensin-converting enzyme inhibitors, 1193, 1196
antihypertensive drug treatment trials, 1237-1247
autonomic control age-related changes and beta blockers for hypertension, 1257-1261
beta blockade effects on respiratory function, 1229-1232
beta blocker use, 1193
calcium antagonist use, 1193, 1196
cilapril for mild to moderate hypertension, 1291-1294
EWPH study results concerning systolic hypertension, 1249-1251

factors in treatment of hypertension, 1263-1267
hypertension and its causes, 1197-1200
neuroendocrine mechanisms and cardiovascular homeostasis, 1209-1212
pulse wave velocity and nifedipine effect in hemodialysis patients, 987, 990
quality of life, 1278-1279, 1304
STOP-Hypertension Study results of antihypertensive treatments, 1253-1255
therapy of choice, 1303-1304
thromboembolic complications from serotonin, 1446

Elderly hypertensives
cerebral blood flow in the elderly, 1217-1220
nifedipine and calcium antagonist therapy, 947-950
nifedipine slow-release for long-term therapy, 941-944

Electrocardiographic changes, propafenone levels in antiarrhythmic therapy, 285

Electron paramagnetic resonance (EPR) spectroscopy, free radical generation in the heart measured, 791-793

Electrophysiologic studies (EPS)
antiarrhythmic drugs, 535-539
arrhythmia causes, 773
encainide, 567-571
encainide for supraventricular arrhythmias analyzed, 574-576
intravenous xamoterol for sinus node dysfunction, 523-526
myocardial energy metabolism, 756
nifedipine, 890
propafenone and WPW syndrome, 681-682
sotalol, 619-621
sotalol efficacy in controlling reentrant supraventricular tachycardias, 625-627
trimetazidine, 808-809

ventricular tachycardia nature and mechanism, 613-615, 617

Wolff-Parkinson-White syndrome, 666
zofenopril pretreatment effect on pig model, 695-702

Enalapril
absorption rate not modified by food, 201, 202, 205
antihypertensive effects and prostaglandins, 201
bioavailability, 202
chronic renal failure patients given stable renal function, 224
combination therapy with nifedipine for hypertension, 965
congestive heart failure, 205
coronary blood flow affected, 1378-1380
diuretic combination for renal artery stenosis, 232
elimination kinetics, 202-204

glycosuria as side effect with chronic renal failure, 225
heart failure survival improved, 1314
interaction with indomethacin, 964
myocardial infarction attenuated by, 1381

nonosulfhydryl ACE inhibitor, 199-201
parasympathetic activity affected, 265-267

pharmacokinetic and pharmacodynamic effects, 202

preventing rise in systemic and glomerular pressure in kidney, 1326, 1327
reducing dilated cardiomyopathy mortality, 675

renal effects, 207, 211-213
renal protective effects, 204
24-hour action and timing of cardiovascular events, 437
vs. celiprolol, 1195
vs. delapril, 1417
vs. ketanserin for essential hypertension, 123-125
vs. ketanserin in elderly hypertensives, 138

Enalapril/Enaprilat, renal effects, 211

Enaprilat, 199

bioavailability, 202
elimination kinetics, 202-203
lisinopril as lysine derivative, 200
pharmacokinetic and pharmacodynamic effects, 202

Enantiomers, 541

Encainide
Cardiac Arrhythmia Suppression Trial (CAST) results showing risk, 659-664
dose adjustment when kidney function is decreased, 561
effect on conduction characteristics of AV pathways, 621
efficacy in supraventricular arrhythmias, 573-577
efficacy/tolerance ratio, 584
electrophysiologic effects, 567-571
hemodynamic effects, 546, 547
increasing death rate in CAST study, 662-664
management of cardiac arrhythmias, 559-560, 633-634
metabolism of, 561-565
onset kinetics, 570, 571
ophthalmologic abnormalities, 591
oral bioavailability, 561-563
overdosage, 591
pharmacokinetics of, 561-565
plasma protein bindings and drug interactions, 564
poor metabolism phenotype, 543-544
prevention of potentially malignant arrhythmias, 654
proarrhythmia incidence during EPS testing, 539
safety profile updated, 585-594
vs. flecainide for chronic resistant par-

oxysmal atrial tachyarrhythmias, 579-584

End-diastolic pressure (EDP), cromakalim effect on reperfusion cardiac function, 467, 470, 471

End diastolic volume (EDV), reduced during exercise, 919, 921-922

Endogenous digoxinlike immunoreactivity (EDLI), 358-354

Endothelin, ischemia effect on receptor density in isolated hearts, 880, 883, 884

Endothelium

- atherosclerosis pathogenesis, 998-999
- calcium-channel blockers to prevent permeation of a macromolecular marker, 1016-1017
- coronary artery contractions shifted, 8
- mediating vascular remodeling, 239
- release of endothelium-derived relaxing factor, 9-11
- structural/functional integrity determining vascular effects of serotonin, 105

Endothelium-dependent relaxing factor

- atherosclerosis and serotonin, 11
- serotonin and action of, 11

Endothelium-derived relaxing factor (EDRF)

- endothelium in atherosclerosis, 998-999
- serotonin and action of, 7-9
- serotonin augmentation, 138
- serotonin causing response in preeclampsia, 38-40

End-stage renal disease

- essential hypertensive renal disease and, 208, 209
- racial differences in hypertension, 337

End systolic pressure-volume relationship, enoximone's unloading effects differentiated, 1403

End systolic volume, reduced during exercise, 919, 921-922

Energy metabolism, myocardial energy metabolism, 756

Enoximone

- cardiotonic agent for congestive heart failure, 1127, 1133
- congestive heart failure treatment, 1403, 1411, 1413
- end-systolic pressure-volume relations using conductance catheter technique, 1403-1413
- vs. dobutamine, 1411, 1413

Enterolactone, inhibiting Na, K-ATPase activity, 345

Environment, influence on increasing blood pressure with increasing age, 1198

Ephedrine, vs. nicorandil, 1077

4'Epiaudriamycin (4'ADM), hemodynamic effects, 1519-1522

Epidemiology

- hypertension in the elderly, 1197-1200

systolic hypertension in the elderly, 1215-1216

Epidermal growth factor, as vasoconstrictor, 239

Epinephrine

- anginal attacks associated with ST-segment elevation induced by, 894
- pressor response in preeclampsia, 38
- serotonin amplifying platelet reaction, 19-20, 24

Ergonovine, vasospastic potency, 1445

Ergonovine test, after exercise testing and coronary angiography for effort angina, 909-913

Erythrocyte concentration

- dietary sodium variation as environmental factor influence, 329-330
- essential hypertension in blacks, 321-330
- family background as host factor influence, 326-327
- menstrual cycle as host factor influence, 327-328
- oral contraceptives as environmental factor influence, 330
- race as host factor influence, 325-326
- sex as host factor influence, 328-329

Erythrocytes

- deformability after ketanserin administration, 102
- measurement of sodium-lithium countertransport, 357
- Na, K-ATPase activity affected by aldosterone elevation, 335
- sodium concentration affected by ketanserin, 63-66
- sodium content in hypertensives, 368, 369
- sodium transport pathways, 374-375

Essential hypertension, *see also* Hypertension

- ACE inhibitor effect on kidney, 207-214
- compared to renovascular hypertension after captopril treatment, 231
- enalapril therapy, 1417-1422
- 5HT uptake and platelet activation, 105-109
- heredity playing key role in pathogenesis, 335
- ketanserin-captopril interaction, 119-122
- ketanserin effect on microhemodynamics and hemorheology, 101
- nifedipine effect on water-sodium, uric acid, calcium metabolism and aldosterone secretion in hypertension, 977
- nifedipine treatment, 935-939
- serotonin role in pathogenesis, 1445
- verapamil 240 SR vs. verapamil 120 SR therapy, 1501-1506

Essential hypertensive renal disease, pathophysiology, 207-209

Ethacrynic acid

- Na-K-ATPase activity inhibited, 385
- potassium transport stimulated, 385

Etomoxir, inhibition of fatty acid oxidation, 788

European Working Party on Hypertension in the Elderly Trial (EWPHE) antihypertensive drug treatment for the elderly, 115, 947-948, 1193, 1238, 1246, 1302, 1303

antihypertensive treatment benefits the same for both sexes, 1269

application of results to making treatment choices, 1267

drop-outs from study, 1270

key factors in treatment, 1269

study population age and benefit characteristics, 1253

subgroup analyses of results, 1241-1244

systolic vs. diastolic BP for CHD development, 1204

trial results with focus on systolic hypertension, 1249-1251

European Trial on Systolic Hypertension in Patients Aged 60 or More (SYST-EUR), 1251

Evans County, Georgia Study (1980), systolic vs. diastolic BP, 1203-1204

Evening primrose oil, Raynaud's phenomenon, 49

Exercise hemodynamics, newer antihypertensive agents, 1136-1139

Exercise-induced angina, calcium antagonists' effect, 893-896

Exercise testing

- atrial natriuretic peptide plasma concentration effect, 289-295
- autonomic control and cardiovascular performance in the elderly, 1257-1258
- dobutamine increasing tolerance for heart failure patients, 1105, 1106, 1108-1109
- elderly hypertensives, 1264, 1265
- flosequinan, 1314, 1395, 1396, 1398-1400
- hemodynamics of amlodipine, diltiazem, and verapamil, 457-462
- induced ischemia in clinical setting and ACE inhibition, 1379-1380
- nicorandil, 1082-1083
- nifedipine vs. nifedipine in angina pectoris, 452-455
- proprionyl carnitine in effort angina, 481-485
- sodium-lithium countertransport affected, 360-361, 368
- total ischemic burden, 837
- trimetazidine effect in effort angina, 820-823
- trimetazidine vs. nifedipine for effort angina, 853-859

Extended release formulation, felodipine, 1495-1500

Factor VIII consumption, preeclampsia, 39

"Fast" sodium channel, KT-362 primary inhibitory effect, 1350, 1353

Felodipine
effect on hypertensive kidney, 1331-1334
efficacy and tolerability of long-term treatment in hypertension, 641-647
for hypertension with chronic renal failure, 222
hemodynamic interactions with diuretics in hypertensives, 1151-1155
hypertension and impaired renal function treatments, 253-258
hypotensive action 24-hour profile, 439-442
pharmacokinetics and hemodynamic and diuretic/natriuretic effects, 1495-1500
pretreatment abolishing positive response to hyperventilation, 895
profile showing increase in heart rate and cardiac output, 462
to prevent poststenotic myocardial ischemia, 443-448
vs. hydrochlorothiazide, 641-647

Fenfluramine, carcinoid syndrome, 57

Fenofibrate, lipid-lowering Italian trial, 1387

Fibroblasts, cultured human skin affected by HMG CoA reductase, 69-72

Fibronectin, preeclampsia syndrome, 39

Fish-oil capsules, Raynaud's phenomenon, 49

Flecainide
acetate dose-concentration relationship in cardiac arrhythmias, 1161-1164

Cardiac Arrhythmia Suppression Trial (CAST) comparison to encainide, 591

Cardiac Arrhythmia Suppression Trial (CAST) results showing risk, 659-664

conduction abnormalities, 592, 594

drug interactions, 1164

effect on conduction characteristics of AV pathways, 621

efficacy and side effect profiles, 449-552

efficacy in atrial fibrillation, 549, 550

efficacy/tolerance ratio, 584

electrophysiologic effects, 620

hemodynamic effects, 546, 547

increasing death rate in CAST study, 662-664

junctional tachycardias treatment, 550-551

LV function proarrhythmic effect, 559

not useful in controlling atrial fibrillation in WPW syndrome, 684

onset kinetics, 571

poor metabolism phenotype, 543

prevention of potentially malignant arrhythmias, 654

proarrhythmia incidence during EPS testing, 539

proarrhythmic side effects, 552

ventricular arrhythmia treatment, 551-552

ventricular tachycardias' treatment, 550

vs. encainide for chronic resistant paroxysmal atrial tachyarrhythmias, 579-584

vs. quinidine for ventricular tachycardia, 551

Flordipine, antiatherosclerotic effect, 1021

Flosequinan
combined with captopril for severe heart failure, 1313

congestive heart failure treatment, 1395-1401

hemodynamic effects in short term for relief of heart failure, 1313-1314

hemodynamic effects with congestive heart failure, 705-711

vs. captopril, 1314

Flunarizine
antiatherogenic effects and mechanisms of action, 1015-1018

serum calcium reduced and atherosclerosis prevented by, 1021

Flurbiprofen, drug interactions, 965

Flushes
carcinoid syndrome, 53-56
caused by bendrofluazide, 127, 129-130

felodipine, 647

Focal segmental glomerulosclerosis, chronic renal failure and, 222, 223

Folkow's postulate, blood pressure related to wall/lumen ratio, 1199-1200

Forearm blood flow, celioprol effect on circulation, 745-748

Fosinopril, phosphorus-containing ACE inhibitor, 200

Fourier regression, verapamil difference between two treatments for systolic and diastolic BP, 1503, 1505

Framingham Heart Study (1974), 1215, 1285, 1302, 1303

blood pressure rates variable with patient age, 947

cardiovascular disease risk in elderly, 1197-1198

incidence of myocardial infarction unrecognized, 833-834

prognosis for myocardial infarctions, 930

systolic BP and coronary heart disease, stroke, congestive heart failure and intermittent claudication, 1203

systolic hypertension as independent risk factor, 1263

systolic vs. diastolic BP for CHD development, 1204, 1205

Frank-Starling principle, 1264

Free fatty acids, delivery decreased by glucose provision, 787

Free radicals
blunted by nifedipine in silent ischemia, 930

formation during ischemia in isolated rat heart, 791, 794

in postischemic renal injury, 816, 817

not components of clastogenic factors, 800-803

trimetazidine protection of red blood cells against damage by, 818-819

trimetazidine protective effect induced by, 861

French European Eminase Mortality Study (EMS), anistreplase vs. heparin in acute myocardial infarction, 1337-1343

Furosemide
interaction with indomethacin, 964

Functional residual capacity (FRC), effect of pulmonary hypertension following cardiac surgery, 21

Furosemide
cardiac effects induced in guinea-pig atria, 1477-1483

for ventricular dilatation, 244

inhibiting sodium and potassium fluxes, 323, 327, 328

intralymphocytic sodium affected, 364-365

Na, K-ATPase activity inhibited, 385

Na, K, Cl cotransport system inhibited, 385

torsades de pointes following injection of, 615-617

with delapril for hypertension, 1422

Gallopamil
LV relaxation and filling dynamics in myocardial infarction improved, 1509-1513

pharmacokinetics, 1510

verapamil derivative, 723

vs. KT-362, 1347-1348

Gallopamil/verapamil, efficacy on coronary vasomotility, 896

Gemfibrozil, hyperlipidemia treatment used in Helsinki Heart Study, 1385

Gender, as factor in 5HT uptake in hypertensive patients, 105-107

Generics, thiazides, 1440

Genetic control, lipoproteins and receptors, 1001

Glibenclamide
pharmacologic antagonist of K-channel openers, 1119-1126

potassium loss in ischemia decreased by, 784

GLIM package (Generalized Linear Interaction Modelling statistics package), 128

Glipizide, interactions with ranitidine, 487, 490

Glomerular endotheliosus, 38

Glomerular filtration rate
angiotensin II role, 230, 233, 234

calcium antagonist effect, 1331-1335

chronic renal failure and ACE inhibitors, 222, 223

essential hypertensive renal disease, 207-214

felodipine antihypertensive therapy, 254-257

Glomerular hemodynamics, not different in treated and untreated rats, 1328

Glomerular sclerosis, more frequent in hypertrophied nephrectomized group, 1326, 1328-1329

Glucose, ischemia and flux of, 783-788

Glutathione, trimetazidine effect on oxygen radical species in post-ischemic rat acute renal failure, 816-817

Glyburide (glibenclamide), inhibiting protective effects of cromakalim in model, 470-473

Glyceryl trinitrate
clinical efficacy, 247-250
silent myocardial ischemia treatment, 931

Glyceryl trinitrate (NTG) oral spray
bioavailability, 480
hydrophilic formulation vs. lipophilic solution 475-480

Glycogen
complex role in ischemia, 777-788
source of glycogenesis, 778

Glycolysis, maintenance playing role protecting membrane function in ischemia, 777-788

Glycosuria, ACE inhibition side effect for chronic renal failure, 225

Granulocyte aggregation, interaction with morphine in myocardial ischemia, 303

GR 43175, high agonistic potency, 1459

Griseofulvin, Raynaud's phenomenon, 48

Guanabenz
antisympathetic agent lowering blood pressure, 380
isolated systolic hypertension treatment, 1206-1207

Guanadrel, ineffective as monotherapy for hypertension, 380

Guanethidine
antihypertensive drug for elderly in trial, 1240
cold pressor responses abolished by, 1259
ineffective as monotherapy for hypertension, 380
Raynaud's phenomenon, 45, 48, 50

Guanfacine, antisympathetic agent lowering blood pressure, 380

Guinea-pig atria
inotropic action of milrinone on, 509-512
muzolimine and furosemide induced cardiac effects compared, 1477-1483

Gut tumors, carcinoid syndrome, 53

HAPPHY trial, 1246
drugs of choice, 1269

Heart
cardiovascular changes in black and white essential hypertensives, 337-338

imaging of myocardial metabolism, 847-850
rate affected by nifedipine, 924

Heart failure
angiotensin converting enzyme inhibitors, 243-244

diltiazem vs. Ro 40-5967's negative inotropic effect studied, 731, 735

dobutamine repeated infusion effects, 1105-1110

elderly hypertensives, 1197

flecainide with amiodarone effect on dose-concentration relationship, 1161-1164

flosequinan hemodynamic effects, 705

ketanserin as vasodilator long-term treatment, 85-87

muscle energy metabolism, 756

Helsinki Heart Study, lipid-lowering treatment successful in reducing myocardial infarction, 1385

Hemodialysis
nifedipine effects on LV function in hypertensives undergoing, 991-992
nifedipine effect on pulse wave velocity, 987-990

Hemodynamics
aging as cause of changes, 1276-1277
antiarrhythmic drugs, 545-547
atenolol at rest and during isometric exercise, 737-742

calcium-channel blockers, 457-462, 1015

celiprolol better preserving normal function in elderly, 1277

changes in forearm blood flow due to nifedipine, 936-938

deterioration as major side effect of diuretic therapy, 515, 519-520

deterioration in patients with depressed cardiac function, 937

dilevalol, 1463-1465

dobutamine infusion for chronic heart failure, 1107-1109

enoximone, 1403-1413

felodipine, 1495-1500

flosequinan, 705-711, 1396, 1398-1400

interactions between diuretics and calcium antagonists in hypertensives, 1151-1155

nicardipine, 1525-1531

nifedipine, 889-890

nitroglycerin oral spray formulations, 475-480

pindolol at rest and during isometric exercise, 737-742

Ro 40-5967 compared to verapamil, 733-736

sotalol, 1431

sotalol vs. quinidine for arrhythmias, 608

Hemorheology, ketanserin effect with essential hypertension, 101-104

Heparin
at start of percutaneous transluminal coronary angioplasty, 688

bovine vs. porcine for post-operative bleeding, 269-272

chronic renal failure effect, 222

inhibiting VSMC growth and antihypertensive, 240

platelet aggregation, 19, 20

postoperative bleeding affected in cardiopulmonary bypass patients, 269-272

vs. anistreplase in acute myocardial infarction French multicenter trial, 1337-1343

zofenopril in experimental infarction, 696

Hepatic dysfunction, effect on encainide pharmacokinetics, 562-564

Hepatitis, after loading dose of amiodarone, 1467-1468

HEP trial, hypertension in the elderly, 947, 948

Hexamethonium, autonomic blockade restoring nitrate effects, 250

Histamine, carcinoid syndrome, 53-55

HMG CoA reductase activity cultured human skin fibroblast, 69-72, 137

simvastatin for atherosclerosis in hypercholesterolemic patients, 1389-1393

Holter monitoring
atrial fibrillation, 582
atrial tachycardia, 583-584

CAST substudy patients, 661-662

diagnostic use of 24 and 48 hour ambulatory monitoring, 560

encainide efficacy for supraventricular arrhythmias, 575

ischemic cardiomyopathy, 861

risk stratification process for malignant arrhythmias, 665, 667

silent myocardial ischemia, 929-931

simultaneous electrocardiographic recording for nifedipine efficacy in coronary spasm, 916

to detect myocardial ischemia, 841-845

to rule out late arrhythmogenesis, 654

ventricular arrhythmia evaluation, 670-673

ventricular tachycardia, 614, 616

vs. programmed ventricular stimulation, 555-558

Hormone release, clonidine effect when mediated through opiate receptors, 1113-1116

Hospital vs. general practice, ketanserin pharmacokinetics for elderly hypertensives, 89-92

Hyaline arteriolosclerosis, 207

Hydralazine
antihypertensive drug for elderly in trial, 1237, 1240, 1241

cardiac effects, 244

combined with beta blocker to control blood pressure and reduce LVH, 431-432

congestive heart failure treatment, 1395
for hypertension with chronic renal failure, 222
interaction with indometacin, 964
not used for initial hypertension
monotherapy, 1439
preventive cardiology, 755
sinus node disease treatment, 525
stopped before felodipine treatment, 255
third- or fourth-level therapy for hypertension, 380
vs. converting enzyme inhibitors, 240
vs. nifedipine for sympathetic and cardiac function, 499–503

Hydrochlorothiazide (HCT)
antihypertensive treatment for blacks, 391
blood pressure normalization without Na^+ transport abnormalities, 376–377
cation transport in black hypertensives affected, 384–385
combined with hydralazine and reserpine (HHR) to induce decline in resistance, 1326, 1327
combined with oxprenolol when treating black hypertensives, 1275
diclofenac interaction, 965
diuretics for hypertension in elderly, 1238
drug interactions, 965
effect on LV mass, 503
efficacy and tolerability of long-term treatment in hypertension, 641–647
for hypertension with chronic renal failure, 222
hemodynamic interactions with calcium antagonists in hypertensives, 1151–1154
ibuprofen interaction, 965
not a monotherapy to achieve LVH reversal, 432
preferred over propranolol for antihypertensive treatment in blacks, 390
respiratory function in the elderly affected, 1231
STOP-Hypertension Study treatment, 1254
to achieve goal diastolic blood pressures, 428, 429, 431
vs. diltiazem, 1089
vs. felodipine, 641–647
with enalapril to show renal protective effects, 204

Hydrogen, sodium antiport, 339

4-Hydroxy-debrisoquine, minimum effective values for antiarrhythmic therapy, 281–283, 285

6-Hydroxydopamine, pretreatment before methyldopa injection, 30

5-Hydroxyindoleacetic acid (5HIAA)
carcinoid syndrome, 54, 57
excretion higher in hypertensive men than women, 105, 106, 108

4-Hydroxy-3-methoxy-mandelic acid (HMMA), urinary excretion rate related to weight reduction, 400

5-Hydroxy-propafenone, pharmacokinetics and antiarrhythmic effects, 281–287

5-Hydroxytryptamine (5HT), *see* Serotonin

5-Hydroxytryptophan
carcinoid syndrome, 53–55
serotonin synthesized from, 138

Hypercalcemia, nifedipine effect, 983–986

Hypercholesterolemia
cilprolol or atenolol effect on plasma lipids, 1287–1289
endothelium function, 11

Hyperkalemia, ACE inhibitor therapy side effect with chronic renal failure, 225

Hyperkinetic syndrome, serotonin and, 33

Hyperlipidemia, clinical relevance, 1385–1388

Hyperplastic elastic arteriosclerosis, 207

Hypertension, *see also* Essential hypertension
ACE inhibitors and cardiac effects, 243–244
ACE inhibitors for reversal, 199–205
age and increased efficacy of ketanserin, 89
age and LV hypertrophy regression and function changes with ketanserin, 81–84
age related to type of drug used in therapy, 947–950
aging and autonomic control in the elderly, 1257–1261
aging and treatment risk factors, 1263–1267
aging effect on, 1209–1212
antihypertensive drugs available in the U.S., 1440
atherosclerotic complication, 13
beta-blocker effect on respiratory function with chronic obstructive lung disease, 1145–1148
beta blockers and calcium-entry blockers for treatment of blacks, 389–392
bisoprolol vs. captopril in the elderly, 261–264
calcium antagonists to reduce glomerular injury, 1325
calcium deficit and low potassium intake as its cause in blacks, 403–405
captopril, 751–754
cilprolol or atenolol effect on blood lipid profile with hypercholesterolemia, 1287–1289
cilprolol treatment, 1195–1196
cerebral blood flow in the elderly, 1217–1220
cerebral infarcts and hemorrhages, 238
chronic renal failure in nondiabetics and, 222
concomitant diseases and choice of anti-hypertensive drug therapy, 1440
costs of treatment, 1439–1441
diltiazem in tablet form, 1089–1096
discontinuation of antihypertensive therapy, 1487–1492
drug interactions (NSAIDS), 965
drug interactions with nifedipine, 964–966
drugs and lipid profiles affected, 1277–1278
drug therapy response racial differences, 338
early regression of LV diastolic abnormalities if patients given nifedipine, 957–960
elderly, 1197–1200
elderly and ketanserin efficacy and tolerability, 115–117
elderly and ketanserin vs. bendroflauzide for beta blockade symptoms, 127–130
elderly and oral dosing of ketanserin, 111–114
elderly pharmacologic treatment for systolic BP, 1203–1207
enalapril effect on parasympathetic activity, 265–267
environmental factors, 363
erythrocyte sodium transport and abnormalities, 373–377
EWPHE Study results with focus on systolic hypertension, 1249–1251
excess frequency in blacks confirmed, 317
felodipine treatment, 253–258, 641–647
felodipine 24-hour profile of hypotensive action, 439–442
hemodynamic interactions between diuretics and calcium antagonists, 1151–1155
hemodynamic responses to newer antihypertensive agents, 1135–1142
hypertrophy reversal with labetalol or propranolol, 431
isradipine vs. prazosin multicenter treatment comparison, 413–417
ketanserin and carcinoid syndrome, 53
ketanserin effect on LV hypertrophy, 73–75
KT-362, calcium release and cardiovascular disease, 1345–1353
LDL cholesterol reduced by ketanserin, 72
LV function after sublingual administration of nifedipine, 969–974
LV hypertrophy regression with long-term ketanserin, 77–80
mechanisms of, 317–319
membrane transport of ions, 367–370
nicardipine and ambulatory blood pressure control, 435–437
nifedipine effects on LV function in hemodialysis patients with, 991–992
nifedipine effect on serum lipoprotein metabolism with, 1083–1085

nifedipine influence, 1028–1030
 nifedipine slow-release for long-term therapy, 941–944
 nifedipine vs. hydralazine effects on sympathetic activity and cardiac function, 499–503
 obesity in blacks and, 395–401
 pathophysiology, 1263–1267
 portal, and serotonin, 5, 33–34
 postoperative systemic following cardiac surgery, 19–24
 preeclampsia, 37–38
 preventive aspects of cardiology, 755
 race/sex differences in mortality from, 398
 racial differences in therapy, 379–381
 reduced by ketanserin, 133–135
 relationship between age and cardiovascular response to meals, 493–496
 revascular and ACE inhibition, 229–234
 risk factor in INTACT Study of coronary artery disease, 1053–1056, 1065
 serotonin and, 5, 9, 11
 socioeconomic factors, 397–398
 sodium-lithium countertransport and lipid correlations, 357–361
 sodium, potassium, transport systems in black hypertensives, 321–330
 STOP-Hypertension Study results in Sweden, 1253–1255
 tertatolol use and interactions with rifampicin and ranitidine, 487–490
 therapy achievements, 1302–1303
 therapy of choice in the elderly, 1303–1304
 trials in the elderly, 1237–1247
 volume expansion as factor for blacks, 383–386

Hypertension Detection and Follow-up Program Study (HDFP study), 948, 1240, 1243
 antihypertensive treatment equally good in elderly as total population, 1253
 discontinuation of antihypertensive drug therapy, 1490
 systolic vs. diastolic BP for CHD development, 1204
 withdrawal due to adverse reactions, 1298

Hypertension Stroke Cooperative Study, 1243

Hypertension Trial in Elderly Patients in Primary Care (HEP), 1250

Hypertensive nephropathy, felodipine for hypertension, 254, 256

Hypertensive nephrosclerosis, 207, 209, 213
 racial differences in hypertension, 338

Hypertensive retinopathy, racial differences in hypertension, 337–338

Hypertrophic cardiomyopathy, *see also* Cardiomyopathy
 beta blockers to improve symptoms, 1517

calcium antagonists to improve symptoms, 1517
 propranolol vs. verapamil long-term effects preventing sudden death, 1515–1518

Hypertrophy
 left ventricular dysfunction, 1363
 noninfarcted myocardium, 1365–1370
 vascular, and hypertension, 237–240

Hyperventilation, ischemic response abolished by nifedipine, 894–895

Hypoalgesia, ketanserin effect, 133–135

Hypocalcemia, action-potential duration lengthened as antiarrhythmic mechanism, 598–599

Hypoglycemia, beta blockade and, 1278

Hypokalemia
 ketanserin and potassium-losing diuretic treatment, 95
 QT prolongation when diuretic-induced, 139

Hypotension, celiprolol for treatment of elderly, 1291–1294

Hypothalamus, digitalislike circulating factor, 344

Hypothetical hammer syndrome, 47

Hypothyroidism, action-potential duration significantly increased, 598, 602

Hypoxia, diltiazem effect on oxyhemoglobin level in rat heart during, 719–722

Hypoxia of kidneys, calcium time-dependent increase, 1319–1321

Ibuprofen
 hydrochlorothiazide interaction, 965
 infarct expansion affected, 1370

ICS 205930, 29

Idiopathic dilated cardiomyopathy, plasma concentrations of atrial natriuretic peptide, 290

Iloprost, Raynaud's phenomenon, 49

Imaging techniques, 766

Imipramine, conduction abnormalities, 592, 594

Implantable cardioverter defibrillator, to reverse mechanism of sudden cardiac death, 533

Incessant atrial tachycardia, encainide vs. flecainide, 582

Indacrinone, potassium transport stimulated, 385

Indapamide, vasodilation action, 748

Indians of Natal, sodium and potassium urinary and intracellular studies, 363–365

Indolamines, ketanserin depleting stores of, 138

Indomethacin
 abolishing effects of captopril and ramipril in myocardial ischemia, 1380
 blood-pressure lowering effect of captopril and, 201

drug interactions, 964
 pretreatment effect on pressor response, 38, 39

renal prostaglandin synthesis inhibited, 963–964

venoconstriction response to DHEC and DHE experiment, 1456 vs. nicorandil, 1076

Individual therapy, costs for hypertension, 1439–1441

Infarct expansion
 greatest in first, transmural myocardial infarctions, 1363–1365
 prevention of, 1370–1372

Infarct size, reduction in dog models by cromakalim and pinacidil, 465–469, 471–473

Injury, determinants of tissue, 767–774

Inotropic agents, added with muzolimine to compare cardiac effects on guinea pigs, 1478–1483

Inotropy
 enoximone effect, 1411–1413
 milrinone's action on guinea-pig atria, 509–512
 OPC-8212, 713, 716

INTACT Study (International Nifedipine Trial on Antiatherosclerotic Therapy)
 angiographic evaluation features, 1037–1044

nifedipine retardation of coronary artery disease, 1047–1065

Internal mammary artery (IMA), serotonin-induced contractions and ketanserin, 59–61

International Society of Hypertension, antihypertensive treatment recommendations, 1269–1270

INTERSALT Study
 environmental/dietary influences on blood pressure with increasing age, 1198
 weak relationship between elderly salt intake and BP, 1211

Interstitial nephritis, captopril therapy and, 225

Interventional cardiology, angioplasty and, 995–996, 1001–1003

Intimal hyperplasia, response to angioplasty injury, 993, 996

Intraarterial blood pressure, ambulatory measuring technique for decrease by felodipine, 439–442

Intracoronary nifedipine, pretreatment protective effect on myocardial ischemia and dysfunction, 887–890

Intracranial atherosclerosis, racial differences in hypertension, 337

Intraocular pressure (IOP), reduced by ketanserin treatment, 97–98

Intrapulmonary shunting
 ketanserin effect, 19, 21–22, 24

nitroprusside effect, 21

Intravital videomicroscope system (IV-VMS), to record microcirculation kinetics on human bulbar conjunctiva, 101

Intrinsic sympathomimetic activity (ISA)

beta blockers and respiratory function in the elderly, 1230

celiprolol, 1281-1284, 1298

pindolol, 1283

propranolol, 1284

Ion transport

- abnormalities, 374-377
- in hypertension, 367-370
- sodium-lithium countertransport and lipid correlations, 360, 361
- sodium transport and hypertension classifications, 373-377

IPPPSH Study, 1246

Ischemic area, ECG recording and Holter tapes for calculating, 842-845

Ischemic cardiomyopathy, trimetazidine cardioprotective effect, 861-865

Ischemic heart disease

- amiodarone, 529
- brief repetitive episodes causing "stunning" effect, 880, 881
- calcium channel blocker effects, 457-462
- definition, 777
- diuretics effect, 101
- effect on endothelin receptor density in isolated hearts, 880, 882-883
- ergonovine-induced prevented by intravenous nifedipine, 909-913
- flosequinan hemodynamic effects, 705
- free radicals during reperfusion and, 791-794
- glucose to perfusion ratio studied, 850
- intracoronary nifedipine pretreatment protective effects, 887-890
- J-shaped curve present with, 1246
- leading possibility to sudden death, 555
- mechanisms, 827-830
- metabolic pathways and implications of increased glycolysis, 777-788
- mortality and racial characteristic, 398
- nicardipine treatment, 1525-1531
- nicorandil efficacy, 1453
- nifedipine treatment for silent myocardial, 929-933
- race/sex differences in mortality from, 398
- pathophysiology, 835-837
- serotonin having pathogenetic role, 1446
- severity of, 780
- sudden cardiac death prevention, 675-676
- tissue injury determinants, 767-774
- total burden in coronary artery disease, 833-838
- trimetazidine effects on DADs and upstroke velocity of action potential, 806-807
- trimetazidine enzymatic and electrical response in myocardial ischemia model, 808-809
- trimetazidine NMR spectroscopy study in rat heart, 812-813
- trimetazidine's electrocardiographic assessment of properties, 810-811
- ISIS Study, atenolol for ischemic heart disease, 676
- Isolated coronary artery occlusion, nifedipine vs. isosorbide dinitrate effects on exercise tolerance, 907
- Isolated heart (rat), diltiazem effect on oxyhemoglobin level during hypoxia, 719-722
- Isolated systolic hypertension (ISH) drug treatment response, 1250
- most cases "essential" and its prevalence, 1203, 1205-1207
- Isometric exercise, hemodynamic effects of pindolol and atenolol during, 737-742
- Isoprenaline, heart rate response reduced with age, 1234
- Isoproterenol, inotropic effect measured with ZSY-39, 1128, 1129, 1131, 1133
- Isosorbide dinitrate (ISDN)

 - administered before coronary angiography to increase coronary diameter, 1037, 1050
 - cardiac effects, 244
 - LV diastolic function therapy for impairment, 951-954
 - synergistic increase of blood flow when captopril added, 250
 - vs. nicorandil, 1077, 1079, 1080, 1082, 1084-1085, 1453
 - vs. nifedipine on exercise tolerance, 905-907

- Isovolumic relaxation time, LV diastolic function, 952, 954
- Isoxsuprime, Raynaud's phenomenon, 48
- Isradipine

 - antiatherogenic effects and mechanisms of action, 1015, 1016, 1018
 - compared with prazosin for essential hypertension treatment, 413-417
 - effect on hypertensive kidney, 1331-1334

- Italian Multicenter Atherosclerosis Progression-Regression Trial, lipid-lowering treatment, 1387
- Japanese trial (by Kuramoto), 1237, 1243
- Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (1988)
- ISH treatment in elderly with nonpharmacologic therapy, 1206
- risk factors indicating benefit from anti-hypertensive drug therapy, 1487
- J-shaped curve, 1233
- elderly mortality with antihypertensive drug treatment, 1246
- Junctional ectopic tachycardia, encainide efficacy, 573
- Junctional tachycardia, flecainide and propafenone treatments, 550-551
- Kallikrein

 - carcinoid syndrome, 54
 - urinary excretion different in blacks vs. whites, 336, 383

- Kallikrein-kinin-prostaglandin systems, ACE inhibitor effects, 204
- Kallikrein kinin system

 - ACE inhibition therapy, 210
 - differing profile between whites and blacks, 390
 - hypertension incidence correlated in blacks, 317

- KB-944, vs. SD-3211, 1469
- K-channel openers, coronary blood flow increased by, 1119-1126
- Ketanserin

 - acute electrophysiologic effects in humans, 1157-1160
 - age-related antihypertensive efficacy on left ventricular hypertrophy, 81-84
 - antiarrhythmic drugs not recommended in combination, 14, 16, 17
 - antihypertensive actions, 13-14
 - captopril interaction in treating hypertensives, 119-122
 - carcinoid syndrome, 53, 55-57
 - decreasing HMG CoA activity, 137
 - diuretics not recommended in combination, 14-17
 - effect on LV hypertrophy in hypertensive patients, 73-75
 - effect on transmembrane cation transport, 63-66
 - efficacy in elderly hypertensives, 115-117
 - elderly hypertensives and oral dosing, 111-114
 - erythrocyte deformability, 102
 - 5HT₂ blocker, 30
 - 5HT₂ receptor blocker effect on DHEC and DHE, 1459
 - for treating postoperative systemic and pulmonary hypertension, 20-24
 - hemorheology affected in essential hypertension, 101-104
 - hypertension treatment, 1443
 - hypotensive effect mechanism, 7, 10, 11
 - increased efficacy not due to altered pharmacokinetics, 89-92
 - inhibiting S₂ receptor in preeclampsia, 40
 - inhibitor of thrombotic complications of atheroma, 14
 - LV hypertrophy regression during long-term treatment, 77-80
 - mammary artery contractions reversed, 59-61
 - microhemodynamics affected in essential hypertension, 101-104
 - nifedipine interaction, 965-966
 - only 5HT₂-receptor antagonist causing antihypertensive effect, 1445
 - pain perception affected in arterial hypertension, 133-135
 - pharmacokinetics in elderly hypertensives, 89-92
 - portal pressure reduction, 33

preventing early restenosis after percutaneous coronary angioplasty, 15

Raynaud's phenomenon, 45, 46, 48–50, 1445

reducing intraocular pressure due to open-angle glaucoma, 97–98

serotonin neurons and mean arterial pressure, 29

tolerability in elderly hypertensives, 115–117

to lower portal venous pressure, 138

to reduce adverse symptoms of beta blockade, 127–130

as vasodilator long-term treatment for heart failure, 85–87

ventricular ectopic activity suppressed in normokalemic patients, 95

vs. enalapril for essential hypertension, 123–125

Ketanserinol elimination half-life in elderly hypertensives, 89–92

Ketanserin tartrate, effect on HMG CoA reductase activity in cultured human skin fibroblasts, 69–72

Kidneys

- ACE inhibitors and renal impairment, 202–204
- ACE inhibitors in renovascular hypertension, 229–234
- alpha-adrenergic receptor activity, 383–384
- beta blocker effect on elderly, 1274
- calcium antagonists' effects, 1317, 1331–1335
- calcium entry blockers producing effects, 979–981
- calcium handling by renal tubules during oxygen deprivation injury prior to reoxygenation, 1319–1323
- ciloprolol effect on renal function, 1297
- changes in black and white essential hypertensives, 337–338
- enalapril for hypertension with normal or impaired renal function, 1417–1422
- drag-reducing polymers, 297–300
- essential hypertension and ACE inhibitors, 207–214
- felodipine effects, 1495, 1500
- geriatric hypertension affected by function of, 1200
- glomerular injury affected by calcium antagonists, 1325
- impaired renal function and felodipine, 253–258
- last target organ for cotransport abnormalities, 376
- nicardipine renal clearance, 1528–1529
- nitrendipine beneficial effect for hypertension, 1029
- renal disease effect on encainide pharmacokinetics, 562–564
- renal tubular disorders and calcium excretion lowering methods, 983
- trimetazidine effect on oxygen radical species in rat renal failure, 816–817

Kinins, carcinoid syndrome, 53–55

KT-362

- effects on intracellular calcium release, arrhythmias, myocardial ischemia, and hypertension, 1345–1353
- vs. diltiazem, 1346
- vs. nicorandil, 1348
- vs. nifedipine, 1346–1348
- vs. nitroglycerin, 1346, 1348
- vs. nitroprusside, 1348
- vs. quinidine, 1350–1351
- vs. verapamil, 1346, 1350

Labetalol

- alpha blockers and beta blockers in combination for hypertension, 380
- antihypertensive treatment for blacks, 390
- blood lipid profile affected, 1277
- clinical disadvantages of, 1281
- elderly patient use, 1299
- for reversal of LV hypertrophy, 427–432
- in-vitro adrenoceptor activities, 1283
- silent myocardial ischemia treatment, 931
- vs. celiprolol, 1282

Lactate, end product of anaerobic glycolysis, 780–782

Lactate dehydrogenase (LDH) release, cromakalim effect, 467, 470–472

Langendorff perfusion, diltiazem effect studied on oxyhemoglobin level of hypoxic rat heart, 719–720

Left ventricular (LV) diastolic function, hydralazine vs. nifedipine effects, 499–503

Left ventricular (LV) dilatation

- captopril and myocardial ischemia, 1381
- congestive heart failure following, 1363–1372
- prevention of, 1370–1372

Left ventricular (LV) function

- amiodarone and sotalol well tolerated, 546, 547
- anistreplase vs. heparin in acute myocardial infarction trial, 1343
- assessment after nifedipine sublingual administration for hypertension, 969–974
- dobutamine infusion level of benefits related to, 1109
- enoximone effect, 1410–1413
- filling improved by gallopamil, 1512
- flecainide proarrhythmic side effects, 552
- 4'epiadiamycin reversing, 1522
- hemodynamics of nicorandil vs. nitroglycerin effect in conscious dogs, 1449–1453
- ketanserin antihypertensive therapy for elderly patients, 81–84
- LV filling pattern, cardiac index, and nifedipine, 923–927
- nifedipine effect evaluation with an ambulatory radionuclide detector (VEST), 918
- nifedipine effects in hemodialysis hypertensive patients, 991–992
- not impaired by long-term ketanserin treatment, 79, 80
- programmed ventricular stimulation for providing information on, 556

Left ventricular hypertrophy (LVH)

- epidemiology of hypertension in elderly, 1198
- ketanserin effect in hypertensive patients, 73–75
- racial differences in hypertension, 337
- regression achieved by converting enzyme inhibitors, 243
- regression and function changes with ketanserin in elderly hypertensives, 81–84
- regression during long-term ketanserin, 77–80
- reversal by ketanserin, 138
- reversal with labetalol and propranolol, 427–432

Left ventricular (LV) relaxation, gallopamil effect in myocardial infarction, 1509–1513

Left ventricular systolic function, hydralazine vs. nifedipine effects, 499–503

Leukemia, hemodynamic effects of chronic 4'epiadiamycin treatment with, 1520–1522

Leukotrienes, modulating vascular growth, 239

Lidocaine

- decrease in cardiac output and worsening of congestive heart failure, 545–546
- interaction with ranitidine, 490
- onset kinetics, 571
- plasma protein bindings and encainide, 564
- proarrhythmic incidence during EPS testing, 539
- sodium-channel block, 542

Light transmission method, to measure platelet aggregation, 106

Lignocaine, interaction with ranitidine, 487

Lipid-lowering therapy

- chronic renal failure effect, 222
- clinical relevance, 1385–1388

Lipid peroxides

- components of elastogenic material, 800
- thiobarbituric acid reactants as index of, 791–794
- trimetazidine influence, 814–819

Lipid profile, antihypertensive drugs and their effect on, 1277–1278

Lipids

- accumulation as hallmark of atherosclerotic lesions, 1017
- atherosclerosis stabilization on simvastatin with hypercholesterolemia, 1389–1393

celiprolol or atenolol effect with hypercholesterolemia, 1287-1289

correlation with Na, K-ATPase activity, 369, 370

correlation with sodium-lithium countertransport, 368

nifedipine effect in mild hypertension, 1033-1035

role in atherosclerotic plaques, 993-995, 997, 1000

sodium-lithium countertransport and hypertension, 360

Lipoproteins

- hyperlipidemia clinical relevance, 1385-1388
- nifedipine effect in mild hypertension, 1033-1035
- sodium-lithium countertransport and environmental stimuli, 360

Lisinopril

- absorption rate not modified by food, 201, 205
- beta-receptor density increased, 1367
- bioavailability, 202
- congestive heart failure, 205
- elimination kinetics, 203
- interaction with indomethacin, 964
- modest SI reduction, 1140
- nonstiffydril ACE inhibitor and lysine derivative of enalaprilat, 199, 200
- pharmacokinetic and pharmacodynamic effects, 202
- renal effects, 207, 211, 213

Lithium, analogue of potassium and sodium, 323

Liver

- acute hepatitis after loading dose of amiodarone, 1467-1468
- encainide safety evaluation, 591
- hepatitis disease effect on encainide pharmacokinetics, 562-564
- reversible abnormalities of function tests with nicardipine, 437

Long QT syndrome (LQTS)

- beta blockers reducing sudden death rate in, 675
- risk stratification process, 665-667

Lorcainide

- effect on conduction characteristics of AV pathways, 621
- onset kinetics, 571

Low-renin hypertension, blood vessel sensitizing activity with respect to nor-epinephrine, 344, 346

LY 53587, selective 5HT2-receptor antagonist, 1445-1446

Lymphocyte, beta-receptor density tested in dobutamine evaluation, 1106-1107, 1109, 1110

Lymphomas, hemodynamic effects of chronic 4'epidiamycin treatment with, 1520-1522

Mahaim type syndrome, encainide efficacy and AV reentry, 573, 574

Malignant arrhythmias, risk stratification process, 665-667

Malondialdehyde (MDA)

- production not changing with trimetazidine treatment, 814
- reaction with thiobarbituric acid (TBA) studied, 818, 819
- trimetazidine and oxygen radical species in post-ischemic rat renal failure, 816-817

Mammary artery (human), serotonin-induced contractions and ketanserin, 59-61

Mannitol, renal actions, 297-300

MAPHY Trial

- beta-blocker mortality lower than that of diuretic group, 1245
- metoprolol protection against coronary disease, 1439

MCI-176

- cardiovascular profile similar to SD-3211, 1474
- vs. SD-3211, 1469

MDL 72222, 29

Meals, cardiovascular response to and relationship between age, 493-496

Medical Research Council (MRC) Treatment Trial for Mild Hypertensives

- cold pressor responses, 1259, 1302, 1303
- confidence limits not given, 1269
- mild hypertension after drug therapy withdrawal, 1490
- mild hypertension in younger patients, 1243, 1250
- placebo group, 1270
- withdrawal of propranolol from elderly, 1492

Medroxalol, improving forearm arterial compliance, 748

Membrane currents, OPC-8490 effect on, 713-717

Membrane fluidity, hypertensive, 367-370

Membrane potentials, OPC-8490 effect on, 713-717

Mercurials, Na, K-ATPase activity inhibited, 385

Metabolic profile

- enalapril, 123-125
- ketanserin, 123-125

Metabolism (myocardial), imaging by positron emission tomography, 847-850

Metapyrone, increasing digoxinlike immunoreactivity, 346

Metergoline, abolishing pressor response, 28

Methacholine, causing coronary vasoconstriction in patients with variant angina, 1079

Methionine (IV), effect on responsiveness to glyceryl trinitrate, 248, 249

Methiothepin

- antagonizing vasoconstrictor responses to serotonin, dihydroergocristine and dihydroergotamine, 1455-1459
- coronary artery contraction shifted, 8

Methoxamine

- induced responses inhibited by KT-362, 1348
- maintaining aortic pressure at normal level with effort angina, 907

Methoxy-O-desmethyl-encainide (MODE), electrophysiologic properties, 567

3-Methoxy-O-desmethyl-encainide (3-MODE), pharmacokinetics of encainide, 561-565

Methyldopa

- antihypertensive actions, 13
- antihypertensive drug treatment for elderly, 1237
- antihypertensive drug treatment for elderly in trial, 1238-1241
- antisympathetic agent lowering blood pressure, 380
- combination therapy for hypertension, 947, 948
- diminishing LV mass, 73
- EW PHE Study drug treatment, 1269 for LVH regression, 431, 432
- nifedipine interaction, 964, 966
- Raynaud's phenomenon, 48
- serotonin to mediate hypotensive action of, 27, 30-31

Methylene blue, pretreatment effect on pressor response, 39

Methysergide

- carcinoid syndrome, 57
- Raynaud's phenomenon, 46
- serotonin neurons and mean arterial pressure, 29, 30
- to control symptoms of carcinoid syndrome, 139

Metipranolol, ineffective antihypertensive drug for blacks, 389

Metomidate, zofenopril in experimental infarction, 696

Metoprolol

- adverse reactions in elderly, 1273
- antihypertensive actions, 13
- blood lipid profile affected, 1277
- combination therapy effect on anginal frequency, 900
- compared to bisoprolol, 261
- dilated cardiomyopathy treatment, 675
- for LVH regression, 432
- ineffective antihypertensive drug for blacks, 390
- interaction with ranitidine, 490
- ischemic heart disease treatment, 676-678
- maximal comparable workload and LV volume reduced, 484-485
- no kinetic interaction with nifedipine, 1529
- pharmacokinetic interactions, 559
- slow release producing a 24-hour hypotensive response, 437
- smoking not affecting metabolism in elderly, 1274

STOP-Hypertension Study treatment, 1254
vs. captopril, 1278-1279
vs. celiprolol, 1195, 1277

Mexiletine
antiarrhythmic drug, 594
decrease in cardiac output and worsening of congestive heart failure, 545-546
onset kinetics and encainide electrophysiological effects, 570, 571
proarrhythmia incidence during EPS testing, 539
sodium-channel block, 543
stereochemical influences, 541, 542
tolerated by patients with LV dysfunction, 547

MIAMI Trial, metoprolol for sudden death prevention, 678

Microdialysis, 28

Microhemodynamics, ketanserin effect with essential hypertension, 101-104

Midazolam, interaction with ranitidine, 487, 490

MILIS Study, sudden cardiac death, 651-652

Milrinone
cardiotonic agent for congestive heart failure, 1127, 1133
purine compounds involved in inotropic action of, 509-512

Minoxidil
not used for initial hypertension
monotherapy, 1439
stopped before felodipine treatment, 255
third- or fourth-level therapy for hypertension, 380

Mitochondrial function, trimetazidine effect, 814-815

Mitral valve disease, plasma concentrations of atrial natriuretic peptide, 290, 293

Mitral valve prolapse (MVP), risk stratification process, 665, 666

Modulated receptor theory, 541-543

Moduretic Mite, STOP-Hypertension Study treatment, 1254

Monoclonal theory, atherosclerosis, 1002

Monocrotaline (MCT)
heart failure model for trimetazidine and cardiomyopathy administered by, 865
pulmonary vascular injury resulting after administration, 814-815

Moricizine
antiarrhythmic drug used in Cardiac Arrhythmia Suppression Trial (CAST), 591, 594

Cardiac Arrhythmia Suppression Trial (CAST), 659-664
conduction abnormalities, 592

Morphine, interaction with granulocyte aggregation in myocardial ischemia, 303

Mortality
captopril for infarct expansion, 1371
cold pressor responses in the elderly, 1260
EWPHE study results showing decrease in, 1249-1250
intention-to-treat analysis of EWPHE trial, 1238-1239
lipid-lowering treatment effect on rates of coronary heart disease, 1385-1388
major trials and key factors in treatment, 1269
nitroglycerin effect on infarct expansion, 1370
not decreased much by active treatment in antihypertensive trial, 1240-1241, 1243-1245
systolic blood pressure related, 1301-1302

MPIP Study, cardiac sudden death, 651-652

Multiple Risk Factor Intervention Trial (MRFIT), 930, 1487

Screening Study (1988) on systolic vs. diastolic BP for CHD development, 1204, 1205

Multiple-system atrophy (MSA), *see* Shy-Drager syndrome

Muzolimine
cardiac effects induced in guinea-pig atria, 1477-1483
vs. verapamil, 1477, 1479-1480

Myocardial contractility
Ro 49-5967 vs. verapamil for negative inotropic effects, 732-733, 735

Myocardial energy metabolism, 756, 768

Myocardial infarction
ACE inhibitors not yet recommended for treatment, 1375-1382
anistreplase vs. heparin French multicenter trial, 1337-1343
case-fatality rate decreased in EWPHE trial, 1239
elderly hypertensives, 1197
electrocardiogram showing ventricular fibrillation, 1180
gallopamil effect on LV relaxation and filling dynamics, 1509-1513
lipid-lowering treatment and its clinical relevance, 1385-1388
not reduced by hypotensive drug treatment, 1245-1246
prevented by early reperfusion with zofenopril, 695

Myocardial ischemia
ACE inhibitor treatment not yet recommended, 1375-1382
enoximone therapy side effect, 1412, 1413
ergonovine-induced prevented by intravenous nifedipine, 909-913
Holter-detected, 841-845
interaction between morphine and granulocyte aggregation, 303
KT-362 treatment, 1346, 1352-1353

potassium channel activator protective effects, 465-473
prevented by felodipine, 443-448
reperfusion and dilevalol effect during, 1462-1464
total ischemic burden with coronary artery disease, 833-838

Myocardial performance, after 4'epiadrine chronic treatment, 1519-1522

Myocardial protection, perioperative assessment of the quality of, 797-803

Myocarditis, phorbol ester effect on human coronary artery, 1360

Myocyte migration, calcium dependent and inhibited by calcium antagonists, 1027-1028, 1030

Myocyte proliferation, calcium-channel inhibition by calcium antagonists, 1028, 1030

Myosin light chain phosphorylation, contractile force increased in vascular smooth muscle, 1355-1361

N-Acetylcysteine, potentiation of nitrate-induced vasodilation, 248, 249

N-Acetyl metabolite of procainamide (NAPA), lengthening action-potential duration, 599, 602

Nadolol
antihypertensive treatment for blacks, 390
autonomic blockade restoring nitrate effects, 250
blood lipid profile affected, 1277
combination therapy for arrhythmia, 582, 583
dose adjustment when glomerular filtration rates fall, 1273, 1274
for black hypertensives, 383

Nafidrofuryl, antihypertensive properties missing, 7

Naloxone
combined therapy with clonidine for hormone inhibition, 1113-1116
effect on morphine in myocardial ischemia, 303
effect on pain threshold, 135
hormone release affected when mediated by opiate receptors, 1113-1116

Naproxen, drug interaction, 965

National Heart, Lung and Blood Institute Type II Coronary Intervention Study
cholestyramine for lipid-lowering treatment, 1386-1387
cholestyramine to retard CAD progression in Type II hyperlipidemia, 1392

Natriuresis, felodipine as extended-release tablet, 1495, 1498-1500

N-Desmethyl-encainide (NDE)
electrophysiologic properties, 567
pharmacokinetics of encainide, 561-564

Negative inotropic action
clentiazem, 1097, 1101, 1102, 1103
clentiazem and diltiazem effect on rabbit aorta and myocardium, 723-729

cromakalim, 1122, 1125
 KT-362, 1345, 1346, 1352, 1353
 nicorandil, 1121, 1125, 1126
 Ro 40-5967 compared to verapamil, 735
 Neurohumoral regulation, flosequinan effect, 1401
 Neutrophil function, inhibition by morphine, 303
 Niacin
 lipid-lowering Italian trial, 1387
 lipid-lowering treatment in Coronary Drug Project, 1386
 with colestipol in lipid-lowering treatment, 1387
 Niacin derivatives, Raynaud's phenomenon, 48
 Nicardipine
 antiatherogenic effects and mechanisms of action, 1016, 1018
 combined with nifedipine, 1529
 effect on hypertensive kidney, 1331-1334
 kinetics and hemodynamic effects when modified by previous propranolol taken orally, 1525-1531
 lipoproteins metabolism effect, 1033
 nifedipine derivative, 723
 pharmacokinetics, 1527, 1528
 profile showing increase in heart rate and cardiac output, 462
 Raynaud's phenomenon, 47, 938-939
 serum-calcium reduced and atherosclerosis prevented by, 1021
 sustained release with 24-hour blood pressure control, 435-437
 vs. celiprolol, 1196
 vs. clentiazem, 1530, 1531
 vs. nifedipine, 1531
 vs. verapamil, 1530, 1531
 Nicorandil
 acute myocardial ischemia treatment, 1079
 angina pectoris treatment, 1075, 1078, 1080-1083, 1453
 cardioprotective properties, 473
 coronary blood flow increased by K-channel opening mechanism, 1119-1126
 dosage and administration, 1084-1085
 drug interactions, 1084
 pharmacodynamics, 1080-1081
 pharmacokinetics, 1080-1081
 pharmacology and therapeutic effects of, 1075-1085
 side effects, 1083-1084
 therapeutic trials, 1081-1083
 vs. isosorbide dinitrate, 1453
 vs. KT-362, 1348
 vs. nitroglycerin LV effects in dogs, 1449-1453
 Nicotine, interaction with beta blockers, 1273, 1274, 1276
 Nicotinic acid
 cause of flushes, 55
 lipid-lowering treatment, 1386, 1387

Nifedipine
 after-drug effect, 917-918
 antiatherosclerotic effect in cholesterol-fed rabbits of, 1021-1025
 antiarteriosclerotic effects, 1012
 antiatherogenic effects and mechanisms of action, 1015, 1017-1018
 antihypertensive drug treatment for elderly in trial, 1239-1240
 antihypertensive treatment for blacks, 391
 antihypertensive treatment similar to isradipine, 416, 417
 bioavailability, 455
 blunting the degree of LV dysfunction from ischemia, 930
 cardiac function with coronary artery disease evaluated with ambulatory radionuclide monitoring, 919-922
 cardioprotection and, 875, 877
 causing early regression of LV diastolic abnormalities in hypertensives, 957-960
 clearance affected by propranolol, 1529
 combination therapy with captopril for hypertension, 965
 combination therapy with enalapril for hypertension, 965
 combined with atenolol, 646-647
 combined with atenolol for stable angina, 899-903
 combined with propranolol for angina, 900, 901
 combined with trimetazidine for effort angina, 824-825
 coronary artery disease retardation: results of INTACT Study, 1047-1065
 derivatives, 723
 drug interactions, 964-966
 drug interactions in hypertensive patients, 963-966
 drug interactions with NSAIDS, 963-964
 drug interaction with ranitidine, 487, 490
 effect on forearm arteries of hypertensive patients, 748
 effect on hypertensive kidney, 1331, 1333, 1334
 effect on LV diastolic dysfunction after myocardial infarction, 923-927
 effect on LV diastolic function in hypertension, 951-954
 effect on plasma triglycerides, plasma cholesterol, and sudanophilic lesions, 880-884
 effect on water-sodium, uric acid, calcium metabolism and aldosterone secretion in hypertension, 977
 experimental cardioprotection and, 879-884
 glomerular sclerosis reduced, 1327, 1328
 increasing exercise duration for chronic stable angina, 894-896

influence on angiographic progression of coronary artery disease, 1037-1044
 influence on experimental arteriosclerosis, 1027-1030
 intravenous to prevent ergonovine-induced myocardial ischemia with effort angina, 909-913
 ketanserin interaction, 965-966
 LV diastolic filling in CAD enhanced, 1509
 LV diastolic function therapy for impairment, 951-954
 LV function after sublingual administration for hypertension, 969-974
 LV function in hemodialysis hypertensive patients, 991-992
 maximal comparable workload and LV volume changes, 484-485
 myocardial ischemia and dysfunction and, 887-890
 oxyhemoglobin level increased in hypoxic rat heart, 719
 prescribed for percutaneous transluminal coronary angioplasty patients, 688-690
 preventive aspects of cardiology, 755
 pulse wave velocity of chronic hemodialysis patients, 987-990
 Raynaud's phenomenon, 45, 47, 49-50
 reduction of vascular resistance and increase of heart rate and cardiac output, 462
 serum calcium reduced and atherosclerosis prevented by, 1021-1025
 serum lipoprotein metabolism with mild hypertension, 1033-1035
 silent myocardial ischemia treatment, 931-933
 slow-release efficacy on ischemic attacks with variant angina, 915-918
 slow-release for hypertension in the elderly, 948-950
 slow-release long-term essential hypertension therapy, 941-944
 slow release producing a 24-hour hypotensive response, 437
 stopped before felodipine treatment, 255
 "stunned" myocardium affected, 880 to prevent poststenotic alpha-adrenergic-mediated vasoconstriction, 443, 448
 urinary excretion in hypercalcemia, 983-986
 use in hypertension and Raynaud's phenomenon, 935-939
 vs. celiprolol, 1196
 vs. clentiazem, 1097, 1100-1103
 vs. hydralazine for sympathetic and cardiac function, 499-503
 vs. isosorbide dinitrate on exercise tolerance, 905-907
 vs. KT-362, 1346-1348
 vs. nicardipine, 1531
 vs. nicorandil, 1078, 1081, 1082, 1084

vs. nisoldipine for angina pectoris, 451-455
vs. trimetazidine for effort angina, 853-859

Nifedipine-TIAP Study, nifedipine treatment of silent ischemia, 932, 933

Nilvadipine, antiatherogenic effects and mechanisms of action, 1016, 1018

Nimodipine
antiatherogenic effects and mechanisms of action, 1016-1018
nifedipine derivative, 723
preventing vascular lesions, 1029, 1030

Nisoldipine
antiatherogenic effects and mechanisms of action, 1016
bioavailability, 455
chronic renal failure progression attenuated, 980
compared to nifedipine for angina pectoris, 451-455
hemodynamic response to, 1135-1139
nifedipine derivative, 723
nifedipine electrophysiologic effects compared to, 890
oxyhemoglobin level increased in hypoxic rat heart, 719
profile showing increase in heart rate and cardiac output, 462
Raynaud's phenomenon, 47
vasodilatory effects on coronary arteries, 273-278
vs. nifedipine for vascular selectivity, 937

Nitrites
antiischemic mechanisms, 905
isolated systolic hypertension treatment, 1206
tolerance, 247-250
tolerance level affected by nitroglycerin, 1079, 1083

Nitrendipine
antihypertensive treatment for blacks, 386, 391, 392
chronic renal failure patients with adequate tolerance, 980, 981
effect on hypertensive kidney, 1331, 1333, 1334
effect on LV mass peak filling rate, 503
glomerular injury reduced in DOC-SALT rats, 1328
increases in plasma norepinephrine during treatment, 499
influence on hypertension-induced vascular disease, 1028-1029
nifedipine derivative, 723
vs. nifedipine for vascular selectivity, 937

Nitroglycerin
allowed during trimetazidine vs. nifedipine study, 854, 855
antiischemic effects of pretreatment, 889
combined with clentiazem, 1098

effort angina, nifedipine and coronary collaterals studied, 906
ischemic changes relieved during ergonovine maleate test, 910
maximal comparable workload and LV volume changes, 484-485
metabolism requiring sulphydryl group interaction, 247-250
oral spray hemodynamic and coronary vasodilatory action, 475-480
parallel reductions in number of anginal episodes, 981
preventing infarct expansion, 1370-1371
preventing narrowing of stenoses during exercise, 894
reduction in LV filling pressure, 927
reference drug used with nicorandil to increase coronary blood flow, 1119-1121, 1123-1125
sublingual for angina pectoris, 451, 452
trimetazidine combined with nifedipine in effort angina, 824-825
variant angina treatment, 916, 917
vasorelaxation induced in rabbit aorta, 724
vs. KT-362, 1346, 1348, 1349
vs. nicorandil, 1076-1080, 1082-1083
vs. nicorandil LV effects in dogs, 1449-1453
Nitroglycerin ointment, Raynaud's phenomenon, 45, 48

Nitroprusside
cardiac effects, 244
vasodilating drugs effect attenuated after withdrawal, 249, 250
vasodilator action activated, 1379
vs. ketanserin for systemic hypertension after cardiac surgery, 19, 21-22
vs. KT-362, 1348

Nitroprusside-like drugs, isolated systolic hypertension treatment, 1206

N-methyl-D-aspartate (NMDA), 30

Nondiabetic chronic renal disease, angiotensin converting enzyme inhibition effect, 221-225

Nonhydroxypyridine calcium antagonist, SD-3211, 1469-1475

Non-insulin-dependent diabetes mellitus (NIDDM), obesity as risk factor, 398

Nonmodulators, 214

Nonpharmacological treatment, dietary management of hypertension, 1487, 1488, 1491

Non-steroidal antiinflammatory drugs (NSAIDs)
antihypertensive drug interactions, 965
inhibition of prostaglandin synthesis effect, 963, 966
interactions with nifedipine, 963-964

Nonsulphydryl ACE inhibitors, 200

Nonsustained ventricular tachycardia (NSVT), marker of sudden cardiac death, 669-672

Noradrenaline, carcinoid syndrome, 56

No-reflow phenomenon, 774

Norepinephrine (NE)
as alpha-adrenoceptor agonist in isolated rat aorta, 1282
attenuating effect of vasodilating drugs, 249
depletion from sympathetic nerve endings with nifedipine, 502
differential attenuating effect, 1334
dobutamine trial evaluation for chronic heart failure, 1106, 1108, 1110
increased in the elderly after meals, 496
increases during treatment with nitrindipine, 499
induced responses inhibited by KT-362, 1348-1349
low-renin hypertension, 344, 346, 347
mammary artery contractions and ketanserin, 60
pressor response in preeclampsia, 38
Raynaud's phenomenon, 48
release inhibited by ACE inhibitors, 210
serotonin amplifying platelet reaction, 19-20, 24
stimulating cell growth later blocked by terazosin, 431
vascular reactivity decreased by chlorothiazide, 383
weight reduction of obese patients related to level of, 400

Norverapamil, plasma levels, 1503, 1505, 1506

Nuclear magnetic resonance spectroscopy (NMR), antiischemic effects of trimetazidine studied, 812-813

Nystatin, enhancing cell membrane permeability during sodium loading, 323

Oakley Study, nifedipine combined with propranolol, 931

Obesity
hypertension in blacks and, 395-401
socioeconomic factors, 396-398

Obesity-associated hypertension, 395-401
mechanisms, 400
physiologic characteristics, 399-400
sodium sensitivity, 400-401

O-desmethyl-encainide (ODE)
electrophysiologic properties, 567-570
pharmacokinetics of encainide, 561-565

OPC-8212
inhibiting PDE activity, 713, 716
long-term efficacy and safety for mild chronic heart failure, 419-424

OPC-8490, effect on membrane potentials and membrane currents of guinea-pig myocytes, 713-717

Open-angle glaucoma, intraocular pressure reduced by ketanserin, 97, 98

Open-heart surgery, catecholamine level, 19

Oral spray, nitroglycerin formulations compared, 475-480

Organ and tissue blood flows, dilevalol effect, 1464-1465

Osler test, 1301

Oslo Primary Prevention Trial, lipid-lowering treatment successful in reducing myocardial infarction, 1385, 1386, 1388

Oxfenicine, inhibiting fatty acid oxidation, 788

Oprenolol

- blood lipid profile affected, 1277
- combined with hydrochlorothiazide when treating black hypertensives, 1275
- effect on respiratory function in hypertension with chronic obstructive lung disease, 1145–1148
- enhanced by a diuretic in elderly treatments, 1275
- ineffective antihypertensive drug for blacks, 390
- interaction with indomethacin, 964

Oxygen free radicals, trimetazidine protecting human red blood cells against damage from, 818–819

Oxygen paradox, damage occurring during reperfusion, 767, 769

Oxygen radical species, trimetazidine effect in post-ischemic acute renal failure in rat, 816–817

Oxymyoglobin, diltiazem effect in hypoxic rat heart, 719–722

PACK (prevention of Atherosclerotic Complications with Ketanserin) trial, 13–15, 93, 95, 139

Pain, perception in arterial hypertension affected by ketanserin, 133–135

Pancreatic tumors, carcinoid syndrome, 53

Papaverine, Raynaud's phenomenon, 48

Parachloromercuribenzoate, enhancing cell membrane permeability during sodium loading, 323

Parachlorophenylalanine, preventing pressure increase, 27

Paracrine renin-angiotensin system, hypertension affected, 237–240

Parasympathetic activity, enalapril effect, 265–267

Parathyroid hormone (PTH)

- blacks demonstrating higher levels than whites, 336
- nifedipine effect, 983–986
- regulation of serum and cell calcium levels as protection against vascular lesions, 1029, 1030

Parkinson's disease

- lung function in elderly and beta blockade, 1229
- tendency to postural hypotension, 1265

Paroxetine, 106

Paroxysmal atrial fibrillation

- encainide vs. flecainide for treatment, 581–582
- flecainide treatment, 1161

Paroxysmal atrial tachyarrhythmias, encainide vs. flecainide for treatment, 579–584

Paroxysmal supraventricular tachycardia, propafenone preventing atrial fibrillation, 684

Partial agonist activity (PAA), celiprolol, 1291

Pathophysiology, hypertension in the elderly, 1197–1200

Penbutolol, antihypertensive treatment for blacks, 390

Penicillin, supplement in culture of human skin fibroblasts, 69

Pentagastrin, carcinoid syndrome, 55, 56

Percutaneous transluminal coronary angioplasty (PTCA), 232, 1338, 1340

- risk stratification after, 687–692

Perindopril

- coronary blood flow affected, 1380
- nonsulphydryl ACE inhibitor, 200
- Perindopril, hemodynamic response to, 1135–1139

Peripheral artery disease, elderly hypertensives, 1197

Peripheral hemodynamics, captopril effect in essential hypertension, 751–754

Peripheral vascular disease, serotonin pathophysiologic role, 1444–1445

Peripheral vascular resistance, flosequian, 1395, 1397–1399

Pertussis toxin, endothelium-derived relaxing factor and, 8, 9, 11

Pharmacogenetics, antiarrhythmic agents, 541, 543–544

Pharmacology

- myocardial energy metabolism, 756
- nicorandil, 1075–1080

Phenazine methosulfate (PMS), erythrocyte treatment in which K⁺ loss and free radical generation observed, 818–819

Phenoxybenzamine

- carcinoid syndrome, 54–55, 57
- Raynaud's phenomenon, 48

Phentolamine

- alpha-adrenoceptor blocking drug effect on dihydroergocristine, 1459
- arterial blood pressure, 23
- blocker for hypotensive action of methyldopa, 30
- potentiated antihypertensive action by ritanserin, 137

Phenylephrine

- alpha-agonistic effect, 22–23
- digital vasoconstriction and ketanserin, 46
- increase in force in vascular smooth muscle, 1357–1358
- portal pressure rise induced, 33

Phenylethanolamine-N-methyl transferase (PNMT), 29

8-Phenyltheophylline

- inotropic effect in muzolimine study of guinea-pig atria, 1477–1483

purine compound inotropic effects antagonized by, 512

Phenytoin, antiarrhythmic drug, 594

Phloretin, inhibiting sodium-lithium countertransport, 323

Phosphofructokinase, factors accelerating activity during anaerobiosis, 778–781, 787

Phosphoinositide system, 370

Phospholipids, fatty acid composition affected by hypertension, 369, 370

Phosphorus-containing ACE inhibitors, 200, 202

Pig, zofenopril pretreatment model for early reperfusion and subsequent electrophysiologic stability, 695–702

Pinacidil

- hemodynamic response to, 1135–1138, 1140
- protective effects on reperfusion function and infarct size in animal models, 465–473

Pindolol

- antihypertensive drug treatment for elderly in trial, 1241
- blood lipid profile affected, 1277
- dilating large arteries as well as arterioles, 745
- for black hypertensives, 383
- hemodynamic effects at rest and during isometric exercise, 737–742
- ineffective antihypertensive drug for blacks, 390
- interaction with indomethacin, 964
- intrinsic sympathomimetic activity (ISA) affected, 525
- silent myocardial ischemia treatment, 931
- sinus node dysfunction treatment, 525
- STOP-Hypertension Study treatment, 1254
- vs. celiprolol, 1281, 1284

Pirbuterol, lymphocyte beta-receptor levels decreased by, 1110

Piretanide, diuretic monotherapy in congestive heart failure, 515–520

Piridoxilate, cardioprotective effect during ischemia and reperfusion, 808–809

Piroxicam

- propranolol interaction, 965
- timolol interaction, 965

Piroximone, cardiotonic agent for congestive heart failure, 1127

Pituitary hormone release, clonidine effect when mediated through opiate receptors, 1113–1116

Pivalopril, sulfhydryl ACE inhibitor, 200

Pizotifen, 5HT₂-receptor blocker and contractile responses to DHEC, 1459

Placebo, failure of therapy for congestive heart failure piretanide study, 520

Plaques

- progression/regression of, 1386–1387
- severity of, 1009–1010

Plasma concentrations, correlated to mean arterial pressure in diltiazem trials, 1092, 1094, 1095

Plasma protein binding, encainide with various drugs, 564

Plasma renin activity (PRA) alterations impaired by cardiopulmonary receptors in elderly, 1225 black hypertensives, 383, 384 blacks vs. whites, 336, 338, 339 calcium-channel blockers for systolic BP in elderly with decreased, 1207 for classifying essential hypertensive patients, 373, 376 hypertensive Zulus and Indians, 364 nifedipine vs. hydralazine effects, 500-501 raised by potassium supplementation in blacks, 404 zofenopril in experimental infarction, 697-699

Plasma volume, decreased with slow-release nifedipine for hypertension, 977

Platelet aggregation, heparin and prothrombin effects postoperative bleeding with cardiopulmonary bypass, 269-272

Platelet-derived growth factor, vascular hypertrophy, 239

Platelets sensitivity to 5HT affected by age, 105, 108 serotonin stored to alter vessel reactivity, 38-40

Polyctic kidney disease, felodipine for hypertension, 254

Polyox, renal actions, 297-300

Portal hypertension, *see* Hypertension

Positive inotropic effect glibenclamide, 1126 isoproterenol, 1127, 1132 ZSY-39, 1127-1129, 1131-1133

Positron electron tomography, 766

Positron emission tomography, direct monitoring of enhanced glycolysis, 777 myocardial metabolism imaging, 847-850

Post-myocardial infarction encainide therapy risk increased, 594 risk stratification process, 665, 666

Postoperative bleeding, heparin used for cardiopulmonary bypass patients, 269-272

Postoperative pulmonary hypertension, serotonin effect, 19-24

Postprandial hypotension, age correlation, 493-496

Post-Treatment Study of Hypertension in the Elderly (POTS-Hypertension), antihypertensive drug treatment trial, 1255

Postural hypotension dihydroergotamine treatment, 1455 in the elderly, 1301

Potassium cellular regulation differences in blacks vs. whites, 337 elderly susceptibility to hypokalemia, 1211 erythrocyte concentrations and transmembrane fluxes of, 321-330 intracellular concentration in essential hypertension, 323-324 loss from diuretics used with ketanserin, 14-17 loss in ischemia, 784 supplementation effect on blood pressure, 403-404 systemic regulation differences in blacks vs. whites, 336-337 urinary intracellular studies of blacks and Indians, 363-365

Potassium channel activators, cromakalim and pinacidil protective effects, 465-473

Potassium channel opener, hemodynamic response to, 1140

Potassium-sparing diuretics, drug-reducing polymers, 297-300

Potential-dependent calcium entry, KT-362 effect, 1351

Practolol, respiratory function affected in the elderly, 1230, 1231

Prazosin cardiac effects, 244 confirmation of alpha-1 blockade, 380 congestive heart failure treatment, 1395 decreasing HMG CoA activity, 137 elderly susceptible to postural hypotensive effects of, 1212 first-dose reaction with marked hypertension, 1139 HMG CoA reductase activity in cultured human skin fibroblasts, 69-72 interaction with indomethacin, 964 in-vitro adrenoceptor activities, 1283 nifedipine interaction, 964 not able to block LVH regression, 431 phenolamine used in its place before, 23 preventive cardiology, 755 Raynaud's phenomenon, 45, 47-48, 50 reinforced by ritanserin, 137 stopped before felodipine treatment, 255 vs. isradipine for essential hypertension treatment, 413-417

Preeclampsia incidence in blacks, 351 serotonin role in, 5, 37-41, 128

Pregnancy, increase in sodium-lithium countertransport, 357

Pregnancy-induced hypertension (PIH), sodium transport inhibitors, 351-355

Preload reduction of LV, antiischemic action of nicorandil, 1449-1453 reduction of only LV end-systolic dimension decreased by nifedipine (afterload), 971-972, 974

Premature ventricular contractions (PVCs) risk marker of sudden cardiac death, 651, 653 suppression using sotalol, 603-610

Prenalterol, treatment effects similar to xamoterol, 526

Prenylamine, antiarteriosclerotic effects, 1011

Preventive aspects of cardiology, 755

Primary aldosteronism, nifedipine decrease of mean arterial pressure, plasma aldosterone and potassium clearance, 977

Prinzmetal's angina, coronary vasoconstrictive role, 893, 1445

Proarrhythmia of antiarrhythmic drugs observed during electrophysiologic evaluation, 539 definition of early effect, 672 encainide safety profile, 587-589, 593 encainide treatment reaction in supraventricular arrhythmias, 576 side effects of propafenone and flecainide, 552 sotalol, 1431 sotalol in reentrant ventricular tachycardia, 614-617

Procainamide antiarrhythmic drug, 594 decrease in cardiac output and worsening of congestive heart failure, 545 effect on conduction characteristics of AV pathways, 621 onset kinetics, 571 proarrhythmia incidence during EPS testing, 539

Prodrugs, converted by liver into active ACE inhibitors, 200, 201

Programmed electrical stimulation, sotalol therapy and, 1428, 1430, 1431

Programmed ventricular stimulation, vs. Holter monitoring, 555-558

Propafenone aggravating or inducing congestive heart failure, 653 effect on conduction characteristics of AV pathways, 621 efficacy and side-effect profiles, 449-452 efficacy in atrial fibrillation, 549-550 electrophysiologic evaluation, 537 hemodynamic effects, 546 junctional tachycardias treatment, 550-551 pharmacokinetics and antiarrhythmic effects, 281-287 poor metabolism phenotype, 543-544 proarrhythmic side effects, 552 ventricular arrhythmia treatment, 551-552

Wolff-Parkinson-White syndrome treatment efficacy, 681-685

Propranolol adverse reactions in elderly, 1273-1274

antihypertensive drug treatment for blacks, 389-391
 antihypertensive drug treatment for elderly in trial, 1241
 arterial tree action, 745
 blood lipid profile affected, 1277
 combination therapy effect on anginal frequency, 900, 901
 drug interactions, 965, 1164
 effect on LV mass, 503
 effect on respiratory function in hypertension with chronic obstructive lung disease, 1145-1148
 efficacy in prevention of ventricular tachycardia induction, 536
 electrophysiologic properties compared to those of sotalol, 600
 for black hypertensives, 383
 for reversal of LV hypertrophy, 427-432
 hemodynamic response, 1139
 interaction with indometacin, 964
 in-vitro adrenoceptor activities, 1283
 ischemic heart disease treatment, 676, 678
 maximal comparable work-load reduced, 484
 no interaction with ranitidine, 490
 piroxicam interaction, 965
 plasma protein bindings and encainide, 564
 pretreatment (oral) before nicardipine treatment, 1525, 1526, 1528-1529, 1531
 pretreatment to block celiprolol concentration-dependent relaxation, 748
 preventive cardiology, 755
 reducing chronotropic response during LBNP tests, 1259
 renal vasodilation, 1297
 respiratory function affected in elderly, 1230
 silent myocardial ischemia treatment, 931
 smoking effect in elderly, 1273-1274, 1276
 Trimetazidine European Multicenter Study, 842
 vs. celiprolol, 1281, 1291-1294
 vs. nicorandil, 1078, 1081, 1082, 1084-1085
 vs. propranolol in preventing sudden death, 1515-1518
 vs. sotalol, 547, 603-606, 609-610
 withdrawal of antihypertensive drug therapy, 1490, 1492
 D-Propranolol, devoid of beta blocking activity, 559
 L-Propranolol, pharmacokinetic interactions, 559
 Proprionyl carnitine, activity evaluated for stable angina pectoris of effort, 481-485
 Prostacyclin
 infarct expansion affected, 1370

Raynaud's phenomenon, 49
 release during pregnancy stimulated by serotonin, 38-40
 Prostacyclin/thromboxane ratio, pre-eclampsia, 38, 39
 Prostaglandins
 carcinoid syndrome, 54
 mediating captopril hemodynamic responses, 201
 modulating vascular growth, 239
 Raynaud's phenomenon, 46, 49, 50
 released during pacing-induced myocardial ischemia and angiotensin interactions, 1376-1377, 1381-1382
 role in low-renin essential hypertension given enalapril, 201
 Protamine
 platelet aggregation, 19
 platelet loss cause after cardiopulmonary bypass, 269, 272
 Protein kinase C
 generating signal for increased transcriptional activity, 1368-1370
 phorbol esters causing contractions in vascular smooth muscle, 1358-1361
 Protein restriction, chronic renal failure, 222
 Proteinuria, decreased by ACE inhibitors, 221-225
 Protons, accumulation as effect of severe ischemia, 777, 780-782, 786
 P (substance), 30
 Pulmonary artery diastolic pressures (PADP), plasma concentrations of atrial natriuretic peptide during physical exercise, 289, 291-293, 295
 Pulmonary artery occlusion pressure (PAOP)
 calcium-channel blocker effect, 457-459, 462
 reduced by amlodipine, 457, 459
 Pulmonary artery pressure, right atrial pressure related, 289, 291-295
 Pulmonary edema, verapamil side effect, 1516
 Pulse wave velocity (PWV), nifedipine effect in chronic hemodialysis patients, 987-990
 Quality of life
 double-blind comparison of bisoprolol and captopril for elderly hypertensives, 261-264
 ketanserin treatment improvement for elderly hypertensives, 116, 117
 OPC-8212 treatment questionnaire for mild chronic heart failure patients, 420-423
 Quantitative coronary angiography, CAAS system, 1038-1044
 Quinalapril, coronary blood flow affected, 1379, 1380
 Quinapril, nonsulphydryl ACE inhibitor, 200

Quinidine
 chronotropism inhibited by, 509
 decrease in cardiac output and worsening of congestive heart failure, 545
 effect on conduction characteristics of AV pathways, 621
 hemodynamics, 547
 long QT syndrome, 667
 mechanism of action, 597, 602
 noncardiac adverse events incidence, 590
 onset kinetics, 571
 poor metabolism phenotype, 544
 proarrhythmia incidence during EPS testing, 539
 sodium-channel block, 542-543
 vs. encainide for supraventricular arrhythmias, 575
 vs. flecainide for ventricular tachycardias, 551
 vs. KT-362, 1350-1351
 vs. nicorandil, 1084
 vs. sotalol, 606-610, 1431
 vs. sotalol for sinus rhythm after conversion of atrial fibrillation, 631
 QTc interval, prolongation by ketanserin, 1157, 1159
 QT interval
 ketanserin and atherosclerosis, 14, 15
 ketanserin side effects and adverse reactions with carcinoid syndrome, 57
 no significant prolongation by ketanserin during atrial pacing, 1158, 1159
 prolongation associated with ketanserin treatment, 93-95
 prolongation by ketanserin, 139
 prolongation by ketanserin initiating and worsening ventricular arrhythmias, 1159-1160
 propafenone electrophysiologic effects, 282
 torsades de pointes, 1178
 Rabbit, antiatherosclerotic effect of nifedipine in cholesterol-fed, 1021-1025
 Radionuclide ventriculography, ADM-induced cardiotoxicity assessed by, 1519, 1521
 Ramipril
 coronary blood flow affected, 1378-1380
 nonsulphydryl ACE inhibitor, 200
 synergistic increase of blood flow not detected, 250
 vs. delapril, 1417
 Ramiprilat, coronary blood flow affected, 1379-1380
 Ranitidine
 carcinoid syndrome, 57
 drug interactions, 487, 490
 effect of tertatolol elimination and plasma levels, 487-490
 Raynaud's phenomenon
 nifedipine use, 935-939
 pathogenesis and treatment, 45-50

serotonin effect, 5, 14, 45
 serotonin's role in pathogenesis, 138
 symptoms alleviated by ketanserin, 130
 Receptor-linked calcium entry, KT-362, 1351
 Reentrant supraventricular tachycardia, sotalol efficacy (oral), 613-617
 Reentrant ventricular tachycardia, sotalol efficacy (oral), 613-617
 Reentry, sotalol for supraventricular tachycardia, 625, 626
 Reflex tachycardia
 captopril and lack of, 265
 enalapril and lack of, 267
 ketanserin not inducing, 20, 24, 80
 Regenerated endothelium, 11
 Regional myocardial blood flow, dilevalol effect, 1461
 Remnant kidney, calcium antagonist effect on oxygen utilization, 1329
 Remodeling
 captopril and myocardial ischemia, 1381
 congestive heart failure following, 1363-1372
 Renal artery stenosis, renin release role, 230, 232, 233
 Renal blood flow, poststenotic loss, 234
 Renal disease, ketanserinol clearance impaired, 91
 Renal failure
 effect on encainide pharmacokinetics, 562-564
 race/sex differences in mortality from, 398
 Renal function, *see* Kidneys
 Renal hypertrophy, glomerular injury related to, 1325-1329
 Renal plasma flow, chronic renal failure and ACE inhibitors, 222-224
 Renal tubules, calcium handling during oxygen deprivation kidney injury prior to reoxygenation, 1319-1323
 Renal vascular resistance (RVR), 207, 210-213
 reduced by calcium antagonists, 1331-1335
 Renin
 circulating pressor substance from induced experimental hypertension, 229-232
 correlation of level of hypertension incidence in blacks, 317, 319
 low profile characteristic of elderly, 1273
 open-heart surgery, 19
 sodium homeostasis and ANP, 1210-1211
 unreliable classification for antihypertensive treatment, 390
 urinary and intracellular studies of blacks and Indians, 364, 365
 Renin-angiotensin system
 calcium entry blockers' effects, 980
 paracrine, autocrine, or intracrine role, 1369-1370
 piracetamide's minor effects, 520
 Rentiapril, sulphydryl ACE inhibitor, 200
 Reoxygenation, after O₂ deprivation in hypoxic renal injury, 1320, 1323
 Reperfusion
 absence of, 769
 arrhythmias attenuated by ACE inhibitors, 1375, 1380
 cardioprotective effect during, 808-809
 clinical criteria of, 1337-1340, 1342
 free radicals during ischemia and, 791-794
 myocardial ischemia and dilevalol during, 1462-1464
 tissue injury determinants, 767-774
 zenopropafenone pretreatment effect on, 695-702
 Reperfusion cardiac function, protective effects of cromakalim and pinacidil, 465-473
 Reperfusion damage, 765-766
 Reperfusion injury, KT-362 treatment, 1351-1353
 Reserpine
 antihypertensive drug treatment for elderly in trial, 1237, 1240
 antihypertensive treatment in combination with verapamil, 391
 antisympathetic agent lowering blood pressure, 380
 for hypertension with chronic renal failure, 222
 Raynaud's phenomenon, 45, 48, 50
 to eliminate noradrenaline influence, 1478, 1482
 Resibufogenin, blocking K⁺ vasodilation, 345
 Respiratory function
 beta blockade effects in the elderly, 1229-1232
 ciliprolol for preservation of, 1277
 Respiratory sinus arrhythmia, parasympathetic activity, 266-267
 Rest angina, nifedipine for treatment, 1083, 1085
 Rest hemodynamics, calcium-channel blockers amlodipine, diltiazem and verapamil, 460
 Restrictive cardiomyopathy, amiodarone for treatment, 529
 Retroperitoneal fibrosis, serotonin effect, 139
 Rifampicin
 effect on tertatolol elimination and plasma levels, 487-490
 influence on kinetics of beta blockers, 490
 Right atrial pressure (RAP), plasma concentrations of atrial natriuretic peptide during physical exercise, 289-295
 Right-sided cardiac lesions, serotonin effect, 139
 Risk stratification
 after percutaneous transluminal coronary angioplasty (PTCA), 687-692
 malignant arrhythmias, 665-667
 Ritanserin
 antihypertensive properties missing, 7
 arterial blood pressure affected, 22, 23, 30
 decreasing HMG CoA activity, 137
 HMG CoA reductase activity in cultured human skin fibroblasts, 69-72
 portal pressure reduction, 33-34
 prolongation of QT interval, 94
 reinforcing antihypertensive effect of prazosin, 137
 selective 5HT₂ receptor antagonist, 1445-1446
 to lower portal venous pressure, 138
 Ro 40-5967, vs. verapamil for negative inotropic effect, 731-736
 Rubidium, analogue of potassium and sodium, 323
 Ryanodine-like action, KT-362 intracellular calcium antagonist, 1345, 1349-1350, 1352, 1353

Safety, encainide profile, 585-594
 Sarafotoxin S6b, binding displaceable by, 882
 Saralasin
 coronary blood flow affected, 1379
 normalizing blood pressures in renovascular hypertension, 230, 231, 233
 to block angiotensin II effects and increase parasympathetic activity, 267
 SATAPEC (computer system), cardiac electric potential recordings processed, 810-811
 Scleroderma, Raynaud's phenomenon, 49
 SD-3211
 cardiac versus coronary dilator effects in dog hearts, 1469-1475
 vs. diltiazem, 1469, 1474, 1475
 vs. verapamil, 1469, 1474, 1475
 Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT), 877
 Separan, renal actions, 297-300
 Serotonin (5-hydroxytryptamine)
 acute disorders following cardiac surgery, 19-24
 amplifying platelet response in 5HT uptake, 105-109
 carcinoid syndrome, 53-55, 57
 creatinine sulphate, 106
 effect on transmembrane cation transport, 63-66
 endothelium-derived relaxing factor and, 7-8
 human mammary artery contractions produced, 59-61
 involvement in pathophysiology of hypertension, 123-125
 ketanserin acute electrophysiologic effects in humans, 1157-1160
 ketanserin-captopril combination for hypertensives, 119-122

ketanserin to reduce adverse symptoms of beta blockade, 127–130

liberation resulting from platelet aggregation, 13

mediating vasoconstrictor responses, 1459

modulating vascular growth, 239

platelet bound, 137

portal hypertension decrease, 33–34

preclampsia–eclampsia syndrome, 37–41

Raynaud's phenomenon vasospasm induction, 46, 47

receptors, 29, 48, 59–61

role in cardiovascular diseases and their treatment, 5, 1443–1446

spinal content, 28

vascular disease and, 7–11

SG-86 (N-2-hydroxyethyl nicotinamide), nicorandil converted to, 1080

Shy-Drager syndrome, baroreflex sensitivity, 1258

Sickle cell trait, erythrocyte concentration and transmembrane fluxes of sodium and potassium, 326

Signal averaging, zofenopril in experimental infarction, 697, 700, 701

Silent myocardial ischemia, 765

nifedipine efficacy in patients with variant angina, 915–918

nifedipine treatment for, 931–933

pathophysiology, 929–930

rationale for treatment of, 930–931

Simvastatin, atherosclerosis treatment in hypercholesterolemic patients, 1389–1393

SIN-1 (vasodilator), 250

Sinus node dysfunction, xamoterol (intravenous) electrophysiologic effects, 523–526

Sleep disturbance, bendrofluazide as cause, 128, 129, 130

S-methyl captopril, present in circulation, 202

Smoking, *see also* Tobacco consumption

Oslo Primary Prevention Trial (lipid-lowering) stressing cessation of, 1385–1386

prevention recommendations for control of, 1533

propranolol age-related fall-off in systemic clearance, 1274, 1276

risk factor in INTACT Study of coronary artery disease, 1053–1056, 1065

senile emphysema, 1277

serotonin having pathogenic role, 1446

Sodium

- angiotensin loss and enhanced reabsorption, 230
- blood pressure in blacks increased by intake, 383
- cellular regulation differences in blacks vs. whites, 337
- enalapril monotherapy for essential hypertension affected by diet, 213, 214
- erythrocyte concentrations and transmembrane fluxes of, 321–330
- excretion capacity decreased in hypertensive kidney, 238
- excretion level related to blood pressure, 1198–1199
- factor in pathogenesis of hypertension in blacks, 318, 319
- internal, decreased apparent affinity characterizing abnormalities, 375
- intracellular, hypertensives studied, 368
- intracellular concentration in essential hypertension, 323–324, 347–348
- intralymphocytic, 364–365
- proteinuria decreased with dietary restriction, 224–225
- related to increased blood pressure in elderly, 1210, 1211
- systemic regulation differences in blacks vs. whites, 336–337
- urinary excretion augmented by nifedipine, 977
- urinary and intracellular studies of blacks and Indians, 363–365

Sodium diuresis, nitrendipine for essential hypertension, 980–981

Sodium, potassium-ATPase, digitalis-like factor in hypertension, 343–347

Sodium, potassium, Cl cotransport system, abnormalities compensated, 374, 375

Sodium-potassium pump

- digitalis-like factor in hypertension, 343–345, 347–348
- digitalis-sensitive and abnormalities, 374, 375

Sodium transport inhibitor, in pregnancy-induced hypertension, 351–355

SOLVD Study, prevention of LV dilatation, 1371

Somatostatin, carcinoid syndrome, 57

Sotalol

- antiarrhythmic efficacy in ventricular tachyarrhythmias, 1425–1431
- AV nodal tachycardia, 535–536
- beta-blocking activity, 599–602
- blood lipid profile affected, 1277
- combination therapy with amiodarone, 617
- dose adjustment when glomerular filtration rates fall, 1273, 1274
- efficacy in controlling reentrant supraventricular tachycardias, 625–628
- electrophysiologic effects, 619–621
- hemodynamics, 547
- inotropic and hemodynamic effects, 546–547
- issues in arrhythmia management, 559–560
- lengthening QT interval, 15
- management of cardiac arrhythmias, 633–634
- mechanism of action, 597–599
- preventing atrial fibrillation in WPW syndrome, 684

programmed ventricular stimulation, 556, 557

reentrant ventricular tachycardia treatment, 613–617

supraventricular arrhythmias mechanism of action, 619–623

ventricular tachycardia, 537

ventricular tachycardia/fibrillation treatment, 601

vs. Class I and II antiarrhythmic agents, 603–610

vs. propranolol for arrhythmias, 603–606, 609–610

vs. quinidine, 606–610, 1431

vs. quinidine for sinus rhythm after conversion of atrial fibrillation, 631

d-Sotalol

- antiarrhythmic efficacy in ventricular tachyarrhythmias, 1425–1431
- beta blocking activity, 600, 602
- effect on conduction characteristics of AV pathways, 621
- electrophysiologic effects, 622, 623

l-Sotalol

- antiarrhythmic efficacy in ventricular tachyarrhythmias, 1425–1431
- beta blocking activity, 600, 602

Spanish Trial on Sudden Death, 651

Spasm

- caused by acute ischemic stimuli, 829
- variant angina and nifedipine efficacy on ischemic attacks, 915

Spiperone, 5HT₂ receptor blocker effect on DHEC and DHE, 1459

Spontaneous defibrillation, 1180–1181

SQ 13,534, captopril stereoisomer, 204–205

SQ 14,534, free-radical scavenger properties, 204–205

SQ 29852, phosphorus-containing ACE inhibitor, 200

Stanozolol, Raynaud's phenomenon, 49

Steal phenomenon, nisoldipine vs. nifedipine, 455

Step-down Treatment of Mild Systemic Hypertension, 1490

Steroids, interference and endogenous digoxinlike immunoreactivity, 353

Stockholm Ischaemic Heart Disease Secondary Prevention Study, clofibrate with nicotinic acid for lipid-lowering treatment, 1386

Stokes-Adams syncope, torsades de pointes leading to, 1179

Strain gauge plethysmography, captopril and peripheral hemodynamics measured, 751–752

Streptomycin, supplement in culture of human skin fibroblasts, 69

Streptozocin, carcinoid syndrome chemotherapy, 57

Streptozotocin, inducing diabetes mellitus in study of enalapril renal protection, 204

Stroke
 cerebral blood flow in the elderly, 1217, 1218
 elderly hypertensives, 1197
 EWPHE Study results showing decrease in nonfatal, 1250
 hospitalization required and risk factors of, 1263, 1267
 isolated systolic hypertension related, 1205
 mortality related to hypotensive drugs, 1246
 race/sex differences in mortality from, 398
 trials overview and key factors in treatment, 1269

ST-segment elevation
 exercise and vasospastic angina, 893
 myocardial ischemia and intracoronary nifedipine pretreatment, 887-888, 890
 nifedipine in coronary spasm, 916-917
 reperfusion effect, 1342

"Stunned" myocardium
 frequent bouts of ischemia as cause, 930, 933

KT-362 effect, 1352

nicorandil treatment, 1453

nifedipine effect, 880, 881, 883

tissue injury determinants, 767, 771, 773

Sublingual administration, captopril for essential hypertension, 751-754

Substance P, carcinoid syndrome, 53-55

Sudden cardiac death (SCD)
 arrhythmogenic substrate leading to, 555, 556

coronary artery disease incidence, 834, 836-837

definition used, 658, 660, 661

elderly hypertensives, 1197

electrophysiologic evaluation significance for preventing, 537, 538

encainide efficacy, 573

encainide updated safety profile, 585-587, 593

flecainide therapy, 1161, 1164

pharmacologic intervention, 559

premature ventricular contractions as risk factor, 651, 653

prevention by beta blockade, 675-678

propranolol vs. verapamil long-term effects in preventing, 1515-1518

reperfusion arrhythmias, 772

sotalol and sustained ventricular tachycardia, 1429-1430

ventricular fibrillation as cause, 1180

ventricular premature complexes (VPCs) indicative of risk, 669, 672

Sulphydryl ACE inhibitors, 200-205

Sulphydryl groups
 active in captopril, 199, 200

captopril and effects on renal function, 212

captopril donor enhancement of nitrate action, 250

depletion interaction required for nitroglycerin metabolism, 247-249

Sulindac, not attenuating blood-pressure lowering effect of captopril, 201

Sulmazole, cardiotonic agent for congestive heart failure, 1127

Superoxide production in cardiac muscle, trimetazidine effect, 814-815

Supraventricular arrhythmias
 amiodarone plus flecainide to prevent recurrences, 654

class IC drugs for treatment, 549, 551

electrophysiologic evaluation, 535-536

encainide efficacy, 573-577

encainide safety profile, 585-594

sotalol efficacy in controlling, 625-628

Supraventricular tachyarrhythmias, Wolff-Parkinson-White syndrome predisposing, 666

Supraventricular tachycardias, sotalol for termination, 621

Surgical procedures
 ischemic heart disease, 613
 percutaneous transluminal coronary angioplasty follow-up, 690, 691

supraventricular tachycardias, 634

zofenopril pretreatment effect on early reperfusion, 696

Survival and Ventricular Enlargement (SAVE) Trial
 ACE inhibitors and myocardial ischemia, 1381
 prevention of dilatation, 1371

Sustained monomorphic ventricular tachycardia (SMVT), sotalol treatment, 1425, 1427-1431

Swedish League Against Hypertension, 1253-1254

Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Study
 antihypertensive treatment in the elderly in Sweden, 1253-1255

blood pressure as weak predictor for mortality, 1269

mortality correlated to BP and analysis of results, 1270-1271

Sympathetic activity, hydralazine vs. nifedipine effects, 499-503

Symptomatic sick-sinus syndrome, xameterol (intravenous) therapy, 523-526

Symptomatic ventricular premature beats, flecainide treatment, 1161

Systemic hypertension, amiodarone, 529

Systolic blood pressure, terbutaline effect, 1276

Systolic hypertension
 elderly hypertensives, 1215-1216
 EWPHE Study results with focus on, 1249-1251
 major risk indicator, 1270
 pharmacologic vs. nonpharmacologic treatment in the elderly, 1203-1207

Systolic Hypertension in the Elderly Program (SHEP)
 efficacy of diuretic in decreasing systolic BP in elderly with ISH, 1203, 1205-1206, 1215
 withdrawal due to adverse reactions, 1298

Systolic time intervals, echocardiography and, 737, 738, 742

Systolic vs. diastolic blood pressure, 1301-1302

Tepratide
 coronary blood flow affected, 1378-1380
 first ACE inhibitor, 199
 infarct size affected, 1381

Tepratide/captopril, for essential hypertension and causing renal effects, 211

Terazosin, for LVH regression, 431

Terbutaline, systolic blood pressure affected, 1276

Tertatolol
 bioavailability, 487
 interaction with rifampicin and ranitidine pharmacokinetics, 487-490

Theophylline
 interaction with ranitidine, 487, 490
 purine compound inotropic effects antagonized by, 512
 sinus node disease treatment, 525

Thiazides
 antihypertensive drug treatment for elderly in trial, 1237, 1245-1246

EWPHE Study drug treatment, 1269

generic use, 1440

interaction with indomethacin, 964

nifedipine interaction, 965-966

preferred treatment for black hypertension, 388

Thiazole derivative, ZSY-39, 1127-1133

Thirst, changes related to aging, 1209, 1211

Thoracic outlet syndrome, digital artery constriction, 47

Thromboangiitis obliterans, 47

Thrombocytopenia, heparin-induced, 269, 272

Thrombolysis, second, anistreplase in acute myocardial infarction trial, 1338

Thrombosis
 caused by acute ischemic stimuli, 829

encrustation in atherosclerosis, 993, 1000

Thromboxane, modulating vascular growth, 239

Thromboxane A₂
 endothelial dysfunction, 11

inhibitors, 46

liberation resulting from platelet aggregation, 13, 15

Tiagamil
 hemodynamic response to, 1135-1139

verapamil derivative, 723

Tienilic acid, potassium transport stimulated, 385

TIMI II Trial, thrombolysis and beta blockade vs. thrombolysis alone, 678

Timolol
drug interactions, 965
ischemic heart disease treatment, 676
pharmacokinetic interactions, 559
respiratory function in the elderly affected, 1231

Tobacco consumption, *see also* Smoking prevention recommendations for control of, 1533

Tocainide
antiarrhythmic drug, 594
decrease in cardiac output and worsening of congestive heart failure, 545-546
onset kinetics, 571
proarrhythmia incidence during EPS testing, 539
stereochemical influences, 541, 542

Tolazoline, Raynaud's phenomenon, 48

Tolerability, felodipine treatment in hypertension, 641-647

Torsades de pointes
cause of, 634
description of phenomenon, 1177-1179
ECG configurations of ventricular tachycardias, 1173-1176
evaluation of it as electrocardiographic phenomenon, 1169, 1183
forum introduction, 1167
long QT syndrome, 667
proarrhythmia event, 672
sotalol induced, 614-615, 616, 1431
ventricular fibrillation and, 675, 1177-1182

Total peripheral resistance (TPR), as physiologic characteristic of obesity hypertension, 399

Trandolapril, coronary blood flow affected, 1378, 1379

Transient ischemic attacks (TIAs), cerebral blood flow in the elderly, 1218

Transmembrane cation transport, ketanserin treatment effect on sodium transport, 63-66

Transport systems
essential hypertension and, 351-352
for classifying hypertensives, 373-377
lithium-sodium countertransport, studies of hypertensives, 337, 368
pregnancy-induced hypertension and, 352-353
sodium-lithium countertransport, 323, 325, 326, 330, 337, 357-361, 374
sodium-potassium and environmental factor influence, 329-330
sodium-potassium and host factor influence, 325-329
sodium, potassium-ATPase activity, black hypertensives, 384, 385
sodium, potassium-ATPase pump (active), 321-322, 324, 326-330, 337-338
sodium-potassium cotransport, 322-328, 330, 337, 368-369

sodium, potassium transport disagreement on status in the erythrocyte in essential hypertension, 384
trimetazidine protection of red blood cells against oxygen free radical damage, 818-819

Triamterene
combination therapy for hypertension, 948
EWPHE Study drug treatment, 1269

Trigeminal cardiorespiratory reflexes, autonomic control, and age-related changes and beta blockade, 1260

Trigeminal reflexes, elderly hypertensives and beta blockade, 1271

Triglycerides
levels correlated with changes in sodium-lithium countertransport, 357-361
nifedipine effect on serum lipoprotein metabolism with hypertension, 1033-1035

Trimetazidine (TMZ), 766
acute effects on ergometric parameters in effort angina, 820-821
antiischemic effect in myocardial ischemia model, 808-809
antiischemic effects: ³¹P-NMR spectroscopy study in isolated rat heart, 812-813
cardioprotective effect during ischemia and reperfusion, 808-809
cardioprotective effect in severe ischemic cardiomyopathy, 861-865
chronic effects on ergometric parameters in effort angina, 822-823
combined with nifedipine for effort angina, 824-825
delayed afterdepolarization (DADs) and upstroke velocity of action potential, 806-807
effect during reperfusion, 791, 793, 794
electrocardiographic assessment of antiischemic properties, 810-811
glucose flux promotion in ischemia, 787
mitochondrial function and superoxide production in cardiac muscle, 814-815
oxygen radical species effect in postischemic acute renal failure in rat, 816-817
red blood cells and oxygen free radical damage, 818-819

Trimetazidine European Multicenter Study, 842, 845
vs. nifedipine for effort angina, 853-859

Trimetazidine European Multicenter Study, comparison of antiischemic effects of propranolol and trimetazidine, 842, 845

Tryptophan, avoided in study determining 5HT uptake in men, 106

Underperfusion, cerebral blood flow in the elderly, 1219-1220

Unilateral renal artery stenosis, ACE inhibitors, 204

Unloading, enoximone improvement of LV function by, 1403, 1413

Urapidil, antihypertensive treatment, 1443, 1446

Uric acid, nifedipine effect with essential hypertension, 977

U.S. Health and Nutrition Examination Surveys, 1199

U.S. Lipid Research Clinics Coronary Primary Prevention Trial, lipid-lowering treatment successful in reducing myocardial infarction, 1385

U.S. Postmarketing Adverse Experiences Report, encainide safety evaluation, 585, 586, 593-594

Valvular heart disease, 21

Valvular stenosis, ACE inhibitors avoided, 244

Variant angina, *see also* Angina pectoris
nicorandil for treatment, 1083
nifedipine efficacy on ischemic attacks, 915-918
nifedipine for treatment, 909

Variation of heart period (VHP), parasympathetic activity, 265-267

Vascular injury, atherogenesis hypothesis, 993, 995-998, 1001

Vascular relaxation, KT-362, 1346-1350

Vascular resistance
ciliprolol effect, 1276
flosequinan hemodynamic effects in heart failure, 708-711
nicardipine effect, 1531

Vascular smooth muscle
angiotensin II as growth stimulant, 243
arterial wall changes in hypertension, 237, 239

atherosclerosis, 999-1001
blood cells used to monitor changes, 368
cells' endothelin binding, 880
contraction mechanisms, 1355-1361
depolarization subsequent to sodium transport inhibition, 352
glucose and glycogen operating in different cytosolic compartments, 787
impaired relaxation, 248
increased contractile activity due to sodium intake, 343

isradipine as hypertension treatment because of high selectivity for, 413
nicorandil to relax, 1075, 1076
relaxed by cromakalim and pinacidil, 465

serotonin and, 7-11

structure modified by prolonged phosphoinositide hydrolysis, 370

Vascular spasm, atherosclerosis, 1002-1003

Vasoconstriction, vs. cytoplasmic ionized calcium levels, 1355-1361

Vasodilators
 celiprolol therapy of hypertensives, 745-748
 effect of increasing extracellular sodium chloride concentration, 343
 elderly hypertensives, 1267
 flosequian, 705-711, 1395-1401
 for treatment of heart failure, 85, 87
 hypertrophy reversal not achieved, 79
 nifedipine potent arterial properties, 936-937
 nitrate induced, 247, 248, 249
 nitroglycerin oral spray formulations and their effects, 475-480
 serotonin, 1444
 treatment stopped before felodipine antihypertensive therapy, 255
 vascular hypertrophy, 239-240

Vasomotor changes, autonomic control age-related changes, and beta blockade, 1260

Vasomotor tone, under different control mechanisms in epicardial and resistance vessels, 830

Vasopressin
 aging and water homeostasis, 1211-1212
 open-heart surgery, 19, 20

Vasoselectivity, clentiazem vs. diltiazem and nifedipine, 723-725, 1103

Vasospasm, 138
 nitrocompounds for treatment, 276-277
 Raynaud's phenomenon, 45-47, 49

Vena cava balloon occlusion for rapid load changes, enoximone effect on end-systolic pressure-volume relationship, 1405-1407, 1412

Venoconstriction, dihydroergocristine and dihydroergotamine responses, 1455-1459

Ventricular arrhythmias
 anstreplase treatment and frequency, 1340, 1342
 antiarrhythmic drug efficacy, 669-673
 encainide safety profile, 585-594
 flecainide therapy, 549, 551-552
 markers for sudden deaths, 1517
 models to detect and evaluate, 670-671
 physiopathology, 652-654
 plasma concentration/effects relationships, 565
 prognostic classification, 669-670
 propafenone treatment, 551-552
 prevented by KT-362, 1345, 1350-1353
 spontaneous variability, 671-672

Ventricular ectopy
 Holter monitoring requirements, 555, 558
 suppressed by ketanserin in normokalemic patients, 95

Ventricular fibrillation
 ACE inhibitors and arrhythmias during myocardial ischemias, 1380
 characteristics and classification scheme, 1179-1182
 hypothermia and, 1180-1182
 nicorandil treatment effect, 1121, 1124, 1125
 related to sudden cardiac death, 675, 678
 reperfusion-induced, 772
 sotalol treatment, 1425, 1427-1431
 torsades de pointes and, 1177-1182

Ventricular premature beats (VPBs)
 Cardiac Arrhythmia Suppression Trial (CAST), 591, 592
 propafenone minimum effective values in antiarrhythmic therapy, 281-283, 286
 sotalol therapy, 1428

Ventricular premature complexes (VPCs)
 sudden cardiac death possibility, 669-672

Ventricular tachycardias (VT)
 antiarrhythmic effect from lower drug doses in combination, 543
 ECG configurations and interpretations, 1171-1176
 electrophysiologic evaluation, 536-537, 539
 flecainide treatment, 550-552, 1161, 1163
 programmed ventricular stimulation, 556-557
 sotalol efficacy, 613-617, 1425-1431
 two variable foci and classification scheme of, 1171-1176

Ventricular tachycardia/fibrillation
 Holter monitoring results, 556
 sotalol treatment, 601

Ventricular Tachycardia/Heart Disease and Boston studies, encainide safety evaluation, 585, 586, 592-593

Ventrolateral medulla, serotonin content and stimulation of, 28-31

Verapamil
 aggravating number and duration of vagal atrial fibrillations, 581
 angina pectoris treatment, 1509
 antiarteriosclerotic effects, 1011, 1012
 antiatherogenic effects and mechanisms of action, 1015-1018
 antihypertensive therapy for blacks, 391, 392
 antihypertensive treatment similar to isradipine, 416, 417
 AV nodal tachycardia, 535
 bioavailability, 1506
 cardioprotective effect during ischemia and reperfusion, 808-809
 chronic stable angina treatment, 931
 compared to Ro 40-5967 for negative inotropic effects, 731-736
 decreasing conduction capacity of AV node, 619
 derivatives, 723
 drug interactions, 965
 effect on hypertensive kidney, 1331-1332
 effect on renal function by inhibiting Ca^{2+} uptake, 1319, 1322, 1323
 efficacy in prevention of ventricular tachycardia induction, 536
 enhancing metabolism of LDL cholesterol in cultured arterial smooth muscle cells, 1065
 exercise hemodynamics in coronary artery disease, 457-462
 inhibiting vascular myocyte proliferation and migration, 1027, 1028
 ischemic heart disease treatment, 676
 isovolumic relaxation time reduced, 954
 lessening glomerular sclerosis in remnant kidneys, 1327, 1329
 lipoprotein metabolism effect, 1033
 LV diastolic filling in CAD enhanced, 1509
 mechanism of action, 1505
 plasma protein bindings and encainide, 564
 preventive aspects in cardiology, 755
 proarrhythmia incidence during EPS testing, 539
 Raynaud's phenomenon, 47
 serum calcium reduced and atherosclerosis prevented by, 1021, 1024
 stereochemical influences, 541
 supraventricular tachycardias' treatment, 628
 verapamil 240 SR vs. verapamil 120 SR, 1501-1506
 vs. KT-362, 1346, 1350
 vs. muzolimine, 1477, 1479-1481, 1483
 vs. nicardipine, 1530, 1531
 vs. nicorandil, 1084
 vs. nifedipine pharmacologic potency in terms of vasodilation, 936, 937
 vs. propranolol in preventing sudden death, 1515-1518
 vs. SD-3211, 1469, 1474, 1475
 Verapamil hydrochloride, antihypertensive treatment for blacks, 391
 Vesnarinone, cardiotonic agent for congestive heart failure, 1127, 1133
 Veterans Administration Cooperative Study, antihypertensive drug treatment in elderly trial, 1243, 1244
 Veterans Administration Trial on Mild Hypertension, hypertension in elderly men, 948
 Veterans Cooperative Study Group (1975), discontinuation of antihypertensive therapy, 1488, 1489
 Vinyl chloride disease, 47
 Visacor, hemodynamic response to, 1135-1138
 Vitamin D, 336, 405, 983-986

Warfarin
 interaction with ranitidine, 487, 490
 plasma protein bindings and encainide, 564

Western Collaborative Group Study (1976), systolic vs. diastolic BP, 1203, 1204, 1216

Whites

cellular regulation of sodium, potassium, and calcium, 337
heredity and essential hypertension, 335-336
obesity and hypertension, 395-401
relative racially-based efficacy of anti-hypertensive agents, 379-381
systemic regulation of sodium, potassium and calcium, 336-337
Wolff-Parkinson-White (WPW) syndrome
amiodarone treatment, 529, 623
atrial fibrillation induced, 549
electrophysiologic evaluation of antiarrhythmic drugs, 535, 536
encainide efficacy and AV reentry, 573-575
flecainide or encainide safety in use, 654

flecainide therapy, 1161

prevalence in live births in United Kingdom, 527
propafenone efficacy in treatment, 681-685
risk stratification process, 665, 666
sotalol as antiarrhythmic therapy, 609, 619, 620, 625-628

Women, calcium therapy for essential hypertension, 301

World Health Organization, antihypertensive treatment recommendations and studies, 1269-1270, 1302, 1303

Xamoterol (intravenous) (corwin), sinus node dysfunction treatment and its electrophysiologic effects, 523-526

Yohimbine, antagonizing vasoconstriction responses to serotonin, dihydroergocristine and dihydroergotamine, 1455-1459

Zofenopril

bioavailability, 695-696
effect on early reperfusion and electrophysiologic stability in the pig, 695-702

pharmacokinetics, 696

sulphydryl ACE inhibitor, 200
Zofenoprilat, coronary blood flow affected, 1379

ZSY-39, effect on force of contraction and cyclic AMP content in canine ventricular muscle, 1127-1133

